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“Science is more than a body of knowledge. It is a way of thinking; a way 
of skeptically interrogating the universe with a fine understanding of 
human fallibility. If we are not able to ask skeptical questions, to 
interrogate those who tell us that something is true, to be skeptical of 
those in authority, then we are up for grabs for the next charlatan who 
comes rambling along.” 
 
- Carl Sagan 
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ABSTRACT 
Blood monocytes are heterogeneous effector cells of the innate immune system that 
can be divided into at least two functionally distinct subpopulations. In circulation 
these cells are constantly in contact with lipid-rich lipoproteins, yet this interaction is 
poorly characterized. The aim of this PhD was to examine the functional response of 
blood monocyte subpopulations to dyslipidaemia, defined as high levels of plasma 
VLDL and LDL. Initially in the Ldlr-/- mouse, I demonstrated that monocytes 
accumulate cytoplasmic neutral lipid vesicles when exposed to high fat diet induced 
dyslipidaemia. In this model, lipid loaded monocytes exhibit impaired chemotaxis 
towards peritonitis due to retention of monocytes in the greater omentum. In vitro 
assays using human monocytes confirmed neutral lipid vesicle accumulation after 
exposure to LDL or VLDL, via several receptors including CD36. Neutral lipid 
accumulation did not inhibit other functions including phagocytosis, endothelial 
adhesion and transendothelial migration, nor did it lead to an overtly pro-
inflammatory phenotype. However, lipid loading led to a migratory defect in both 
monocyte subsets towards C5a and was accompanied by a disruption of cytoskeletal 
regulation. These cytoskeletal changes included subset specific differences in cell 
morphology, and an inhibition of RHOA activation and myosin light chain 
phosphorylation. These data emphasise the functional consequences of blood 
monocyte lipid accumulation and reveal important implications for treating 
inflammation, infection and atherogenesis in the context of dyslipidaemia.  
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1. INTRODUCTION 
1.1. The	  Mononuclear	  Phagocyte	  System	  
1.1.1. 	  History	  of	  the	  MPS	  
In 1908, the Russian zoologist Ilya Metchnikoff was jointly awarded the Nobel Prize 
for his controversial discovery of motile phagocytes, from the Greek ‘phagos’ (to eat) 
and ‘cyte’ (cell) [1,2]. While taking refuge from political instability in a private lab in 
1882, Metchnikoff wounded transparent starfish using splinters from a tangerine tree 
and observed an accumulation of cells at the site of inflammation, attempting to 
envelope the foreign objects [3]. In doing so, he was the first to recognise that the 
phagocyte has key functions not only in development via the engulfment of 
phagocytic bodies, but also in the defence from invading microbes. Due to this 
striking ‘eating’ behaviour, Metchnikoff hypothesized that these cells could not only 
‘eat’, but also ‘feed’ other cell types due to their high level of motility [3]. While he 
could not have understood the systemic implications of his theory, the concept that 
phagocytes are metabolically active cells forms a cornerstone of the work presented 
here and is a theory as old as the discovery of phagocytes themselves. The impact 
of this work for subsequent research on innate immunity cannot be overstated, for it 
directly contradicted the dogma of the time that immunity was driven by the humoral 
antibody and complement response, for which Paul Ehrlich shared Metchnikoff’s 
Nobel prize [4]. 
 
Despite these initial findings, phagocytes received limited scientific attention when 
compared to adaptive immunity for the following 60 years. The 1920s saw some 
attempts by Ashcroft and colleagues to classify phagocytes and the creation of the 
‘reticuloendothelial system’ (RES), within which modern macrophages and dendritic 
cells were classified together based on histological appearance as ‘histiocytes’ [5]. 
However, understanding of these cells did not progress much further until the work of 
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Zanvil Cohn and James Hirsch in the late 1960s. Following substantial work on 
neutrophil phagocytosis and degranulation, Cohn turned his attention to mouse 
macrophages. Cohn was the first to describe a culture method for the mouse 
peritoneal macrophage [6] and to use phase and electron microscopy to characterize 
the induction of macrophage lysosomes by pinocytic activity and the phagocytosis of 
exogenous particles [7-10]. At the same time, Cohn also described the in vitro 
differentiation of blood monocytes to functional macrophages in a series of seminal 
papers [11], [12]. In later work with his postdoctoral fellow Ralph Steinman, Cohn 
discovered morphologically abnormal phagocytes in the mouse spleen while 
studying the induction of primary antibody responses, which were termed ‘dendritic 
cells’ (DCs) [13]. Using the lack of Fc-receptor expression by DCs, the pair 
developed a method of enriching populations of dendritic cells and macrophages for 
culture, allowing for distinction between the two cell types [14]. Steinman would go 
on to posthumously receive the Nobel Prize for this discovery and a lifetime of 
subsequent work on DCs. Cohn continued to generate seminal work in monocyte 
and macrophage biology until his death in 1993, perhaps most notably observing 
that monocyte transendothelial migration was dependent on endothelial PECAM-1 in 
1989 [15]. 
 
Following publications with contemporaries Cohn and Hirsch, Ralph Van Furth 
proposed a new classification of all cells with high levels of phagocytic activity to 
other experts in the field at the 1969 Conference on Mononuclear Phagocytes in 
Leiden: the ‘mononuclear phagocyte system’ or MPS [16]. Largely eschewing 
morphological criteria, this system of phagocyte classification relied on fundamental 
functional properties in addition to phagocytosis, including adhesion to a glass 
surface and expression of immunoglobulin receptors [16]. A key distinction was 
made in Van Furth’s system between macrophages and the recently discovered 
myeloid dendritic cells, with the latter not deemed phagocytic enough to be classified 
within the MPS [16]. Fundamentally, this is the root of a debate regarding the 
function and ontology of these two cells types which continues today [17]. Crucially, 
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consensus at this time was that all cells in the MPS must originate from the blood 
monocyte, a conclusion that would subsequently be disproven.  
1.1.2. Myelopoeisis	  and	  embryonic	  macrophages	  
The classical model of myelopoeisis is centred on the sequential differentiation of 
precursor cells in the bone marrow and the original definition of the MPS dictated 
that all cells in the system must derive from blood monocytes in a linear fashion. 
Indeed, the primary role of monocytes was seen as a source of ‘immature’ 
macrophages to replenish supplies in peripheral tissues, both during homeostasis 
and inflammation [12]. In the most widely accepted model, monocytes develop from 
haematopoietic stem cells (HSCs) via series of increasingly committed progenitors, 
including the common myeloid progenitor (CMP), the granulocyte/macrophage 
progenitor (GMP), the macrophage/DC progenitor (MDP) and the common monocyte 
progenitor (cMoP) [18-20], although the existence of a bona-fide MDP is subject to 
ongoing debate [21], [20]. Major discoveries in the 1990s by Siamon Gordon and 
others determined that this process is dependent on the growth factor colony 
stimulating factor (CSF)-1 and the transcription factor PU.1 [22,23]. Crucially, the 
recent discovery of cMoP and extensive proteomic analysis has determined that 
monocytes and monocyte-derived macrophages are derived from a distinct 
clonogenic precursor to DCs, thus largely ending the longstanding debate on the 
functional independence of these cell types [17,20].  
 
However, as early as the late 1980s it became apparent that the accepted dogma of 
blood monocytes as obligatory precursors for tissue macrophages during 
homeostasis was incomplete. In the mouse, primitive macrophages appear on the 
ninth day of gestation (E9), prior to the development of the bone marrow [24,25]. 
This led to fate mapping studies to determine the origin of adult tissue macrophage 
populations. In rodents, there are two major waves of embryonic haematopoiesis. At 
around E7, primitive nucleated myeloid cells and erythrocytes are generated in the 
yolk sac, resulting in primitive macrophages appearing in the blood islands of the 
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yolk sac by E9 without the requirement for a monocytic precursor [24,25].  By E10, 
the embryonic circulatory system is fully established [26], and these primitive yolk 
sac macrophages spread throughout the body to seed all tissues [27]. However, in 
all macrophages that have been studied, with the possible exception of the brain 
microglia [27], these cells are subsequently replaced by a second wave of 
haematopoiesis. At E10.5, haematopoietic stem cells (HSCs) are generated in the 
aorta-gonad-mesonephros (AGM) of the embryo, which then spread to the foetal 
liver [28]. Primitive foetal liver monocytes are generated from these HSC precursors 
[28] and from yolk sac- derived erythro-myeloid progenitors (EMPs) at E11.5-12.5 
[29], although the relative contribution of these two sources remains unclear and 
from this point forward the origin of tissue macrophages is still debated. In 2012, 
Schulz et al were the first to demonstrate that this embryonic macrophage seeding 
from the foetal liver was widespread and applicable to the majority of tissues 
including the liver, spleen, lung, pancreas and kidney, although importantly was 
proposed to be independent of the HSC transcription factor Myb [30]. In addition, 
subsequent work demonstrated that these Myb independent tissue-resident 
macrophages are a separate lineage of MPS to bone marrow derived infiltrating 
macrophages, that can self maintain via in-situ proliferation with minimal contribution 
from blood monocytes [31]. However, Ginhoux and colleagues have demonstrated 
that the contribution of Myb independent, yolk sac derived precursors to tissue 
macrophages is minor [27]. As such, while it is clear that the vast majority of tissue 
macrophages are seeded before birth and self-renew in situ, their exact 
developmental origin requires further confirmation. Current understanding of the 
ontogeny of tissue macrophages is summarized in Figure 1.1 and was recently 
reviewed by Varol and colleagues [32].  
 
A notable exception to this process is the homeostasis of intestinal macrophages. 
For many years it was difficult to distinguish between macrophages and dendritic 
cells in the intestinal lamina propria, as gut macrophages have a phenotype that 
overlaps heavily with DCs and both express CD11c and high levels of MHCII [33,34]. 
A key discovery was the expression of CD64 by gut macrophages but not DCs, thus 
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allowing for distinction between these two populations [35]. While resident and pro-
inflammatory macrophages are found in the colon, these cell populations do not 
proliferate in situ and both require continuous replenishment from Ly6Chi blood 
monocytes [36,37]. At present the gut is the only tissue thought to require this 
process during homeostasis. In the case of resident macrophages, infiltrating 
monocytes differentiate through several intermediate stages over 4-5 days to 
generate a mature F4/80hiCD64+MHCII+CD11c+CX3CR1hi resident population, while 
during intestinal inflammation these cells arrest in a CX3CR1low inflammatory state 
during maturation [36]. Currently there is limited understanding of the signals which 
mediate renewal of gut macrophages by blood monocytes. Monocyte recruitment is 
dependent on CCR2, as both CCR2 and CCL2 knockout mice have a substantial 
decrease in the number of macrophages in the intestinal mucosa [38]. However, the 
source of intestinal CCL2 driving recruitment is the subject of ongoing work. There 
have also been suggestions that recruitment is mediated by IL-8 and TGF-β 
produced by epithelial cells and lamina propria mast cells, although these data 
derive only from in vitro studies [37].  
 
It is also clear that the tissue microenvironment is the biggest influence on 
macrophage phenotype and function. Far from the rigid M1/M2, classic vs alternative 
model of macrophage activation, a complex spectrum of stimuli can program 
macrophages in a reversible and dynamic manner [39,40]. Recent comparative 
transcriptional profiling of tissue macrophages from the spleen, liver, lung, 
peritoneum and brain has revealed that these populations are transcriptionally 
distinct in their expression of all gene families that have classically characterized 
macrophage phenotype, including chemokine receptors, Toll-like receptors and 
scavenger receptors, while sharing expression of common surface markers such as 
CD64 and MerTK [41]. Incredibly, the tissue microenvironment of the lung is 
sufficient to program naive macrophages. When fluorescent bone marrow-derived 
macrophages (BMDM) are transplanted into the alveoli in mice, transplanted cells 
can be detected proliferating in the lung of the recipient 1-year after transplant and 
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possess a phenotype that is indistinguishable from host tissue-resident 
macrophages [42].  
 
Of all tissue macrophages, those in the peritoneal cavity are the best defined in the 
context of local signals which define their phenotype. Compared to other tissue 
resident populations, bone marrow-derive macrophages and fetal liver macrophages, 
resident peritoneal macrophages express high levels of the zinc finger transcription 
factor GATA6 [41,43,44]. This expression is induced by the action of retinoic acid on 
macrophages in the ‘milky spots’ of the omentum, which mature and migrate into the 
peritoneal cavity to form a resident population, often termed ‘large peritoneal 
macrophages’ (LPMs). It is important to note that monocyte-derived macrophages 
recruited during peritoneal inflammation are not dependent on retinoic acid and do 
not express GATA6, forming a distinct population of ‘small peritoneal macrophages’ 
(SPMs) [43]. As more work is performed to characterize resident populations the 
specific signals in other tissues will undoubtedly be identified, but at present the 
peritoneum remains the best described.  
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Figure 1.1 Monocyte and macrophage origins during homeostasis.  
Tissue macrophages seed during embryogenesis during two waves of haematopoiesis. At E7.5, 
primitive macrophages appear in the yolk sac and subsequently spread throughout the embryo 
via the blood in a Myb independent process. From E9.5, progenitor cells from the yolk sac and 
AGM appear in the foetal liver and give rise to Myb dependent primitive monocytes, which 
colonize all tissues as macrophages with the possible exception of the brain microglia, 
progressively replacing yolk sac- derived cells. During adulthood, following development of the 
bone marrow, canonical haematopoiesis gives rise to GR1high classical monocytes, which 
constantly replenish intestinal macrophages. In the blood, GR1high monocytes differentiate to a 
GR1low subpopulation, which are not thought to contribute to the macrophage pool in the steady 
state. 
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1.1.3. Blood	  monocyte	  subpopulations	  and	  effector	  functions	  
Far from being inert precursors, it is now known that blood monocytes are a 
heterogeneous, functionally independent population of innate immune effector cells. 
At least two blood monocyte subsets exist in the human, mouse, rat, pig and cow, 
each with independent effector functions [45-49]. In the mouse, two subsets exist 
based on their expression of GR1: GR1high ‘inflammatory’ monocytes and GR1low 
‘patrolling’ monocytes [45]. In humans, these can be characterized based on 
expression of CD16 (FcγRIII) and CD14: ‘classical’ CD14high CD16neg, ‘non-classical’ 
CD14low CD16pos [46] (Figure 1.2). A third ‘intermediate’ CD14high CD16pos subset has 
been postulated to exist in humans, although they are poorly characterized and 
some studies have suggested that they resemble the human ‘non-classical’ CD14low 
CD16pos population based on transcriptional and functional analysis [50,51]. We 
have confirmed these findings in the Woollard lab via hierarchical clustering and 
principal component analysis of published microarray data (data not shown) and 
therefore define our human monocytes as CD16pos and CD16neg for all functional 
work, as previously described [51].  
 
In addition, there is now evidence that classical GR1high monocytes in the mouse are 
obligatory precursors for the GR1low subset, which represent an older, mature 
population [52]. Although the stimuli that trigger this conversion are not known, there 
is evidence that the development of GR1low monocytes is dependent on both Nuclear 
receptor subfamily 4 group A member 1 (NR4A1)[53] and Sphingosine 1-phosphate 
receptor 5 (S1PR5)[54]. In S1pr5-/- animals there is a complete absence of peripheral 
GR1low non-classical monocytes, while the bone marrow remains unaffected [54]. 
The authors hypothesize that S1PR5 may be required for GR1low monocyte egress 
from the bone marrow; although in the context of newer date on peripheral monocyte 
conversion this seems unlikely. It is possible that S1PR5 controls GR1low monocyte 
half-life and clearance from circulation rather than affecting conversion and this 
possibility requires further investigation.  Interestingly, NR4A1 deletion affects both of 
these compartments, with the few remaining GR1low monocytes in the bone marrow 
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exhibiting cell cycle arrest and apoptosis [53]. If this data is extrapolated to humans 
and the continuum of CD14/CD16 expression, any definition of subpopulations is 
arbitrary due to continuous inter-conversion.  
 
However, while they clearly possess considerable plasticity, these subpopulations 
have been shown to be functionally distinct in response to a range of stimuli.  Based 
on gene expression, CD14high CD16neg human monocytes resemble the GR1high 
murine subset and also share similarities in their functional response, whereas 
GR1low monocytes are the functional homologues of the human CD14low CD16pos 
subset [46]  [50,51]. Both CD14high CD16neg and GR1high subsets display a potent 
cytokine and chemokine response to LPS stimulation in vitro, producing high levels 
of reactive oxygen species (ROS), IL-8, IL-6, IL-10, RANTES and CCL-2, whereas 
the GR1low/ CD14low non-classical monocyte LPS response is minimal and 
characterized by TNF-α production [46,51]. In contrast, GR1low/ CD14low monocytes 
respond to viruses, nucleic acids and immune complexes, producing IL-1β, TNF-α 
and CCL3 via a TLR7/TLR8- MEK pathway, while the CD14high CD16neg  response to 
viral stimuli is characterized almost exclusively by IL-8 production [46]. In addition, 
human CD14high monocytes display high phagocytic activity regardless of CD16 
expression, whereas CD14low CD16pos monocytes are poor phagocytes [46].  
 
In vivo, functional heterogeneity is also becoming clearer in both homeostasis and 
inflammation. Most obviously, non-classical CD16pos/ GR1low monocytes are unique 
in their ability to patrol the vasculature in the steady state. Whereas leukocyte rolling 
on the endothelium is transient and at a velocity of approximately 40µm/second [55], 
‘patrolling’ monocytes crawl 100-1000 fold slower, independent of the direction of 
blood flow and do not extravasate without inflammatory stimuli [46] [56]. This 
behaviour requires firm adhesion to the vascular endothelium and is mediated by 
high expression of the chemokine receptor CX3CR1 and the Β2-integrin LFA-1, 
whereas CD16neg/ GR1high monocyte rolling and capture is mediated by the well-
characterized classical adhesion cascade [56]. Currently, GR1low monocyte patrolling 
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has been visualized in small blood vessels in the vascular beds of the dermis, 
mesentery and cremaster, although preliminary observations from our lab also 
suggests that this behaviour occurs in larger vessels, including the aorta (Woollard, 
K. Unpublished data). In the kidney cortex, these patrolling cells monitor for virally 
infected or necrotic endothelium, simultaneously clearing cellular debris and 
recruiting neutrophils during vascular inflammation [57]. As expected from in vitro 
data, during a range of viral infections including hepatitis B and dengue virus 
CD16pos patrolling monocytes produce a dramatically more pronounced inflammatory 
response than their CD16neg counterparts [58,59]. In contrast, it has long been 
appreciated that CCR2 mediated recruitment of GR1high murine monocytes is 
essential for the control of bacterial infection in the mouse, most markedly in the 
response to intracellular pathogens such as Listeria monocytogenes [60] and 
Mycobacterium tuberculosis [61], although corresponding functional data is yet to be 
gathered in humans. Strikingly, GR1high monocytes are able enter and survey 
peripheral tissues under homeostatic conditions, traffic to the lymph nodes and 
present antigen without differentiating to macrophages or DCs [62].  
In conjunction with the new appreciation of embryonic tissue macrophages described 
above, these data re-enforce a revised paradigm of monocytes, macrophages and 
DCs as functionally independent populations. 
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Figure 1.2 Gating strategies for monocyte subset identification in the human and 
mouse.  
Monocytes were gated in a population of whole blood leukocytes using flow cytometry. In the 
mouse (A), at least two monocyte subsets can be identified from CD11b+ CD115+ leukocytes 
based on their expression of GR1/ Ly6C. In humans (B) at least two subsets are can be defined 
from CD16 and CD14 expression patterns, from a population of HLA-DR+, Lineage- (CD2-, 
CD19-, CD15-, CD56-) cells. Adapted from [63]. 
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1.2. Lipid	  metabolism	  and	  lipoproteins	  
1.2.1. Homeostasis	  
Blood lipoproteins act as transport vehicles for cholesterol and triacylglycerol are 
among the most abundant components of the human plasma proteome [64]. They 
are therefore in constant contact with blood monocytes and may impact on monocyte 
function, yet little work has been performed to investigate this hypothesis. 
Fundamentally, cholesterol is a Janus molecule: under homeostatic conditions, the 
delivery of circulating cholesterol to all cells is essential for the maintenance of cell 
membrane fluidity and as a precursor in a range of biosynthetic pathways (e.g. 
steroid hormones), while inappropriate cholesterol accumulation can be lethal. At the 
core of this issue is the insolubility of cholesterol in water, necessitating a 
mechanism of plasma cholesterol transport which was elegantly delineated in the 
Nobel Prize winning work of Brown and Goldstein [65]. In eukaryotes this 
mechanism is heavily conserved and involves the packaging of cholesterol and 
triacylglycerol into lipoprotein molecules with a core of neutral lipids and cholesterol 
esters surrounded by a hydrophobic surface monolayer of phospholipids and non-
esterified cholesterol, stabilized by a protein [65], [66]. The five major classes of 
lipoproteins, in order of increasing density are chylomicrons, very low density 
lipoprotein (VLDL), low density lipoprotein (LDL), intermediate density lipoprotein 
(IDL) and high density lipoprotein (HDL) [65]. 
 
Lipoprotein metabolism is exceedingly complex and has been reviewed extensively 
elsewhere [65,67], but an overview will be provided here and summarised in Figure 
1.3. Fundamentally, the process can be split into three distinct yet interconnected 
stages: (1) the packaging and transport of dietary lipid, (2) the hepatic metabolism of 
endogenous lipid and (3) reverse cholesterol transport from peripheral tissues. 
Following dietary intake, lipid is packaged into chylomicrons with apolipoprotein B 
(apoB) by intestinal enterocytes and secreted into the blood. The triacylglycerol in 
the chylomicrons is hydrolysed in the blood by free lipoprotein lipase (LPL) to form 
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chylomicron remnants, which are scavenged by the liver via LDL-like receptor 
protein (LRP).  It is at this stage that dietary lipid enters the cycle of endogenous lipid 
metabolism. Triglyceride- rich VLDL particles are synthesized from the chylomicron 
remnants and secreted into the blood. In the blood these VLDL particles also 
undergo hydrolysis by LPL to produce free fatty acids, glycerol and the smaller 
lipoprotein species IDL. LPL is also highly expressed by highly metabolically active 
tissues with a large requirement for free-fatty acids (FFAs), such as the heart and 
skeletal muscle [68]. At this stage, a proportion of the IDL is removed from circulation 
by the liver via the LDL receptor (LDLR), while the remainder is hydrolysed again by 
hepatic lipase to generate LDL. In the steady state it is the subsequent 
internalization of LDL via binding of apolipoprotein B-100 (apoB-100) to the LDLR 
that is thought to deliver the necessary cholesterol to all peripheral tissues.  
 
Following cholesterol internalization and utilization, the reverse cholesterol transport 
(RCT) pathway efficiently effluxes cholesterol from peripheral tissues to circulating 
HDL to be metabolized by the liver. The mechanisms by which this occurs are still 
not fully elucidated, but considerable progress has been made in the field. In brief, 
ApoA1 is synthesized by the liver and interacts with serum phospholipids to form 
nascent discoidal HDL (ndHDL). ndHDL initially binds cholesteryl esters which have 
already been externalized to the extracellular space by ATP-binding membrane 
cassette protein A1 (ABCA1) [69]. These larger, mature HDL molecules can then 
directly induce cholesterol efflux from the plasma membrane via scavenger-receptor 
B1 (SR-B1) and/or ABCG1 binding [70]. HDL-cholesterol then drains from peripheral 
tissues through the lymphatic vessels to the plasma [71]. Upon reaching the liver, the 
selective uptake of cholesteryl esters from mature HDL is mediated largely by SR-
B1, which in mice has been shown to be responsible for up to 90% of cholesterol 
removal from HDL, ultimately leading to fecal excretion of excess cholesterol [72].  
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Figure 1.3: An overview of lipoprotein metabolism.  
Dietary fat is absorbed by enterocytes in the intestine and packaged into chylomicrons, which are 
secreted into the blood. Highly metabolically active tissues such as skeletal muscle hydrolyse 
chylomicrons via LPL and the liver takes up the chylomicron remnants. The liver synthesizes 
VLDL, which undergoes hydrolysis to LDL in the blood. LDL delivers cholesterol to peripheral 
tissues via the LDLR and excess cholesterol is exported to HDL via SR-BI, ABCA1 and ABCG1. 
The cholesterol in HDL is transported to the liver via SR-B1 and transferred to LDL/ VLDL via 
cholesterol ester transfer protein (CETP).   
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1.2.2. 	  Dyslipidaemia	  	  
1.2.2.1. Monogenic	  Hypercholesterolemia	  
There are several monogenic genetic diseases that affect lipid metabolism and lead 
to severely disruption of one or several of the blood lipoprotein fractions. Of these, 
familial hypercholesterolemia (FH) is the best characterized. FH is dominantly 
inherited monogenic genetic disorder affecting LDL uptake and metabolism and was 
the first genetic disease of lipid metabolism to be clinically characterized [73].  While 
the clinical presentation of FH in the population is high at around 1:200-500, 
homozygous FH is much more rare at around 1: 1 million, although accurate 
estimates of prevalence are confounded by low rates of diagnosis and treatment 
[74]. FH is characterized by a severe elevation of plasma LDL levels, which presents 
clinically as cutaneous xanthomas and premature cardiovascular disease. In 
homozygotes, untreated individuals rarely survive past the age of 20, while 
heterozygotes often develop severe atherosclerotic plaques before the third decade 
of life [75].  True FH is caused by mutations in the LDLR gene itself, although over 
1000 causative mutations in the LDLR have been described [75]. Within the 
homozygote population the severity of the disease can therefore be further 
characterized based on the degree of loss of LDLR function in their skin fibroblasts: 
those with less than 2% normal LDLR activity are classed as LDLR negative and 
have the worst prognosis, while those with 2-25% activity are receptor-defective 
[73,76].  
 
Among other forms of monogenic hypercholesterolemia, mutations in the LDL 
protein apoB-100 are the most clinically similar to bona-fide FH. In these cases, a 
mutation in the LDLR-binding domain of apoB-100 results in a failure to clear LDL 
from the plasma, thus resulting in a similar but slightly less severe 
hypercholesterolemia than FH patients [77]. Among Europeans prevalence is around 
1:1000 and a molecular distinction is often not established between true FH and 
apoB-100 mutants [74]. Mutations in the proteinase PCSK9 can also cause a similar 
clinical phenotype, although the mechanisms are still not entirely understood [78]. 
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In addition to mutations affecting LDL uptake, there are also some individuals with 
monogenic disorders resulting in extreme elevation of plasma triacylglycerol and 
triacylglycerol-rich lipoproteins (TGRL) such as chylomicrons and VLDL. These 
include LPL deficiency and lysosomal acid lipase (LAL) deficiency, both of which are 
rare with prevalence estimated at 1:1 million and 25: 1 million respectively [79,80]. 
Due to the rare nature of these disorders, very little is understood about the impact of 
such high TGRL levels on the function of the innate immune system. 
1.2.2.2. Dyslipidaemia	  of	  obesity	  and	  high	  fat	  diet	  
Obesity is a worldwide epidemic that, in contrast to FH, leads to a dyslipidaemia 
driven predominantly by elevated TGRLs, free fatty acids (FFAs) and low levels of 
HDL, in both the fasting and post-prandial state [81]. Obesity is often accompanied 
by metabolic syndrome, characterized by insulin insensitivity and a chronic 
peripheral inflammation driven by macrophages and adipocytes [82]. The major 
contribution of obesity to dyslipidaemia is an inhibition of both LPL expression and 
activity in skeletal muscle[83] and adipose tissue [84] through poorly defined 
mechanisms. Ultimately, this leads to impaired FFA and TGRL clearance from the 
plasma accompanied by an increase in the density of plasma LDL [85].  While TGRL 
elevation is now implicated in atherosclerosis and will be discussed below, FFAs can 
be directly cytotoxic and induce a pronounced inflammatory response. In particular, 
these is strong evidence that saturated fatty acids (SFAs), such as the predominant 
dietary FA palmitic acid [86], can stimulate nuclear factor kappaB (NFκB) activation 
and subsequent inflammatory cytokine production, including TNF-α and IL-6 [87]. In 
some instances, this is due to direct binding of SFAs to TLR4 due to a structural 
similarity between SFAs and the lipid A moiety of bacterial lipopolysaccharide (LPS) 
[88,89]. However, despite this wealth of evidence of a tissue inflammatory response 
to obesity and metabolic syndrome, limited research has been performed on blood 
monocytes that are constantly bathed in a dynamic pool of TGRLs and FFAs.  
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1.3. The	  MPS	  and	  atherosclerosis	  
1.3.1. 	  The	  ‘response	  to	  retention’	  hypothesis	  of	  atherogenesis	  
It is not possible to discuss dyslipidaemia and the MPS without touching upon 
atherosclerosis and cardiovascular disease (CVD), the leading cause of death 
among developed nations [90]. Traditionally, atherosclerosis has been thought of as 
a chronic, inflammatory disorder characterised by the expansion of the arterial intima 
over a number of decades. Although scientific opinion in the 1980s, driven by 
Russell Ross and others, was that early atherogenesis was driven by injury to the 
vascular endothelium [91], the most widely accepted hypothesis is now the 
‘response to retention’ hypothesis, elegantly outlined by Ira Tabas [92]. Since 
elevated plasma LDL has long been established as the one of the strongest risk 
factors for atherosclerosis [93], ‘response to retention’ postulates that the key event 
in atherogenesis is the deposition of apoB-containing lipoproteins (i.e. LDL and 
VLDL) in the arterial intima. It is important to note in this context that atherosclerotic 
lesions occur predominantly at vascular bifurcations and branch points, where 
alterations in blood rheology such as oscillatory shear stress can alter vascular 
function; increasing LDL uptake by endothelial cells and increasing vascular 
permeability [94,95]. In addition, oscillatory or low shear stress environments can 
activate the endothelium to increase expression of surface adhesion molecules 
including ICAM-1, VCAM-1 and E-Selectin [96,97]. 
 
Endothelial activation at these sites is perpetuated further by the subendothelial 
deposition of LDL, which can become oxidized once trapped in the vessel intima. 
Oxidized LDL can then stimulate up-regulation of surface P-Selectin, ICAM-1 and 
VCAM-1 on endothelial cells, both in the steady state and after TNF-α treatment 
[98,99], which are all ligands for integrins on circulating monocytes. VCAM-1 
expression is strongly localized to atherosclerotic lesion sites and blockade of 
VCAM-1 using a monoclonal antibody significantly decreases atherosclerosis 
severity in mouse models [100,101]. Concurrently, activated endothelial and smooth 
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muscle cells can secrete chemokines that lead to the recruitment of blood 
monocytes. Mostly notably, endothelial cells produce CCL2 and IL-8 in response to 
modified LDL [102,103], while platelets can be induced to produce CCL5 that is 
deposited on the activated endothelium [104]. In vitro perfusion assays have 
subsequently demonstrated that CCL2 and IL-8 alone are sufficient to trigger firm 
adhesion of monocytes on vascular endothelium [105]. On classical GR1high 
monocytes CCR1 and CCR5 are now thought to be the key chemokine receptors 
mediating recruitment to the plaque. Ccr1-/- and Ccr5-/- monocytes display 
significantly impaired infiltration of the plaque following adoptive transfer into 
atherosclerotic Apoe-/- recipients [106]. It has previously been suggested that CCR2 
also mediates monocyte recruitment, as Ccr2-/- mice have decreased lesion 
formation [107]. However, adoptively transferred Ccr2-/- monocytes do not have a 
recruitment defect and these data can be explained by a requirement of CCR2 for 
monocyte egress from the bone marrow [60,106,108].  For non- classical monocytes 
GR1low monocytes there is less consensus in the literature. While there is some 
suggestion that these cells do make a minimal contribution to the plaque via CCR5 
[109], the majority of evidence in mouse models is that GR1low monocytes do not 
directly contribute to disease progression in atherosclerosis [106,110]. NR4A1 
deletion at either a whole organism or bone marrow level, which prevents the 
development of blood GR1low monocytes, either increases[111,112] or does not 
affect[113] atherosclerosis in mice. This would indicate that the recruitment of GR1low 
monocytes does not play a major part in the progression of the plaque, with the 
worsening in atherosclerosis proposed to be via increased M1 inflammatory 
macrophage polarization [111]. 
 
Interestingly, there is also considerable evidence that activated platelets facilitate 
monocyte recruitment to the atherosclerotic plaque [104,114,115]. In the Apoe-/- 
mouse, intravital microscopy has revealed that acute blockade of platelet membrane 
glycoproteins GPIbα and GPIIb-IIIa reduces platelet adhesion to the endothelium of 
the common carotid artery [114]. When performed chronically over 12 weeks, this 
blockade of platelet adhesion attenuates atherosclerosis severity and decreases 
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leukocyte recruitment to the vascular wall [114], thus implicating platelets in 
leukocyte recruitment during dyslipidaemia. While mechanistic data on this 
phenomenon is incomplete, the chemokines CXCL4 and CCL5 derived from 
activated platelets have been implicated in the process by increasing leukocyte 
binding to endothelial VCAM-1 [115]. In addition to effects on leukocytes, platelet-
derived CCL5 can become immobilized on the inflamed vascular endothelium via an 
undefined binding site to trigger monocyte arrest [104].  In an in vitro co-culture 
system, Rainger and colleagues have demonstrated that platelets can form adhesive 
bridges between monocytes and TGF-β activated endothelial cells, with monocytes 
bound to platelet P-selectin becoming activated by endothelial CCL2 [116].  As such, 
platelets may be an under appreciated therapeutic target during early atherogenesis. 
1.3.2. 	  Macrophage	  proliferation	  in	  the	  plaque	  
In Tabas’ original ‘response to retention’ hypothesis, the recruitment of monocytes by 
the activated vascular endothelium as outlined above was presumed to be 
necessary and sufficient to drive the development of early atherosclerosis. Until very 
recently, strong evidence supported this hypothesis almost to the point of certainty. 
Hypercholesterolemia causes a pronounced monocytosis of GR1high monocytes via 
APOE feedback to progenitors in the bone marrow [110,117]. In turn, fate mapping 
experiments can track these blood monocytes into the vessel wall during 
atherosclerosis and this recruitment seems to be proportional to the extent of 
disease even in the mature atheroma [110,118]. By inhibiting CCL2, CX3CR1 and 
CCR5 this monocytosis can be abrogated and development of atherosclerosis 
reduced by around 90% [119]. However, the discovery that the majority of tissue 
macrophage populations are self-maintained by local proliferation has led to new 
perspectives on the MPS in atherosclerosis. In work that has contradicted decades 
of research, Robbins et al used the Apoe-/- mouse to demonstrate that >90% of 
macrophages in the atherosclerotic plaque proliferate in situ after 8 weeks of HFD 
[120]. More strikingly, chimerism experiments using parabiosis demonstrated that 
while at 4 weeks HFD >70% of aortic macrophages are derived from monocyte 
recruitment, by 8 weeks this number has dropped to less that 5%, with >95% of 
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macrophages derived from local proliferation [120]. As such, these data suggest any 
chemokine-axis inhibition aimed at ameliorating atherosclerosis progression will only 
be effective if administered at the very earliest stages of atherogenesis.  There is 
some contrary evidence that inhibition of monocyte chemokine receptors during 
established atherosclerosis and atherosclerotic plaque regression also decreases 
plaque macrophage content [121]. However these experiments were fairly crude and 
utilised pertussis toxin to inhibit all G protein-coupled receptors, thus the results must 
be interpreted with caution. At present, the essential role of macrophage proliferation 
in the plaque proposed by Robbins et al is supported by convincing data but awaits 
confirmation from others in the field.  
1.4. Aims	  	  
While atherosclerosis is the predominant focus in dyslipidaemia research, the impact 
of dyslipidaemia on other aspects of the innate immunity remains enigmatic.  Given 
the ever-increasing appreciation of monocyte heterogeneity and macrophage 
independence to blood monocytes, the fundamental aim of this thesis was to 
characterize the functional response of blood monocyte subpopulations to 
dyslipidaemia, defined as elevated proportions of plasma VLDL and LDL. This aim 
centres around three key hypotheses to be investigated: 
1.  Blood monocytes interact with plasma lipoproteins in circulation and at 
the endothelial interface. 
2. Dyslipidaemia results in an accumulation of intracellular lipid in blood 
monocyte subpopulations. 
3.  Monocyte intracellular lipid accumulation affects their function as 
immune effector cells in a subset- specific manner. 
To investigate these hypotheses I planned to utilise a mix of in vitro and in vivo 
analysis, examining mouse monocytes in the hypercholesterolemic Ldlr-/- model and 
human monocytes after incubation with atherogenic lipoproteins.  
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2. 	  METHODS	  
 
2.1. Mice	  
Adult male and female mice on a C57Bl/6 background were used for all animal 
experiments. C57Bl/6 mice were purchased from Charles River. C57Bl/6.LDLR-
deficient mice (Ldlr–/–) and B6.129P-Cx3cr1tm1Litt/J (Cx3cr1gfp/gfp) were purchased 
from Jackson Laboratory (Bar Harbor, USA). Ldlr-/- mice were maintained as 
homozygotes for breeding and experiments. Cx3cr1gfp/gfp were kept as homozygotes 
for breeding and male Cx3cr1gfp/gfp animals were crossed with female C57Bl/6 mice 
to generate Cx3cr1gfp/+ heterozygotes for experiments. All animals were housed in 
individually ventilated cages and handled in accordance with institutional guidelines 
and procedures approved by the UK Home Office.  Mice were maintained on a high 
fat (HFD) or standard chow diet for 6-16 weeks, as specified in individual 
experiments. High fat diet contained 15% cocoa butter and 1% corn oil, resulting in a 
total fat and cholesterol content of 16% and 0.25% respectively (Arie Blok Animal 
Nutrition).  
 
2.2. Monocyte	  purification	  and	  flow	  cytometry	  
Human peripheral blood from healthy volunteers was collected by venepuncture into 
ethylenediaminetetraacetic acid (EDTA) coated vacutainers after informed consent 
with ethical approval: REC reference 14/LO0662 (NRES Committee London). 
Human peripheral blood mononuclear cells (PBMCs) were isolated by density 
centrifugation using Lymphoprep (Stem Cell) according to manufacturer instructions. 
Total monocytes were obtained by magnetic depletion of lineage positive leukocytes 
with the Monocyte Isolation Kit II. The manufacturer recommends centrifugation at 
200xg in order to remove platelets at this stage.  However, in our hands this still 
resulted in considerable platelet contamination, therefore 20µl of an anti-CD61-Biotin 
antibody (Miltenyi) was added to the depletion antibody cocktail to eliminate platelet 
contamination (Figure 2.1). Monocytes were separated into CD16pos and CD16neg 
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populations by magnetic positive selection using anti-CD16 MicroBeads (Miltenyi).  
Population purity was confirmed by flow cytometry, as shown in Figure 2.2. average 
purity for total monocytes was >90%. N.B: Figure 2.2C does not represent true levels 
of monocyte CD16 expression, as positive selection using anti-CD16 MicroBeads 
partially blocks subsequent anti-CD16 antibody binding. See Figure 1.2 for realistic 
CD16 levels.  
 
Figure 2.1 Elimination of platelet contamination from monocytes using anti-CD61. 
Human monocytes isolated from PBMCs using (A) Monocyte Isolation Kit II as per manufacturer 
instructions or (B) Monocyte Isolation Kit II with an anti-CD61-Biotin antibody added to the 
negative depletion cocktail. Cells were allowed to adhere to tissue-culture plastic and stained 
using fluorescent phalloidin (green) and DAPI (blue) and imaged on a Zeiss AxioObserver 
fluorescence widefield microscope. Scale bar represents 50µm. 
  
The	  Effects	  of	  Atherogenic	  Dyslipidaemia	  on	  Blood	  Monocyte	  Function	  William	  Jackson	  -­‐	  January	  2016	  
44	   Methods	  
 
 
Figure 2.2 Confirmation of monocyte purity after MACS isolation. 
Human monocytes were isolated from PBMCs using magnetic depletion of lymphocyte 
populations with the Monocyte Isolation Kit II (Miltenyi). A flow cytometry scatter plot of lineage 
(CD2, CD56, NKp46, CD19) versus HLA-DR expression is shown for (A) PBMCs prior to 
magnetic isolation and (B) monocytes after magnetic isolation. Total monocytes were separated 
into CD16pos and CD16neg populations by magnetic positive selection using anti-CD16 
MicroBeads (Miltenyi). (C) CD16 surface expression in the CD16neg and CD16pos fractions 
compared to isotype control antibody. 
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In some experiments, whole leukocytes were isolated by red blood cell lysis from 
human peripheral blood using a hypotonic lysis buffer (dH2O, NH4Cl, NaHCCO3, 
EDTA) and monocyte subpopulations were analyzed by flow cytometry. Monocytes 
were defined as SSCint HLA-DRpos CD2neg CD56neg NKp46neg and subpopulations 
were gated based on expression of CD14 and CD16 (Figure 1.2).  Levels of surface 
protein expression were assessed by flow cytometry median fluorescence intensity. 
 
Mouse monocytes were phenotyped from peripheral blood samples obtained by tail 
vein venipuncture or purified from samples obtained by cardiac puncture under 
terminal anesthesia. Peripheral blood mononuclear cells (PBMCs) were isolated by 
density centrifugation using Lymphoprep (Stem Cell) as above and monocyte 
subpopulations were obtained by FACS according to the gating strategy in Figure 
1.2, Surface protein expression was assessed by flow cytometry. All antibodies used 
in FACS are listed in Table 2-1. 
 
Table 2-1 Antibodies used for flow cytometry, immunofluorescence and Western 
blotting.  
Antigen Target Species Clone Manufacturer 
CD14 Human M5E2 BD Biosciences 
CD16 Human 3G8 BD Biosciences 
HLA-DR Human TU36 BD Biosciences 
CD11c Human 3.9 Biolegend 
CD61 Human Y2/51 Miltenyi 
CD88 Human S5/1 Biolegend 
CD2 Human RPA-2.10 BD Biosciences 
CD56 Human MY31 BD Biosciences 
NKp46 Human 9E2 BD Biosciences 
LPL Human 5D2 AbD Serotech 
pPAK1/2 Human Polyclonal Novus Biologicals 
P38 Human C-20 Santa Cruz Biotech 
pMLC (Ser19) Human N/A Cell Signaling Technology 
CD115 Mouse AF598 eBioscience 
CD11b Mouse M1/70 BD Bioscience 
F4/80 Mouse BM8 BD Bioscience 
CD45 Mouse 30-F11 eBioscience 
GR1 Mouse RB6-8C5 BD Bioscience 
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2.3. Monocyte	  LDL/	  VLDL	  uptake	  and	  lipid	  
quantification	  
2.3.1. 	  DIO-­‐	  LDL	  and	  DIO-­‐	  VLDL	  uptake	  
Human peripheral blood leukocytes were incubated with 100µg/ml Low-density 
lipoprotein (LDL) labelled with 3,3'-Dioctadecyloxacarbocyanine Perchlorate (DIO) or 
Very low-density lipoprotein (VLDL)-DIO (Biomedical Technologies, Inc.) for 
indicated time points. Cells were washed with PBS and stained for flow cytometry 
with anti- HLA-DR, CD14, CD16, CD2, CD56 and NKp46. Monocytes were gated as 
described (Figure 1.2) and percentage of cells LDL/ VLDL positive was determined 
based on fluorescence-minus-one (FMO) control samples containing no DIO. Data 
was acquired on a BD LSR-II analyser. In some experiments, intracellular 
localization of LDL-DIO or VLDL-DIO was confirmed by acquiring cells on an Amnis 
ImageStream X Mark II using 40x magnification. Fluorescence excitation was 
achieved with a 125 mW 405nm laser, a variable power solid state 488 nm laser and 
a 120 mW 658 nm laser and images were collected on a six-channel charge- 
coupled device (CCD) camera. Data was analysed in Ideas software (Amnis). 
2.3.2. 	  Neutral	  lipid	  staining	  
CD16pos/ CD16neg human monocytes were treated with 100µg/ml LDL or VLDL for 
the indicated time points at 37°C. Cells were seeded (1.5x106/ml) into tissue-culture 
treated 0.4µm chamber slides (IBIDI) in Dulbecco's Modified Eagle's Medium 
(DMEM) and allowed to adhere for 30 minutes. Adherent cells were immediately 
fixed in 4% paraformaldehyde (PFA) for 15 minutes and washed with 0.1M glycine. 
For neutral lipid staining, LipidTox-Green (Life Technologies) was diluted 1/200 in 
phosphate buffered saline (PBS). Cells were mounted in 4',6-diamidino-2-
phenylindole (DAPI)-Vectashield (Vector Labs) and imaged using either a Zeiss 
AxioObserver widefield or a Leica SP5 confocal microscope with a 63x/1.4 objective. 
Images were analysed using Imaris software (Bitplane) or ImageJ, as indicated.  
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2.3.3. Membrane	  cholesterol	  staining	  
Cells were processed as for neutral lipid staining above, but stained for unesterified 
cholesterol with 0.05 mg/ml filipin (Sigma) in PBS for 2 hours and imaged on a Leica 
SP5 confocal microscope with a 63x/1.4 objective. Images were analysed using 
Imaris software (Bitplane). 
 
2.4. Peritonitis	  model	  
Ldlr-/- mice were maintained on HFD or chow for 16 weeks. To induce peritonitis, 
mice were injected intraperitoneally (IP) with either 1ml sterile 4% thioglycollate 
medium or 10µg lipopolysaccharide (LPS) in 100µl sterile saline, serotype 055:B5 
(Sigma Aldrich). After 72 hours, mice were culled by exposure to rising concentration 
of CO2 and the peritoneal cavity was lavaged with 10ml ice-cold PBS. Cells were 
counted on a hemocytometer and washed in PBS. Approximately 3 x 105 cells were 
stored in Tri-Reagent (Sigma Aldrich) for RNA extraction, the remainder were 
stained in PBS-0.5% bovine serum albumin (BSA) for flow cytometric analysis in a 
saturating concentration of anti-CD16/32 (2.4G2) using combinations of the following 
antibodies: anti-CD115 (AF598), anti-CD45 (30-F11) (eBioscience), anti-CD11b 
(M1/70), anti-GR1 (RB6-8C5) anti-F4/80 (BM8) (BD Biosciences). Monocytes were 
defined as CD115pos CD11bpos SSCint (Figure 3.4). 
 
In some experiments, omental tissue was harvested by blunt dissection into Hank's 
Buffered Salt Solution (HBSS) and the weight recorded. Tissue was washed and 
digested using Liver Digestion Media (Gibco) for 15 minutes at 37oC.  After washing 
to obtain a single-cell suspension, cells were counted and stained for flow cytometry 
as detailed above.  
 
To track monocyte migration from the blood into the peritoneum, mice were injected 
IV with 100µl 1µm red-fluorescent latex beads at a concentration of 1 x 1010/ml 
(Invitrogen). The beads are manufactured from ultraclean, high-quality polystyrene 
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and were stored without sodium azide preservative to avoid adverse effects in vivo. 
Beads were injected 4 hours prior to IP thioglycollate injection and the peritoneal 
lavage was collected at 72 hours for flow cytometry as detailed above. 
 
2.5. Intravital	  imaging	  
Cx3cr1gfp/+ mice were fed chow or HFD for 6 weeks and were 10-12 weeks of age 
when used for imaging. Blood lipid profiles were generated by automated analysis 
using an Abbott Architect ci8200 (Abbott Diagnostics). Intravital imaging of the ear 
dermis was performed as previously described [1]. Briefly, mice were anesthetized 
using a cocktail of fentanyl/fluanisone and midazolam injected intraperitoneally and 
were maintained at 37°C with oxygen supplementation. The ear to be imaged was 
taped to the center of the coverslip and 80µL of tetramethylrhodamine (TRITC) 
conjugated 70kDa dextran (70µM) was injected intravenously. Light was generated 
from 488-nm and 562-nm lasers, and emitted light signal was detected to generate 
two colour 8-bit images, using a 10x/0.4 objective on a Leica SP5 confocal 
microscope. Images were analysed using Imaris software (Bitplane). Briefly, dextran 
signal was used to select only intravascular cells for tracking and cells were 
automatically selected based on the quality and intensity of their GFP signal. Cells 
were tracked using the inbuilt autoregressive model based algorithm and tracks were 
manually verified for accuracy. In order to analyse intravascular patrolling, cells that 
were present for less than 240 seconds were excluded. 
 
 
2.6. Quantifying	  LDL/VLDL	  modification	  
Human LDL or VLDL were purchased from Biomedical Technologies, Inc. Vials were 
opened upon receipt and left for approximately 1 week at 4oC before use. Lipid 
modification was measured via the absorbance of conjugated dienes at 234nm as 
previously described [2] using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific). 
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2.7. 	  Blocking	  LDL/	  VLDL	  uptake	  
 In some experiments, LDL or VLDL uptake mechanism was investigated using 
receptor-blocking strategies prior to incubation of human monocytes with LDL/ VLDL. 
The appropriate kinetics and concentrations of the blocking agents varies, therefore 
these are detailed in Table 2-2 below. 
Table 2-2 Receptor blocking strategies for LDL/ VLDL uptake 
Blocking agent Manufacturer Target Time Concentration 
RAP Enzo Life Sciences LDLR family 60 minutes 1.25µM 
Anti- CD36 (SMO) Novus Biologicals CD36 60 minutes 10µg/ml 
Dextran sulphate Sigma 
Class A 
Scavenger 
Receptors 
60 minutes 100µg/ml 
Heparinase 1/3 Sigma 
Heparan 
sulphate 
proteoglycans 
60 minutes 5UN/ml 
Tetrahydrolipstatin 
(Orlistat) Sigma Lipases 60 minutes 50µM 
 
2.8. LPL	  Immunofluorescence	  
Human CD16pos and CD16neg primary monocytes were were seeded (1.5x106/ml) 
into tissue-culture treated 0.4µm chamber slides (IBIDI) in DMEM and allowed to 
adhere for 30 minutes. Adherent cells were immediately fixed in 4% PFA for 15 
minutes and washed with 0.1M glycine. Cells were permeabilzed with Triton X-100 
and actin was stained using fluorescently conjugated phalloidin (Life Technologies). 
Lipoprotein lipase (LPL) was stained using a biotin-conjugated anti-LPL primary 
antibody (1/50, AbD Serotech) and a streptavidin-conjugated, PE-labelled secondary 
antibody (1/500, Biolegend). Cells were mounted in DAPI-Vectashield (Vector Labs) 
and imaged using either a Zeiss AxioObserver widefield or a Leica SP5 confocal 
microscope with a 63x/1.4 objective. 
 
2.9. Apoptosis	  
Purified human peripheral blood mononuclear cells were incubated at 5 x 106/ml in 
DMEM for 2 hours at 37oC with or without 100µg/ml LDL or VLDL (Biomedical 
Technologies, Inc). Cells were washed and stained for apoptosis using an anti-
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Annexin V antibody at a concentration of 1/20 according to manufacturer instructions 
(eBioscience). Cells were washed again and stained for flow cytometry using anti- 
HLA-DR (TU36), anti- CD16 (3G8) and anti- CD14 (M5E2). 
 
2.10. qPCR	  and	  microarray	  analysis	  
Following individual experimental treatments, RNA was extracted from cells by acid 
guanidinium thiocyanate-phenol-chloroform extraction using Tri-Reagent (Sigma 
Aldrich). cDNA was synthesized by reverse transcription with SuperScript III Reverse 
Transcriptase (Life Technologies). The qPCR reaction was performed on an 
Eppendorf Mastercycler Ep system using Sensimix SYBR (Bioline). Input cDNA was 
quantified using a standard curve generated with serial dilutions of pooled samples 
and normalized to the mean values of housekeeping GAPDH and 18s-rRNA (mouse) 
or GAPDH and RPLP0 (human). All primers were ordered as custom 
oligonucleotides from Sigma Aldrich and are listed below Table 2-3 (mouse) and 
Table 2-4 (human), with the exception of human CDC42, RAC1 and RPLP0, which 
were Quantitech pre-validated (Qiagen). 
 
2.11. Statistics	  
Comparison between two groups was performed using a two-tailed Mann–Whitney U 
test to avoid assumptions of parametric distribution. Multiple (<2) independent 
groups were analysed using a mixed ANOVA with a post-test following the 
Bonferroni method. P<0.05 was considered significantly different. Throughout, p 
values are represented as follows: p<0.05: *, p<0.01: **, p<0.001: ***. 
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Table 2-3 Mouse RT-qPCR primer sequences 
 
Target Forward Reverse 
Il1b CAACCAACAAGTGATATTCTCC GATCCACACTCTCCAGCTGCA 
Tnf CATCTTCTCAAAATTCGAGTGACAA  TGGGAGTAGACAAGGTACAACCC  
Il10 CAGCCGGGAAGACAATAACTG  CCGCAGCTCTAGGAGCATG  
Gsn CTCTGGACCACCACCTCATT GTTCAGGGCTTTGAGTCGTC 
Cdc42 CCCATCGGAATATGTACCAACTG CCAAGAGTGTATGGCTCTCCAC 
Rac1 GAAAGAGATCGGTGCTGTCAA CAACAGCAGGCATTTTCTCTT  
Rhoa AGCTTGTGGTAAGACATGCTTG GTGTCCCATAAAGCCAACTCTAC 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
18s CTGGAGCCTGTTTTGCTTCTG TGAGATGGACTGTCGTCGGATG 
Cx3cr1 GAGTATGACGATTCTGCTGAGG CAGACCGAACGTGAAGACGAG 
Cxcl10 CTCATCCTGCTGGGTCTGAG  
 
CCTATGGCCCTCATTCTCAC 
 
Table 2-4 Human RT-qPCR primer sequences 
Target Forward Reverse 
RHOA AGCAAGCATGTCTTTCCACA GAAGAGGCTGGACTCGGATT 
GSN GATCGAACTTCTCCACACGC ACCCTGCACAGCCTTGTTAG 
IL1B AAGCCCTTGCTGTAGTGGTG GAAGCTGATGGCCCTAAACA  
TNF GCCAGAGGGCTGATTAGAGA  TCAGCCTCTTCTCCTTCCTG  
IL10 CTCATGGCTTTGTAGATGCCT GCTGTCATCGATTTCTTCCC 
IL8 AGCACTCCTTGGCAAAACTG CGGAAGGAACCATCTCACTG 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
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2.12. Cytokine	  production:	  
MACS isolated CD16pos and CD16neg human monocytes (0.2x106) were incubated 
with 100µg/ml VLDL or PBS for 2 hours at 37°C. Monocytes were then incubated 
with/ without 2µg/ml R848 (Enzo Life Sciences) and 100ng/ml lipopolysaccharide 
(LPS) from Salmonella enterica serotype typhimurium (Sigma-Aldrich) for 16 hours. 
The supernatants were collected and stored at -80°C. TNF-α and IL-1β levels were 
measured using a BD Cytometric Bead Array on a BD Accuri C6 flow cytometer 
according to manufacturer instructions (BD Biosciences).  
 
2.13. Phagocytosis	  
Purified human peripheral blood mononuclear cells were incubated at 5 x 106/ml in 
DMEM for 2 hours at 37oC with or without 100µg/ml LDL or VLDL (Biomedical 
Technologies, Inc). To assess phagocytosis, cells were treated 1/100 with 1µm 
carboxylated fluorescent yellow-green latex beads (Sigma Aldrich) for 1 hour at 
37°C. Cells were washed twice and stained for flow cytometry using anti- HLA-DR 
(TU36), anti- CD16 (3G8) and anti- CD14 (M5E2). 
 
2.14. Transwell	  chemotaxis	  assay	  
Purified human CD16pos and CD16neg blood monocytes were incubated in DMEM for 
2 hours at 37oC with or without 100µg/ml LDL or VLDL (Biomedical Technologies, 
Inc). 1 x 105 cells per well were seeded into 3µm-pore transwell inserts (Corning), 
using a chemoattractant gradient of 250ng/ml recombinant human C5a (RND 
Systems) and incubated at 37oC for 2 hours. Non-adherent cells were removed and 
the transwell inserts were fixed in 4% PFA. Non-migrated cells were removed using 
a cotton bud before the membranes were excised and mounted on microscope 
slides in Vectashield mounting media containing DAPI (Vector Labs). Slides were 
imaged using a 20X/0.7 objective on an Olympus BX51 widefield fluorescence 
microscope and nuclei were counted using ImageJ analysis software.  
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2.15. 2D	  real-­‐time	  migration	  assay	  
Purified human CD16pos and CD16neg blood monocytes were re-suspended at 3 x 106 
cells/ml in DMEM-0.5% BSA and seeded into IBIDI 2D chemotaxis chambers (IBIDI) 
for 1 hour at 37oC with or without 100µg/ml LDL or VLDL (Biomedical Technologies, 
Inc). CD16pos monocytes were labelled for imaging using an AlexaFluor-647 
conjugated anti-CD16 antibody (3G8, Biolegend) 1/25 concentration. For chemotaxis 
experiments, a gradient of 250ng/ml human recombinant C5a was established on 
one side of the chamber according to manufacturer instructions. For chemokinesis 
experiments, C5a was added directly to the cell channel to achieve uniform 
distribution. Slides were allowed to equilibrate for 30 minutes before imaging on a 
Leica SP5 confocal microscope using a 10x/0.4 objective and a 37oC environmental 
chamber. 
 
2.16. Monocyte	  adhesion	  to	  endothelium	  
Human umbilical venous endothelial cells (HUVECs) were a kind gift from Professor 
Justin Mason and were isolated and cultured as previously described [3]. Briefly, 
HUVECs were seeded into collagen-I (Sigma-Aldrich) coated 0.4µm chamber slides 
(IBIDI) at 2 x 106/ml and allowed to adhere 30 minutes at 37°C. Cells were washed 
with complete M199 and left to reach confluence for 24 hours at 37oC. In separate 
experiments, HUVECs or human monocytes were treated with 100µg/ml LDL or 
VLDL for 2 hours at 37oC. Cells were washed and monocytes were stained with 
NucBlue (Life Technologies) and added to the endothelium at 1 x 106/ml for 30 
minutes. Co-cultures were fixed in 4% PFA and washed to remove non-adherent 
monocytes. Slides were imaged using a 20X/0.7 objective on a Leica SP5 confocal 
microscope and nuclei were counted using ImageJ analysis software. 
 
2.17. Transendothelial	  migration	  
For endothelial transmigration experiments, transwell inserts were coated with Type I 
collagen (Sigma Aldrich) overnight, seeded with HUVECs at 1 x 105 cells/cm2 and 
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allowed to reach confluence for 24 hours. HUVECs were activated with 2ng/ml TNF-
a (PeproTech) for 3 hours. Monocytes were labeled with CFSE for 30 minutes to 
allow for distinction from endothelial cells, washed and seeded into transwells as 
described above. Transmigrated monocytes were imaged as described above. 
 
2.18. RHOA	  and	  CDC42	  activation	  assays	  
Human CD16pos and CD16neg primary monocytes (0.5 x 106) were treated with 
combinations of 100 µg/mL LDL/ VLDL and 2µg/ml RHOA activator CN03 
(Cytoskeleton, Inc.) for 2 hours in DMEM at 37oC. Cells were lysed with supplied 
lysis buffer and lysates clarified by centrifugation at 4˚C (14000xg, 3 min). Protein 
concentration for each sample was determined using the bicinchoninic acid (BCA) 
assay (Thermo Fisher Scientific) and remaining lysates were snap-frozen in liquid 
nitrogen for storage at -80˚C. RHOA activity in human primary monocytes was 
measured using a luminescence-based G-LISA RHOA activation kit according to 
manufacturer instructions (Cytoskeleton, Inc.). Chemiluminescence was measured at 
445 nm 5 min after the HRP substrate was added, using a FluoStar Galaxy 
instrument (BMG Lab Technologies). CDC42 activity was assessed in cells treated 
and processed as above using a colorimetric-based G-LISA kit according to 
manufacturer instructions (Cytoskeleton, Inc.) and absorbance at 562 nm was 
measured using a Biotek ELX 800 microplate reader (Bio-Tek Instruments). 
 
2.19. Western	  blot	  
Monocytes were lysed on ice in 70µL of lysis buffer (50 mM NaCl, 250 mM Tris-HCL, 
1% NP-40) supplemented with phosphatase inhibitors (5 mM EDTA, 50 mM NaF, 1 
mM Na3VO4) and protease inhibitor cocktail (Sigma-Aldrich) for 30 minutes. Proteins 
were separated by 15% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) and transferred onto nylon membranes (GE Healthcare). 
Membranes were blocked in TBS containing 5% BSA and 0.1% Tween 20 and 
incubated overnight with anti-phospho-PAK1/2/3 (Novus Biologicals) or anti-p38 
(SC535, Santa Cruz Biotechnology). Protein was detected with horseradish 
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peroxidase-conjugated secondary antibodies (Cell Signaling Technology) in 
combination with Amersham ECL Western Blotting Reagants (GE Healthcare).  
 
2.20. Cell	  morphology	  analysis	  
Human CD16pos and CD16neg primary monocytes were treated with combinations of 
100 µg/mL LDL/ VLDL and 2µg/ml RHOA activator CN03 (Cytoskeleton, Inc.) for 2 
hours in DMEM at 37oC. Cells were seeded (1.5x106/ml) into tissue-culture treated 
0.4µm chamber slides (IBIDI) in DMEM and allowed to adhere for 30 minutes. 
Adherent cells were immediately fixed in 4% PFA for 15 minutes and washed with 
0.1M glycine. Cells were permeabilized with Triton X-100 and actin was stained 
using fluorescently conjugated phalloidin (Life Technologies). Cells were mounted in 
DAPI-Vectashield (Vector Labs) and imaged using either a Zeiss AxioObserver 
widefield or a Leica SP5 confocal microscope with a 63x/1.4 objective. Cell 
morphology was analysed in ImageJ using automatic thresholding and masking on 
the phalloidin channel followed by circularity and area measurement. 
 
2.21. Drosophila	  hemocyte	  imaging	  
Drosophila work was a collaboration with the group of Professor Will Wood at the 
University of Bristol and Dr Kate Comber performed the experiments. I contributed to 
experimental design and analysed the videos provided by collaborators in order to 
generate the data presented here.  
 
Drosophila stocks were maintained under standard conditions at 25oC as previously 
described [4]. All flies used expressed a UAS-GFP construct driven by the 
hemocyte-specific promoters serpent (srp) and croquemort (crq) and were on a w118 
background. Rho1-V14 flies expressed a dominant-negative UAS-Rho1-V14 
construct also driven by these two promoters, as previously described [5]. Stage 11-
12 embryos were injected with LDL-AlexaFluor-594 (Life Technologies) or PBS using 
an Eppendorf Microinjection System (Eppendorf). Embryos were allowed to recover 
for 3 hours prior to imaging at stage 15. Imaging was performed on a Leica SP8 
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confocal laser scanning microscope (Leica) with a 40x/ 1.3 objective. Hemocyte 
motility was analyzed using Bitplane Imaris software (Bitplane). 
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3. THE	  RESPONSE	  OF	  MOUSE	  
MONOCYTES	  TO	  DYSLIPIDAEMIA	  
3.1. Introduction	  
The concept of blood leukocytes interacting with lipid in the plasma is long 
established, yet only sporadically described in leukocyte subpopulations. As early as 
the 1960s, rats fed a high fat, high cholesterol diet were observed to have lipid-rich 
blood leukocytes by light microscopy, which were principally monocytes and became 
known as ‘lipophages’ [1,2]. In the context of atherosclerosis, these lipid rich 
monocytes were hypothesized by some to deliver lipid to the plaque and mature to 
foam cells [2]. In the 1970s, others even went as far as to postulate that infiltrating 
lipophages were a functionally distinct population in the plaque, and that traditional 
foam cells derived from smooth muscle cells (SMC) [3]. However, this theory fell out 
of favour as more evidence arose for the independent subendothelial deposition of 
LDL and the functional response of lipid-loaded leukocytes was dismissed without 
further investigation. More recently, evidence for blood monocyte lipid-loading has 
once again appeared: monocytes from the Apoe-/- mouse have increased granularity 
as measured by flow cytometry side-scatter (SSC) and this appears to be accounted 
for by intracellular lipid [4]. There is some suggestion that this is specific to GR1low 
monocytes, however the functional impact of this lipid loading remains unclear, 
particularly in the context of functionally independent monocyte subpopulations.  
 
I aimed here to confirm and characterize this phenotype using the Ldlr-/- mouse. 
Initially generated in 1993, the Ldlr-/- mouse is a well-established model of 
hypercholesterolemia and atherosclerosis [5,6].  On a normal chow diet, total plasma 
cholesterol doubles compared to Ldlr-competent mice to around 300mg/dl [6]. 
However, after just 2 weeks of HFD these levels rise to approximately 2500mg/ml, 
driven primarily by an increase in VLDL and LDL, while wild-type mice remain 
relatively unaffected [6]. When fed a chronic HFD, these Ldlr-/- animals develop 
advanced atherosclerotic lesions in the aortic sinus after 3 months that extend to the 
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thoracic aorta by 6 months and the abdominal aorta at 9 months [7]. As such, these 
animals are a useful model to investigate the effects of extreme dyslipidaemia on 
blood monocytes. 
3.2. Results	  
3.2.1. Neutral	  lipid	  accumulation	  in	  mouse	  monocytes	  
To examine blood monocytes after short-term high fat diet, Ldlr-/- mice were fed a 
chow or HFD for 6 weeks and the blood sampled for flow cytometric analysis 
Monocyte flow cytometry gating strategy is shown in Figure 3.1A: monocytes were 
defined as CD11bpos, CD115pos and subsets then split into GR1low and GR1high. Other 
groups have reported monocytosis after HFD in the Apoe-/- mouse, which I sought to 
confirm in the Ldlr-/- mouse under these conditions. At 6 weeks HFD in my 
experiments there was no significant difference in GR1low or GR1high monocyte count 
between chow and HFD fed Ldlr-/- animals (Figure 3.1B). After 6 weeks, monocytes 
from animals fed HFD had a significantly increased SSC when compared to chow 
controls, indicating an increase in granularity (Figure 3.1C). I also investigated 
monocyte activation by assessing expression levels of cell surface receptors. 
However, contrary to some previous reports in the Apoe-/- model [8,9], HFD did not 
increase monocyte levels of the cell surface integrin CD11b. There was also no 
increase in surface expression of the colony-stimulating factor 1 (M-CSF) receptor 
CD115 or of GR1. In addition, neutrophils (defined as CD11bpos, CD115neg, GR1pos, 
SSChi) displayed no changes in granularity or surface CD11b levels after HFD, 
indicating a monocyte specific phenotype (Figure 3.1E-I). 
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Figure 3.1: FACS phenotyping of blood leukocytes from Ldlr-/- mice.  
(A) Blood monocyte subpopulations were FACS gated as follows: debris and platelets were 
excluded using FSC and SSC, representing size and granularity respectively. Single cells were 
selected using ratio of SSC area to width, and of those CD115+ CD11b+ cells were gated as 
monocytes. Monocyte subpopulations were then gated as GR1hi or GR1low. Blood monocytes 
from Ldlr-/- mice fed chow or HFD for 6 weeks were analyzed by FACS. (B) Monocytes per ml of 
blood, (C) A representative FACS example of monocyte SSC, (D) quantification of monocyte 
SSC. (E) Monocyte CD11b MFI, (F) CD115 MFI (G) GR1 MFI. Blood neutrophils were analysed 
for (H) SSC and (I) CD11b MFI. N=5 per group, error bars show the mean ± SEM. Groups were 
compared using a two-tailed Mann Whitney U test. 
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Figure 3.2: Blood monocytes from Ldlr-/- mice are lipid loaded.  
(A) Neutral lipid staining of GR1hi and GR1low blood monocytes from Ldlr-/- mice, 16 weeks HFD. 
Scale bar represents 10µm. Staining is quantified as (B) vesicles per cell, (C) % of cells 
containing neutral lipid vesicles and (D) LipidTox vesicle MFI, n=>20 cells per condition, cells 
were pooled from 3 mice per condition. Error bars show the mean ± SEM. Groups were 
compared using a two-tailed Mann Whitney U test. 
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The next step was to investigate the composition of the increased monocyte 
granularity. At 16 weeks after chow/ HFD, peripheral blood mononuclear cells were 
isolated and monocytes were sorted into GR1high and GR1low subpopulations for 
imaging. Cells were adhered to tissue culture plastic and stained for neutral lipid 
content using LipidTOX-Green (Invitrogen). Confocal microscopy revealed a large 
number of neutral lipid vesicles in the cytoplasm of the majority of monocytes in both 
subsets after HFD; representative images are shown in Figure 3.2A. Image analysis 
revealed that percentage of cells containing lipid rose significantly on HFD and the 
mean number of neutral lipid vesicles per cell increased by >10-fold compared to 
chow (Figure 3.2B-C). There was no difference in lipid vesicle intensity between 
monocyte subsets, although there was a trend towards more intracellular neutral lipid 
vesicles in the GR1low monocytes (Figure 3.2B). Interestingly, the accumulation of 
neutral lipid was restricted to cytoplasmic droplets and did not appear to occur in the 
cell membrane. 
 
While this thesis was being prepared for submission, Wu and colleagues published 
work in the Apoe-/- mouse, demonstrating that HFD causes the development of a 
population of lipid-loaded, SSChigh, CD11cpos ‘foamy’ monocytes that contribute to 
lipid trafficking during early atherogenesis [10]. This occurs after as little as 3 days 
HFD, and peaks in severity between 5 and 10 weeks [10]. To confirm this phenotype 
in the Ldlr-/- model, I analyzed blood leukocytes from animals fed chow or HFD for 8 
weeks. As noted in Figure 3.1D, HFD increased the SSC of blood monocytes (gating 
shown in Figure 3.3A), with the proportion of SSChigh monocytes rising from 
approximately 7% on chow to approximately 20% on HFD (Figure 3.3B). In the Apoe-
/- animals on HFD for a similar time point, this figure was over 30% [10]. When 
monocytes were assessed for CD11c expression by flow cytometry, approximately 
10% of SSChigh cells were CD11cpos on both chow and HFD, while CD11c was only 
present on 3-4% of the SSClow population (Figure 3.3C-D). Interestingly, the 
proportion of SSChi monocytes that were also CD11cpos was not altered by HFD, 
perhaps indicating that these cells have a short circulating half-life. In addition, this 
was a much less pronounced phenotype than reported in Apoe-/- mice, in which 70-
80% of SSChigh monocytes express CD11cpos after 8 weeks of HFD [10]. When gated 
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into monocyte subpopulations, over 10% of GR1low monocytes were CD11cpos, while 
in GR1high cells this population was only 1-2% (Figure 3.3E-F). 
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Figure 3.3 Expression of CD11c by murine monocytes on HFD.  
Ldlr-/- mice were fed chow or HFD for 8 weeks and blood monocytes were analyzed for SSC and 
surface CD11c, n=4 per group. (A) Representative flow cytometry plots of SSChigh/ SSClow 
monocyte gating from blood leukocytes. (B) Percentage of monocytes SSChigh on chow or HFD. 
(C) Representative histogram of SSChigh and SSClow monocyte CD11c levels after HFD. (D) 
Percentage of monocytes CD11c positive on chow or HFD. (E) Percentage of GR1high and 
GR1low monocytes CD11c positive on chow or HFD. (F) Representative histogram of GR1high and 
GR1low monocyte CD11c levels on chow or HFD. Error bars show mean ± SEM, data was 
compared using a two-tailed Mann-Whitney U test. 
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3.2.2. The	  response	  of	  lipid-­‐loaded	  monocytes	  to	  sterile	  
inflammation.	  
To investigate the functional impact of blood monocyte lipid loading on their 
response to sterile inflammation, we performed thioglycollate (THG) peritonitis in the 
Ldlr-/- mouse after 16 weeks chow or HFD and FACS analysed cells from the 
peritoneal lavage at 72 hours post-injection; a time point well characterized to 
represent peak monocyte/ macrophage infiltration [11,12]. Originally designed to test 
aerotolerance of bacteria, thioglycollate broth principally contains sodium 
thioglycolate, thioglycolic acid and L-cysteine and induces inflammation when 
injected into mice, although the exact mechanisms of this are not well defined [13]. 
As expected, the peritoneal lavage 72 hours after THG injection was dominated by 
CD115pos monocytes and macrophages in our experiments. The FACS gating 
strategy for peritoneal monocytes/ macrophages is shown in Figure 3.4A. In the 
steady state, there was no change in peritoneal total cell numbers or monocytes/ 
macrophages after HFD (Figure 3.4B-C). However, after THG injection there was a 
significant, approx. 50% decrease in total peritoneal cells, the majority of which was 
accounted for by a decrease in monocytes/ macrophages (Figure 3.4B-C). 
Interestingly, there was also a decrease in CD115neg CD11bpos SSChi granulocytes, 
although these cells were only a very small proportion of the peritoneal population 
(Figure 3.4D).   
 
Due to the poorly defined mechanisms of THG induced inflammation I confirmed 
these findings in a model of endotoxin-induced peritonitis. LPS was injected IP and 
the peritoneal lavage collected and analysed at 72 hours as described above. While 
there was no change in total cell number on HFD (Figure 3.4E), peritoneal CD115pos 
monocytes/ macrophages decreased by approx. 50%, consistent with findings from 
the THG model (Figure 3.4F). The discrepancy in total cell number and monocyte/ 
macrophage number appears to be due to an increase in an unidentified population 
of CD11bneg CD115neg SSClow cells after HFD that would require further investigation 
to characterize. There was also a small and non-significant decrease in CD115neg 
CD11bpos SSChi granulocyte numbers (Figure 3.4G).  
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It has previously been reported that HFD in Ldlr-/- results in a ‘deactivated’ phenotype 
in peritoneal macrophages via desmosterol-LXR signalling, resulting in decreased 
inflammatory gene expression [14]. To confirm this observation, I assessed mRNA 
abundance of targets previously associated with this pathway. In agreement with 
published work, I observed a trend towards less expression of IL1B, IL10 and 
CXCL10 on HFD (Figure 3.4H), although none of these reached statistical 
significance.  
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Figure 3.4: Sterile peritonitis model in dyslipidaemic Ldlr-/- mice.  
Thioglycollate peritonitis (1ml of 4% THG per mouse) was induced in Ldlr-/- mice and the 
peritoneal lavage analysed by FACS at 72 hours post-injection. (A) Representative gating of 
infiltrating monocytes/ macrophages, (B) Total cells/ ml, (C) CD115pos CD11bpos/ ml (D) CD11bpos 
SSChi CD115neg /ml peritoneal lavage from Ldlr-/- mice on chow/ HFD, non-injected or 72 hours 
post- THG IP, n=5 per group. (E-G) Cells/ ml is shown for the same populations are shown after 
72 hours LPS-induced peritonitis (10µg per mouse), n=4 per group. (H) Peritoneal cells after 
THG were analyzed for inflammatory gene expression by RT-qPCR, data shown as HFD log2 
fold chance versus chow. Error bars show the mean ± SEM, groups were compared using a two-
tailed Mann Whitney U test. 
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These data potentially indicated that blood monocyte migration to the peritoneal 
cavity during inflammation is impaired by HFD. To test this hypothesis I utilized a 
strategy previously employed by the Randolph group [15], where blood monocytes 
can be labelled using intravenous (IV) injection of fluorescent latex beads. This 
utilises the high phagocytic ability of blood monocytes and allows them to be tracked 
out of the blood. As expected, injection of 1µm carboxylated latex beads 
predominantly labelled the GR1low subpopulation, but also labelled some GR1high 
monocytes (Figure 3.5A). Peak labelling occurred at 30 minutes post- injection, with 
approx. 10% GR1high bead-positive (beadpos) and 25% GR1low beadpos. By 24 hours 
post-injection these proportions had fallen to approx. 12% and 3% respectively, but 
labelling was still present and detectable. For peritonitis experiments, beads were 
injected IV 3 hours prior to IP THG injection. When the peritoneal lavage was 
collected at 72 hours post THG, the number of beadpos CD115pos CD11bpos cells in 
the peritoneum was decreased almost ten-fold by HFD (Figure 3.5B), confirming that 
the decrease in peritoneal monocytes during HFD is a defect in extravasation to the 
peritoneal cavity. Monocyte/ macrophage mean bead fluorescence intensity was not 
altered between diets, indicating that phagocytosis of beads was not impaired by 
HFD (Figure 3.5C). 
 
I then sought to investigate the fate of blood monocytes on HFD after peritonitis if 
they were failing to reach the peritoneal cavity. Previous work in rodent models of 
peritonitis has indicated that the greater omentum is the major site of leukocyte 
extravasation from the blood into the peritoneal cavity [16,17]. The greater omentum 
is a large fold of visceral tissue that hangs down from anterior stomach and creates a 
physical barrier to the spread of infection and hernia. As discussed earlier, omental 
‘milky spots’ also contain a reserve of maturing tissue resident peritoneal 
macrophages [18,19]. Again using THG peritonitis as a model, I harvested the 
greater omentum at 72 hours post-injection and analysed the leukocyte populations 
in the tissue using flow cytometry. CD45 staining was used to distinguish leukocytes 
from other cells, and representative plots of CD45pos cells stained for CD115 and the 
macrophage antigen F4/80 are shown in Figure 3.6A. Peritonitis decreases the total 
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leukocyte number in the omentum on chow and HFD, as resident macrophages 
migrate out from the omentum into the peritoneal cavity. However, on HFD there is a 
striking approximately 10 fold increase in the number of CD115pos F4/80low 
monocytes present in the inflamed omentum (Figure 3.6C), accompanied by a trend 
towards less CD115neg F4/80high mature tissue macrophages (Figure 3.6D). This 
mirrors the approx. 10-fold decrease seen in blood monocyte migration into the 
peritoneum on HFD using latex-bead labelling, suggesting a HFD- induced migratory 
defect.  
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Figure 3.5: Blood monocyte tracking during peritonitis using latex beads.  
IV injection of 1µm latex beads was used to track monocyte migration out of the blood during 
peritonitis in Ldlr-/- mice with/without HFD. (A) Percentage of blood Gr1hi or Gr1low monocytes that 
were beadpos post- bead injection. (B) Representative FACS plots showing latex bead positive 
populations gated from peritoneal CD115+ CD11b+ monocytes/ macrophages after 72 hours 
thioglycollate peritonitis. (C) Median bead fluorescence intensity of beadpos peritoneal monocytes/ 
macrophages. (D) Representative FACS plots of bead uptake by CD115pos CD11bpos monocytes/ 
macrophages. n=4 per group, error bars show the mean ± SEM, groups were compared using a 
two-tailed Mann Whitney U test. 
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Figure 3.6: Leukocyte accumulation in the omentum after THG peritonitis. 
THG peritonitis was induced in Ldlr-/- mice and cell populations in the omentum were analysed by 
flow cytometry. (A) Representative FACS plots of CD115 and F4/80 staining in the omentum of 
Ldlr-/- mice 72 hours post-THG IP. Gated on CD45+ cells. (B-D) Leukocyte populations per gram 
of tissue from this experiment: (B) CD45+, (C) CD115+ F4/80low, (D) CD115neg F4/80hi, n=4-5 per 
group. Error bars show the mean ± SEM, groups were compared using a two-tailed Mann 
Whitney U test. 
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3.2.3. Intravital	  imaging	  of	  GR1low	  monocyte	  patrolling	  after	  HFD	  
Interested in whether HFD was causing a migratory defect in monocytes, I attempted 
to visualize GR1low monocyte locomotion in real time using the Cx3cr1GFP/+ mouse. 
Created by Jung and colleagues [20], this mouse has been well characterized as a 
model to study the long- range intravascular patrolling behaviour of non-classical 
monocytes, which express high levels of the fractalkine- receptor Cx3cr1 [21,22]. 
C57Bl/6 Cx3cr1GFP/+ mice were fed a chow or HFD for 6 weeks in order to generate 
a mild hypercholesterolemia without genetic alteration of lipid metabolism. At 6 
weeks, animals on HFD had a significantly increased plasma total cholesterol and 
LDL, as has been previously reported in wild-type mice [23] (Figure 3.7A). To 
examine whether this mild hypercholesterolemia was sufficient to cause cytoplasmic 
neutral lipid loading blood monocytes were sorted into GR1high and GR1low 
subpopulations for confocal imaging. Cells were adhered to tissue culture plastic and 
staining for neutral lipid content using LipidTOX-Red (Invitrogen). Although not as 
pronounced as in the Ldlr-/- animals, some blood monocytes from the HFD group did 
contain clear neutral lipid accumulation, which was not present in monocytes from 
mice fed chow (Figure 3.7B). In general, the lipid punctae in monocytes from the 
Cx3cr1GFP/+ animals on HFD were smaller and less numerous than those present in 
the Ldlr-/-.  
 
Given that 6 weeks of HFD affects plasma cholesterol levels and monocyte neutral 
lipid content, I proceeded to intravital imaging of GR1low monocytes in these animals. 
The vasculature in the dermis of the ear is an ideal site for non-invasive confocal 
microscopy of anaesthetised animals and fluorescently labelled 70kDa-dextran was 
injected IV to delineate vascular structure. A representative still image from intravital 
imaging is shown in Figure 3.7C to demonstrate the quality of imaging achievable. 
After 45 minutes imaging, there was a subtle increase in monocyte track speed on 
HFD, however this did not translate to a significant difference in track displacement, 
track length, track duration or confinement ratio (Figure 3.7D-H). In addition, tracks 
plots were visually similar with no clear defects after HFD (Figure 3.7I), leading to the 
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conclusion that modest hypercholesterolemia does not affect intravascular monocyte 
patrolling.  
 
Figure 3.7: Intravital imaging of monocytes in chow or HFD fed Cx3cr1gfp/+ mice. 
Cx3cr1gfp/+ mice were fed chow/ HFD for 6 weeks (A) Blood total and LDL cholesterol levels of 
chow vs HFD mice, n=4 per group, error bars show the mean ± SEM. (B) Neutral lipid staining of 
GR1hi/ GR1low blood monocytes from Cx3cr1gfp/+ mice on HFD. Scale bar represents 10µm. 
Gr1low monocyte vascular crawling was then assessed by intravital microscopy. (C) 
Representative field of view from dermis vasculature, (D) Track straightness (E) Track length 
(µm) (F) track duration (seconds) (G) track speed (µm/ sec) and (H) track displacement (µm) 
length of intravascular monocytes during approximately 45 minutes of imaging. (I) track 
projections of patrolling monocytes from Cx3cr1GFP/+ mice fed HFD or chow during ~45 minutes 
intravital imaging, 4 mice per diet, n=>20 cells analysed per condition. Whiskers display the 10th 
and 90th percentile; groups were compared using a two-tailed Mann Whitney U test.  
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3.3. Discussion	  
In this chapter I present data strongly suggesting that intracellular neutral lipid 
accumulation impairs the migration of blood monocytes towards an inflammatory 
stimulus, in this case peritonitis. The strongest data to support this conclusion is the 
failure of bead-labelled blood monocytes to accumulate in the peritoneal cavity 
during inflammation on HFD, clearly indicating less migration of leukocytes from the 
blood. In addition, it appears that this is due to monocytes being retained in the 
greater omentum while trafficking to the peritoneal cavity, during or after 
extravasation from the blood. However, the mechanism of this migratory impairment 
remains unresolved.  
 
One possibility that is not addressed here is that monocytes are undergoing cell 
death in the hypercholesterolemic environment. Previous data have demonstrated 
that oxidised LDL (oxLDL) treatment can cause apoptosis in macrophages and 
endothelial cells [24,25]. However, contradictory reports show that oxLDL can act as 
a survival factor for macrophages, inhibiting apoptosis [26]. This paradox is mostly 
likely due to different LDL modifications and species mediating distinct effects; while 
heavily oxidised LDL can cause apoptosis, minimally modified LDL acts as a growth 
factor [27]. In addition, no evidence of apoptosis or necrosis was seen by flow 
cytometry in lipid-loaded blood monocytes. While HFD caused monocytes to 
increase their SSC due to cytoplasmic lipid droplets, there was no decrease in 
forward-scatter (FSC), as would be expected if cells were shrinking and becoming 
apoptotic [28]. Furthermore, late-stage cell death and necrosis causes a dramatic 
drop in SSC as cells leak their cytoplasmic constituents, the opposite to what is 
observed in blood monocytes after HFD [28]. However, peritoneal macrophages are 
predominantly cleared via local apoptosis rather than emigration to the lymph nodes 
during thioglycollate peritonitis [29] and it is plausible that HFD accelerates this 
process, thus contributing to the decreased number of CD115+ cells in the 
peritoneum following HFD. In addition, monocyte/ macrophage egress from the 
peritoneum for splenic clearance could be accelerated by HFD and these 
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possibilities cannot be excluded without further cell tracking and kinetic studies using 
this model.   
 
Alternatively, monocytes may be retained in the omentum during peritonitis simply 
due to increased adhesion. As discussed previously, oxLDL activates the 
endothelium to increase expression of numerous adhesion molecules, including P-
Selectin, ICAM-1 and VCAM-1 [30,31], which could retain monocytes at their site of 
extravasation. In addition, monocytes from FH patients have significantly elevated 
cell surface expression of the integrins CD11c [32] and CD11b [33], accompanied by 
increased adhesion to an  endothelial monolayer when compared to healthy controls 
[33]. Others have also shown monocyte CD11b [34] and CD11c [35] expression to 
be increased acutely during post-prandial lipaemia following a high fat meal or after 
incubation with TGRL. In our Ldlr-/- model I did not see any significant increase in 
monocyte CD11b expression on HFD, although CD11c was up regulated in a 
SSChigh population. However, this was a subtle phenotype, as SSChigh CD11cpos cells 
represented only 2% of total monocytes on HFD. Moreover, integrin function is also 
mediated by spatial localization and clustering [36], as well as total surface levels, 
which remain poorly characterized in response to plasma lipoproteins. Taken 
together, it seems unlikely from these data that increased surface integrin expression 
is a key mechanism of monocyte retention in the omentum. Further work in this 
thesis using human monocytes to explore monocyte- endothelial adhesion in vitro 
may help to clarify this issue (Chapter 5.2.4). 
 
It is also interesting that the emergence of CD11cpos SSChigh monocytes in Apoe-/- 
mice on HFD described by Xu et al [10] is much more pronounced than observed 
here in the Ldlr-/- model. While 70-80% of SSChigh monocytes were reported as 
CD11cpos in the Apoe-/- after HFD [10], this figure was closer to 10% in the Ldlr-/-. 
There are several potential explanations for this, one being the severity and 
composition of dyslipidaemia in the Apoe-/- animals versus the Ldlr-/-. While in the 
Ldlr-/- on HFD TGRLs peak at approximately 1500mg/dl and LDL at 1100mg/dl, these 
figures for the Apoe-/- are 2300mg/dl and 1000mg/dl respectively [6]. Caution is 
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required in interpreting these data, as it is exceedingly rare for lipid values achieved 
in the Apoe-/- on HFD to occur in a human. Even in patients with a homozygous 
lipoprotein lipase (LPL) deficiency characterized by very severe hypertriglyceridemia, 
plasma triglyceride has been reported as approximately 1500mg/dl [37], although 
other cases have been recorded with levels above 2000mg/dl [38]. As such, the 
development of CD11cpos monocytes may be dose dependent on triglyceride present 
in plasma chylomicrons and/or VLDL.  
 
Another possibility is that the LDLR itself is required for monocyte up-regulation of 
CD11c in response to HFD. While traditionally thought of as simple endocytic carrier 
receptors, the LDLR family are now appreciated to participate in signal transduction 
[39]. For example, low-density lipoprotein receptor-related protein 1 (LRP1) has been 
implicated in a range of signaling pathways in response to ligand binding [39], via 
adaptor proteins including Shc, JIP1 and JIP2 [40]. While signalling downstream of 
the LDLR itself is less well established, the modular adaptor protein autosomal 
recessive hypercholesterolemia (ARH) binds the cytoplasmic tail of the LDLR and 
promotes its localization in clathrin coated pits [41], and therefore may also affect 
other downstream targets. Conversely, APOE is involved in monocyte homeostasis 
via the modulation of bone marrow progenitor populations [8] and it is also possible 
that reconstitution of APOE would reduce the proportion of CD11cpos monocytes on 
HFD.   
 
Although the monocyte migratory defect described here is present in response both 
TG and endotoxin induced inflammation, it is possible that this phenotype is specific 
to the peritoneum. Since there are less CD115neg F4/80high mature tissue 
macrophages in the inflamed omentum after HFD, it may be the case that HFD is 
affecting the GATA-6 dependent maturation of infiltrating monocytes to peritoneal 
macrophages in the omentum (Figure 3.6D). The binding activity of GATA 
transcription factors can be modulated by LDL in endothelial cells [42], while the 
cholesterol, biosynthesis intermediate desmosterol induces a vast phenotypic shift in 
TG elicited peritoneal macrophages [14]. However, other groups have reported an in 
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vitro defect in macrophage chemotaxis after free- cholesterol loading, mediated by 
the cytoskeletal small- GTPases RHOA and RAC1 [43,44], indicating a more basic 
and universal mechanism may be responsible.  
 
Interestingly, HFD in the metabolically normal Cx3cr1gfp/+ animals did not impair 
GR1low monocyte intravascular locomotion. One simple explanation for this is that 
the very mild dyslipidaemia in these animals was not pronounced enough to cause a 
defect. While Ldlr-/- have total cholesterol levels of around 6mmol/L on chow and up 
to 70mmol/L following HFD [6], we were only able to achieve a modest doubling of 
baseline total cholesterol from 1mmol/L to ~2.5mmol/L using HFD in the Cx3cr1gfp/+ 
mice. Although cytoplasmic neutral lipid was increased in monocytes following HFD, 
it did not take the form of the large, pronounced lipid droplets that are visible in the 
Ldlr-/- monocytes on HFD. In addition, neutral lipid droplets were rarely present in the 
Ldlr-/- on chow, despite total cholesterol levels which are double those found in a 
wild-type mouse fed HFD [6]. As such, it may be that chylomicrons and/or VLDL are 
driving monocyte neutral lipid accumulation, as these TGRL species are elevated in 
wild-type mice on HFD, but not in Ldlr-/- fed chow [6]. The Apoe-/- mouse would 
procide an interesting comparison in this context, as TGRL levels are high even 
when fed a chow diet [6]. Neutral lipid content has previously been reported in 
monocytes of Apoe-/- mice on HFD, however this has always been compared to 
Apoe- competent animals and not to Apoe-/- mice on chow [4,15].  
 
Crucially, intravascular patrolling by GR1low monocytes is thought to happen during 
homeostasis, rather than as a response to injury or inflammation [21]. This 
represents another key difference to peritonitis; GR1low monocytes crawl in a 
seemingly random, chemokinetic manner, with and against the blood flow and are 
not obviously polarized towards a chemotactic stimulus. Indeed, the track projections 
presented here (Figure 3.7I) confirm previous findings that there is no preferential 
migration in one direction. In contrast, TG peritonitis is a strong inflammatory 
stimulus that recruits monocytes predominantly through a MCP-1/ CCR2 chemokine 
axis, as Mcp1-/- mice have substantially decreased monocyte recruitment to the 
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inflamed peritoneum [45]. Interestingly, since GR1low monocytes do not express 
CCR2 [22] and contribute minimally to TG peritonitis [20], it is possible that the HFD- 
induced migratory defect is specific to classical GR1high monocytes. While monocyte 
subpopulation tracking remains extremely challenging in vivo due to cellular plasticity 
and a lack of reliable reporters, these questions and others raised by these data may 
be addressed more easily by characterizing monocyte uptake of LDL/ VLDL and its 
functional impact in vitro. 
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4. UPTAKE	  OF	  LDL	  AND	  VLDL	  BY	  
MONOCYTES	  
4.1. Introduction	  
Although mechanism and functional impact have been only loosely described, there 
are previous descriptions of human monocyte lipid loading. In some instances, this is 
concerning the post-prandial accumulation of what is presumed to be free fatty acids 
or chylomicrons following a high fat meal [1]. In a similar study, carbon-13 (13C) 
labelled palmitic acid was used to track dietary fatty acids into blood leukocytes in 
the post-prandial state, confirming at least in part that intracellular neutral lipid 
accumulation is due to uptake and not a biosynthetic pathway [2]. In addition, 
monocytes from FH patients have been shown to have impaired phagocytosis of 
oxLDL [3]. In the mouse, there is also some evidence that neutral lipid accumulation 
in monocytes from Ldlr-/- animals is via TLR-4 dependent pinocytosis [4]. However, 
very little work has been performed in vitro on monocyte LDL and VLDL uptake and 
the mechanisms of cell entry remain largely undetermined in monocyte 
subpopulations. In addition, there is little evidence that the pronounced neutral lipid 
accumulation described here in the Ldlr-/- mouse in Chapter 3 occurs in human 
monocytes, or indeed whether this accumulation is dependent on endocytosis or on 
an intracellular biosynthetic pathway. Based on previous work in macrophages there 
are several candidate pathways for this phenotype that could be explored.   
4.1.1. LDL	  and	  VLDL	  modification	  
While LDL exists in circulation in its native, unmodified form (nLDL), it is also able to 
undergo a spectrum of oxidative modification to generate a variety of LDL species 
that are often collectively termed ‘oxidised LDL’ (oxLDL). While there are numerous 
groups who have isolated LDL with a negative shift in electrophoretic mobility from 
human and mouse plasma [5-7], and associated this presence with the progression 
and severity of CVD [8,9] the mechanistic details of LDL oxidation in vivo remain 
largely the subject of speculation and conjecture. Heavy oxidative modification of 
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LDL was initially modelled in vitro using acetylation, however these LDL species 
have never been proven to exist in vivo. Furthermore, it is clear that the mechanism 
of uptake of oxLDL in macrophages depends on the extent of its oxidation [10]. 
While minimal oxidative modification of LDL (mmLDL) can lead to fatty acid 
peroxidation, cholesterol conversion to oxysterols and phospholipid oxidation, more 
extensive copper-mediated oxidation often utilized in vitro can extensively alter 
APOB protein structure via the production of reactive aldehydes including 
malondialdehyde (MDA) [11]. There is clear evidence that mmLDL is present in the 
plasma, however the presence of heavily oxidised LDL in the blood seems unlikely. 
There is a high concentration of anti-oxidants such as vitamin C and uric acid in the 
plasma that may prevent any extensive oxidation and oxLDL has an extremely short 
half-life in the blood when injected into both rats and rabbits [12]. As such, evidence 
suggests that heavily oxidised LDL is irrelevant to any phenotype seen in blood 
monocytes and will not be discussed further.  
 
VLDL is less well described, but can also go undergo oxidative modification although 
contradictory reports exist regarding the dependency on VLDL modification or 
oxidation for its uptake by macrophages [13-15]. In our hands LDL undergoes rapid 
minimal oxidative modification during in-vitro use and storage in air (autoxidation), as 
assessed by conjugated diene formation and previously described [11], although 
interestingly this does not happen to VLDL (Figure 4.1). As such, all references to 
‘LDL’ henceforth refer to LDL that has undergone mild oxidative modification. The 
oxidation of LDL has been clearly demonstrated to be a lipid peroxidation process, 
where polyunsaturated fatty acids undergo peroxidation and decomposition to a 
complex mix of reactive aldehyde species such as malondialdehyde and other 
related by-products [16,17]. During autoxidation of LDL, polyunsaturated linoleic and 
arachidonic acid are the main targets of this process, while other saturated and 
monounsaturated species are relatively resistant to peroxidation [17]. Since I do not 
observe autoxidation of VLDL in this manner, it is possible that our VLDL species 
have already been oxidized during isolation, or that differences in the fatty-acid 
composition of VLDL compared to LDL makes it less susceptible to this process.  
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4.1.2. The	  LDL	  Receptor	  
Discovered in Nobel Prize winning work by Brown and Goldstein, the LDLR is the 
canonical pathway of nLDL uptake into peripheral tissues during homeostasis, most 
notably the liver [18]. LDL and IDL bind cell surface LDLR and are internalized on 
average within 10 minutes via receptor- mediated endocytosis into clathrin-coated 
pits [18]. Once internalized, LDL is trafficked to lysosomes for degradation and 
hydrolysis of cholesterol esters, while the receptor itself is recycled to the cell surface 
[18]. Deficiency of the LDLR, as found in Ldlr-/- mouse and in FH patients, elevates 
LDL both by delaying its removal from the blood directly and by delaying the removal 
of its precursor IDL, which leads to increased LDL synthesis [18]. In the context of 
moderate, VLDL-driven dyslipidaemia in metabolically normal mice fed a HFD after 
being reconstituted with Ldlr-/- bone marrow, the macrophage LDLR is crucial in the 
formation of foam cells and the atherosclerotic plaque [19]. In addition, the LDLR 
facilitates VLDL uptake in macrophages and trafficking to distinct intracellular 
compartments to LDL [13,20]. However, given that Ldlr-/- animals succumb to rapid 
and severe atherosclerosis characterized by macrophage foam cell formation when 
fed HFD, clearly this is not the case in extreme hypercholesterolemia [21]. In 
addition, most FH patients with homozygous LDLR defects do not survive into their 
second decade due to advanced cardiovascular disease [22]. As such, the role of 
the LDLR in macrophage foam cell formation remains unclear.  
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Figure 4.1 Measurement of lipoprotein modification by conjugated diene content.  
Conjugated diene content was measured by absorbance at 230nm in fresh, native-LDL (nLDL), 
LDL modified by storage at 4oC in air (mmLDL), copper-oxidised LDL (oxLDL), fresh VLDL and 
VLDL modified by storage at 4oC in air (mmVLDL). One representative experiment is shown of 
two.  
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4.1.3. Scavenger	  receptors	  
Once LDL has undergone a degree of oxidative modification, as discussed above, 
high- affinity binding and endocytosis becomes possible via scavenger receptors 
including Macrophage scavenger receptor 1 (MSR1)[23] and the thrombospondin 
receptor Cluster of differentiation 36 (CD36)[24]; indeed MSR1 was first isolated and 
characterized due to its ability to bind modified LDL [23].  Scavenger receptors are 
an extremely heterogeneous and functionally versatile family, consisting of 8 classes 
with little homology between them [25]. Their ligands are numerous and can 
generally be classes as danger-associated molecular patterns (DAMPs) which 
require clearance for the maintenance of homeostasis or the elimination of disease, 
including lipopolysaccharide (LPS) and lipoteichoic acid (LTA) on the surface of 
bacteria and phosphatidylserine on apoptotic cells [25].  
 
In the context of oxLDL, binding to CD36 or MSR1 on macrophages leads to 
unregulated uptake. Internalization of oxLDL activates the transcription factor 
Peroxisome proliferator-activated receptor gamma (PPAR-γ) via accumulation of the 
fatty acids 9-HODE and 13-HODE, consequently increasing the expression of CD36 
and thus perpetuating the cycle of oxLDL uptake [26,27]. Interestingly, CD36 shares 
significant sequential homology with myelin fatty acid binding protein (MFABP), 
which is involved in the intracellular transport of fatty acids, leading to postulation 
that CD36 possesses a fatty acid binding site at residues 127 and 279[28,29], 
although multiple sites have subsequently been suggested [30]. In vitro, CD36 will 
bind long chain, but not short chain FAs and facilitate their translocation across the 
plasma membrane [29]. However, it was subsequently discovered that this was not 
due to direct fatty acid translocase activity, but instead resulting from the facilitation 
of intracellular esterification of FAs into triacylglycerols, thus increasing the rate of 
FFA uptake [31]. In addition FA binding also increases the binding and uptake of 
oxLDL via CD36, potentially via altering CD36 confirmation [30]. Interestingly this is 
particularly true for elaidic acid [30], which is a trans-fatty acid highly abundant in the 
atherosclerotic plaque, although the role of elevated free fatty acids as a risk factor 
for atherosclerosis remains largely unsupported by epidemiological evidence [32]. In 
both familial hypercholesterolemia patients [3] and Apoe-/- mice [33], dyslipidaemia 
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has also been reported to up-regulate monocyte surface levels of CD36, potentially 
perpetuating a feedback loop of further lipid uptake. 
 
Scavenger receptors have also been implicated in cellular uptake and metabolism of 
VLDL. Scavenger receptor BI (SR-BI) binds to VLDL in vitro [34] and its in vivo 
deletion significantly delays plasma clearance of injected VLDL, predominantly by 
the liver [35]. In addition, SR-BI is required for hepatic VLDL production, potentially 
via the uptake of HDL cholesterol esters that contribute to a pool from which VLDL 
can be synthesised [36]. In addition, SR-BI may act synergistically with CD36, 
heparan sulphate proteoglycans and cell surface lipases to mediate the hydrolysis 
and uptake of FFAs from TGRLs [37,38], although the tissue specificity and exact 
mechanisms of this pathway are still being explored. Following the observation that 
hypercholesterolemia leads to an accumulation of neutral lipid droplets in mouse 
monocytes, I then aimed to determine whether this occurs in vitro in human and 
mouse monocytes and examine some of the likely candidates for neutral lipid entry 
discussed above.  
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4.2. Results	  
4.2.1. 	  Neutral	  lipid	  accumulation	  after	  LDL/VLDL	  treatment	  
Initially I sought to confirm that LDL or VLDL treatment causes neutral lipid droplet 
accumulation in human monocytes, similar to that seen in the Ldlr-/- mouse after 
HFD. Human monocytes were isolated, separated into CD16pos and CD16neg 
subpopulations and treated with 100µg/ml LDL or VLDL for 30 - 150 minutes. When 
incubated with 100 µg/mL LDL or VLDL for the longest time point of 150 minutes, 
both monocyte subsets accumulated cytoplasmic neutral lipid vesicles.  In VLDL 
treated cells, vesicles were present in approximately 70% of CD16neg cells and 40% 
of CD16pos (Figure 4.2A), while in LDL treated cells this was slightly increased to 
100% and 50% respectively (Figure 4.2B). When quantified as the more sensitive 
metric of number of lipid vesicles per cell over time, peak accumulation was at 30 
minutes in VLDL treated cells (Figure 4.2C). CD16neg monocytes containing 
approximately 15 lipid vesicles per cell and CD16pos approximately half this number. 
A similar phenotype was seen with LDL treatment and although peak lipid 
accumulation was delayed to 60 minutes the number or vesicles per cell was largely 
identical to VLDL treatment (Figure 4.2D). Representative images are shown in 
Figure 4.2E, and appear to be visually similar to blood monocytes from the Ldlr-/- 
mouse on HFD. In addition, the relationship between LDL/ VLDL treatment and 
neutral lipid accumulation was investigated further using a dose curve of LDL and 
VLDL, including 0, 20, 100 and 500µg/ml of lipoprotein for 1 hour. As observed in the 
time course in Figure 4.2A-D, CD16neg monocytes have approximately double the 
number of lipid droplets of CD16pos cells after 60 minutes of treatment with VLDL 
(Figure 4.2F) and LDL (Figure 4.2G). An increasing concentration of both 
lipoproteins increased intracellular neutral lipid and this was most pronounced up to 
a concentration of 100µg/ml (Figure 4.2F-G). In CD16neg monocytes treated with 
LDL, no additional effect of 500µg/ml was seen compared to 100µg/ml, suggesting 
that 100µg/ml LDL represents a saturating dose of lipid in these cells (Figure 4.2G). 
Given these data, 100µg/ml was chosen as an appropriate dose of LDL and VLDL 
for future experiments.   
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Figure 4.2 Lipid accumulation over time in LDL/ VLDL treated human monocytes. 
Human CD16pos and CD16neg monocytes were purified and treated with LDL or VLDL (100µg/ml) 
and intracellular neutral lipid was quantified using LipidTOX by confocal microscopy. (A) 
Percentage cells neutral lipid positive after 150mins VLDL treatment (n=10 fields). (B) Number of 
neutral lipid vesicles per cell over time after VLDL treatment (n=25-50 cells). (C-D) Same as A-B 
respectively with LDL treatment. (E) Representative examples of neutral lipid staining, scale bar 
represents 20µm. (F-G) CD16pos/CD16neg monocytes were treated with 0, 20, 100 or 500µg/ml of 
(F) VLDL or (G) LDL for 1 hour and number of neutral lipid vesicles per cell was quantified using 
LipidTOX by confocal microscopy, n=30-35 cells per condition. One representative experiment is 
shown from two. Error bars show the mean±SEM. In A-B, groups were compared using a two-
tailed Mann Whitney U test. In C-D and F-G, groups were compared using a mixed ANOVA with 
a post-test following the Bonferroni method.  
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ABCA1/ ABCG1 knockout in macrophages has previously been shown to increase 
membrane cholesterol content and cause functional defects, although this was not 
observed in LDL treated cells [39]. To investigate this possibility I used filipin staining 
to analyse non-esterified membrane cholesterol content by confocal microscopy. 
LDL and VLDL treatment at 100µg/ml for 120 minutes did indeed cause a modest 
increase in membrane cholesterol measured by filipin staining, however this only 
occurred in CD16neg monocytes (Figure 4.3A). Interestingly, it was VLDL that caused 
a more pronounced phenotype than LDL, although both were subtle. Representative 
images of filipin staining are shown in Figure 4.3B and unlike the neutral lipid vesicle 
accumulation the phenotype is not visually obvious. 
 
Figure 4.3 Membrane cholesterol staining in human monocytes after LDL/ VLDL 
treatment.  
Human CD16pos and CD16neg monocytes were purified and treated with LDL or VLDL (100µg/ml). 
(A) Membrane cholesterol content in monocytes was quantified by filipin staining intensity. (B) 
Representative examples of filipin cholesterol staining, scale bar represents 10µm. n=45-60 cells 
from two pooled experiments, error bars show the mean±SEM.  Groups were compared using a 
two-tailed Mann Whitney U test. 
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4.2.2. Monocyte	  uptake	  of	  fluorescent	  LDL	  and	  VLDL	  
Given that neutral accumulation occurs in human monocytes after LDL and VLDL 
treatment, I then investigated whether these lipid droplets could be due to uptake of 
complete lipoprotein particles or whether LDL/ VLDL exposure was stimulating 
mobilization of neutral lipid from another source. To do this, I utilized fluorescently 
labelled LDL and VLDL species and attempted to detect uptake in monocytes using 
flow cytometry. Whole leukocytes were isolated from human blood from healthy 
donors and incubated for 30-120 minutes with or without 100µg/ml DIO-labelled LDL 
or VLDL. Monocyte subpopulations were distinguished by fluorescent antibody 
staining for surface antigen expression, with monocytes defined as SSCint, HLA-
DR+, Lineageneg, as shown in Figure 1.2. In LDL and VLDL treated cells, the 
percentage of cells containing fluorescence signal from the DIO-labelled lipoproteins 
did rise over time, potentially indicating uptake was taking place. Following LDL 
treatment approx. 25% of CD16neg and 15% of CD16pos monocytes were LDL-
positive (LDL+) after 120 minutes (Figure 4.4A). Of these cells, the LDL median 
fluorescence intensity (MFI) was not significantly different between the two 
subpopulations, although there was a trend towards less LDL uptake in CD16pos cells 
(Figure 4.4B), consistent with previous neutral lipid accumulation data (Figure 4.2C). 
For VLDL, uptake levels were lower and the kinetics appeared to be delayed; at 120 
minutes incubation approx. 15% of CD16pos and 10% of CD16neg monocytes were 
VLDL+, although this difference was not significant (Figure 4.4C). There was also a 
concurrent trend towards slightly less VLDL in CD16pos monocytes at 120 minutes, 
as measured by MFI (Figure 4.4D). Representative histograms of LDL or VLDL- DIO 
signal from monocyte subpopulations are shown in Figure 4.4E and Figure 4.4F 
respectively, which display a positive shift in LDL/VLDL signal after incubation 
without clear positive or negative populations. 
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Figure 4.4 Uptake of fluorescent LDL and VLDL by human monocyte subpopulations.  
Human blood leukocytes were purified and treated with DIO-labeled LDL or VLDL (100µg/ml). 
Lipoprotein uptake was assessed in CD16pos and CD16neg monocytes using fluorescent antibody 
staining and flow cytometry, with monocytes defined as SSCint, HLA-DR+, Lineageneg, n=3 
donors. (A) Percentage of CD16pos and CD16neg monocytes that were LDL+ over time. (B) LDL-
DIO median fluorescence intensity (MFI) of LDL+ monocytes after 120 minutes incubation. (C) 
and (D) represent the same data for VLDL-DIO treatment. (E-F) Representative histograms of 
(E) LDL-DIO and (F) VLDL-DIO signal intensity in untreated total leukocytes (grey) or monocyte 
subpopulations after 120 minutes LDL/VLDL treatment (magenta). (G) Representative 
ImageStream micrograph from 3 independent experiments of CD16pos and CD16neg monocytes 
after 120 minutes treatment with LDL-DIO. Error bars show the mean±SEM. 
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Figure 4.5 Uptake of fluorescent LDL by mouse monocytes in vivo. 
C57Bl/6 mice were injected IV with 25µg LDL-DIO per mouse. Blood GR1high and GR1low 
monocytes were analyzed for LDL uptake at 4 and 24 hours post-injection, n=3 mice per group. 
(A) Percentage of cells LDL-positive. (B) Representative flow cytometry plots of LDL signal in 
GR1high and GR1low monocytes (Gated as CD11bpos CD115pos). Error bars show the mean±SEM. 
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Due to the subtle nature of the uptake as measured by flow cytometry, I decided it 
was important to try and confirm that: 1) the LDL and VLDL were entering the cell 
and not stuck to the outside of the cell membrane and 2) the signal from the DIO 
channel was not due to non-specific labelling of the cells due to free dye in the 
lipoprotein preparations. To eliminate some of this possibility I utilized Amnis 
ImageStream technology to analyse LDL-DIO uptake, which allows for high-
resolution fluorescence microscopy during flow cytometry. Cells were treated the 
same as for conventional flow cytometry and representative images of LDL+ 
monocyte subpopulations are shown in Figure 4.4G. Clear intracellular punctae of 
DIO signal were seen in LDL+ cells and the signal was not outside of the cell 
membrane. In addition CD16pos monocytes seemed to contain less LDL punctae 
than CD16neg, which is in agreement with conventional flow cytometry LDL-MFI data 
(Figure 4.4B).  
 
To confirm that fluorescent LDL uptake also occurred in mouse monocytes in vivo, 
wild-type C57Bl/6 mice were intravenously injected with 25µg of LDL-DIO. Blood was 
taken at 4 and 24 hours post-injection in order to assess GR1high and GR1low 
monocyte (CD115pos CD11bpos SSCint) LDL uptake by flow cytometry. Approximately 
7% of GR1high and 10% of GR1low monocytes had internalized LDL after 4 hours, and 
there was a subtle fall in these proportions in both subsets by 24 hours (Figure 4.5A-
B). Therefore, even at this low dose, LDL uptake can be seen in mouse monocytes 
within 4 hours of exposure.  
 
4.2.3. 	  Blocking	  monocyte	  LDL/	  VLDL	  uptake	  
While neutral lipid accumulation in the Ldlr-/- mouse would suggest that the LDLR is 
not involved in LDL/ VLDL uptake in mouse monocytes, at this stage there was no 
clear evidence regarding the LDL or VLDL uptake mechanism in human monocyte 
subpopulations. As such, I attempted to utilize receptor-blocking strategies to 
determine the uptake pathways for these lipoproteins. Initially, I targeted the LDLR 
family using Low density lipoprotein receptor-related protein-associated protein 1 
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(RAP). RAP is an endoplasmic reticulum- resident protein that acts as a chaperone, 
preventing ligand binding and facilitating receptor maturation during the intracellular 
transport of the LDLR, low-density lipoprotein receptor-related protein (LRP) and 
other members of the LDLR family [40,41]. An excess of exogenous RAP binds to 
LDLR family members and antagonizes lipoprotein binding in an allosteric manner 
[40]. Therefore, cells were incubated with 1.25µM RAP for 1 hour, which is greater 
than the previously reported saturating concentration for blocking LDLR family 
members [42]. Monocytes were then treated with LDL-DIO and VLDL-DIO and 
assessed for uptake by flow cytometry as described above. RAP treatment resulted 
in an approx. 50% decrease in percentage of CD16neg monocytes that were LDL+, 
and a trend towards less CD16pos LDL+ cells (Figure 4.6A). However, this was only 
accompanied by a slight decrease in LDL signal intensity in monocytes when 
assessed by histogram (Figure 4.6B).  Similar results were seen for VLDL, with 
modest decreases in uptake following RAP treatment in both CD16neg and CD16pos 
subpopulations (Figure 4.6C-D).  
 
Another likely candidate for LDL and VLDL uptake in monocytes was the class-B 
scavenger receptor CD36. Antagonism of CD36 binding was performed using a 
blocking antibody as previously described [43], with monocytes treated at a 
concentration of 10µg/ml for 1 hour prior to 2 hours of LDL-DIO or VLDL-DIO 
treatment. CD36 blockade led to a greater than 5-fold decrease in the percentage of 
monocytes LDL+ in both subpopulations, although this change was only significant in 
CD16neg cells (Figure 4.6E). This was accompanied by a notable shift in LDL-DIO 
histogram peak in all monocytes (Figure 4.6F). However, anti-CD36 treatment had 
no significant effect on percentage of monocytes to uptake VLDL, with a trend 
towards less uptake in the CD16neg subset (Figure 4.6G-H). Given that neither the 
LDLR family nor CD36 seemed to be major contributors to VLDL uptake; I 
proceeded to examine other candidate pathways. Previously there has been some 
suggestion that class-A scavenger receptors are involved in VLDL uptake [44] and 
this group of receptors can be competitively blocked using dextran sulphate (DS) 
treatment [45]. Using chondroitin sulphate (CS) as a control glycosaminoglycan 
(GAG), monocytes were treated with/ without 100µg/ml CS or DS for 1 hour before 
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LDL or VLDL treatment and analysis by flow cytometry as above. However, this 
methodology had two major technological problems: 1) the CS control increased the 
percentage of monocytes which uptake VLDL compared to PBS (Figure 4.6I) and 2) 
CS abolished any CD16 staining in monocytes (Figure 4.6J-K). It was thus 
impossible to make any conclusions regarding the ability of DS to block VLDL 
uptake, or to make any comparisons between monocyte subpopulations. This issue 
existed on every occasion the experiment was performed and resulted in no further 
investigation of the class-A scavenger receptors in this context.  
 
To additionally confirm that the LDLR played on a minor role in LDL and VLDL 
uptake in monocytes, murine Ldlr-/- total blood monocytes were purified and treated 
with 100µg/ml LDL or VLDL-DIO for 2 hours as in previous experiments. By flow 
cytometry, loss of the LDLR did not significantly decrease the percentage of 
monocytes positive for LDL or VLDL uptake (Figure 4.6L).  
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Figure 4.6 Blocking LDL/ VLDL uptake via the LDLR-family, CD36 and Class-A 
Scavenger Receptors.  
In all experiments, human blood leukocytes were purified and lipoprotein uptake was assessed in 
CD16pos and CD16neg monocytes using fluorescent antibody staining and flow cytometry, n=3 
donors. To block the LDLR family, cells were pre-treated with 50µg/ml RAP or BSA control, 30 
minute and then treated with DIO-LDL or VLDL (100µg/ml), 2 hours.  (A) Percentage of cells 
LDL-positive. (B) Representative histogram of LDL uptake with/ without RAP pre-treatment. (C) 
and (D) show the same experiment with VLDL. To block CD36, cells were pre-treated with 
10µg/ml anti-CD36 antibody for 1 hour and then treated with DIO-LDL or VLDL (100µg/ml), 2 
hours. (E) Percentage of cells LDL-positive. (F) Representative histogram of LDL uptake with/ 
without RAP pre-treatment. (G) and (H) show the same data for VLDL. To block class-A 
scavenger receptor, cells were treated with 100µg/ml DS or CS control. (I) Percentage 
monocytes VLDL- positive, (J-K) Representative flow cytometry plots of monocyte (SSCint, HLA-
DR+) CD14 and CD16 staining after (J) PBS treatment or (K) CS treatment. Monocytes from 
wild-type or Ldlr-/- mice were purifed and treated with DIO-LDL or VLDL (100µg/ml), 2 hours, n=4 
pooled technical replicates. (L) Percentage of cells monocytes LDL or VLDL positive. Error 
shows the mean ± SEM, groups were compared using a two-tailed Mann Whitney U test.  
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4.2.4. Blocking	  monocyte	  neutral	  lipid	  accumulation	  
Given the relatively low percentage of monocytes which uptake exogenous LDL/ 
VLDL by flow cytometry (10-20%) and the generally weak signal obtained from 
internalized LDL or VLDL-DIO using this method, I decided to investigate uptake 
mechanisms further using neutral-lipid staining and confocal microscopy following 
LDL or VLDL treatment. As shown in Figure 4.2, 40-100% of monocytes are lipid-
positive following treatment using this metric, and the exact number, size and 
localization of lipid vesicles can be accurately assessed. Initially, I sought to confirm 
the observation made by flow cytometry that CD36-blocking impairs LDL uptake in 
monocytes. Monocyte subpopulations were treated with an IgM isotype control 
antibody or an anti-CD36 antibody for 1 hour as described above, followed by 2 
hours of LDL treatment. Cells were then stained for neutral lipid and analysed by 
confocal microscopy. Intriguingly, although LDL significantly increased neutral lipid 
vesicle number in both monocyte subpopulations as expected, anti-CD36 treatment 
did not impair this lipid accumulation (Figure 4.7A-B). This raised the interesting 
possibility that the neutral lipid vesicles observed on microscopy after LDL or VLDL 
exposure do not represent complete endocytosed lipoprotein particles, but are in fact 
generated via a separate uptake or biosynthetic pathway.  
 
For VLDL, others have previously described a pathway in smooth muscle cells and 
macrophages where the lipoprotein binds to heparan sulphate proteoglycans 
(HSPG) on the cell surface, which facilitates the hydrolysis of triacylglycerol to free 
fatty acids by membrane bound lipases, most notably lipoprotein lipase (LPL) [37]. 
This process could occur independently of scavenger receptors and could explain 
the discrepancy between LDL endocytosis and neutral lipid accumulation. To test 
this possibility monocyte subsets were pre-treated with 5UN/ ml mixed heparinase-I 
and heparinase-III for 1 hour in order to cleave cell surface HSPGs, as previously 
described [46]. Subsequently monocytes were exposed to LDL or VLDL and imaged 
as in previous experiments. Heparinase treatment resulted in an almost complete 
inhibition of VLDL- induced neutral lipid vesicle formation in CD16pos monocytes, 
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while no effect was seen in the CD16neg subset (Figure 4.8A-B). A similar effect was 
also seen following LDL treatment, restricted to CD16pos monocytes (Figure 4.8C-D).  
 
Figure 4.7 The effect of anti- CD36 blocking antibody on LDL induced neutral lipid 
accumulation.   
Human CD16pos and CD16neg monocytes were purified and treated with 10µg/ml anti-CD36 or 
IgM isotype control antibody for 1 hour. LDL or VLDL (100µg/ml) was then added for 2 hours and 
intracellular neutral lipid was quantified using LipidTOX by confocal microscopy, n=30-45 cells. 
(A) Number of neutral lipid vesicles per cell. (B) Representative examples of neutral lipid staining, 
scale bar represents 20µm. Error bars show the mean±SEM, groups were compared using a 
two-tailed Mann Whitney U test. 
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Figure 4.8 The effect of heparinase treatment on LDL and VLDL induced neutral lipid 
accumulation.  
Human CD16pos and CD16neg monocytes were purified and treated with 5UN/ml heparinase or 
vehicle control for 1 hour. LDL or VLDL (100µg/ml) was then added for 2 hours and intracellular 
neutral lipid was quantified using LipidTOX by confocal microscopy, n=35-50 cells, data shows 1 
representative experiment of 3. (A) Number of neutral lipid vesicles per cell after VLDL treatment. 
(B) Representative examples of neutral lipid staining in VLDL treated cells. The same data is 
shown for LDL treatment in (C) and (D). Scale bars represents 20µm. Error bars show the 
mean±SEM, groups were compared using a two-tailed Mann Whitney U test.  
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These data suggested that proteoglycan binding and cell surface lipase might indeed 
be involved to some degree in neutral lipid uptake. As such, I used 
immunofluorescent staining of monocytes to determine whether LPL is present on 
the cell membrane. As shown in Figure 4.9A, punctae of LPL staining can be seen in 
monocytes from healthy donors by confocal microscopy and appears to localize to 
the cell surface, although this staining pattern was present in both monocyte 
subpopulations. In these cells, fluorescent actin staining with phalloidin was also 
used to delineate cell structure. To assess the role of LPL in neutral lipid uptake 
monocytes were treated with 50µM tetrahydrolipstatin (orlistat), a commercially 
available lipase inhibitor that is used clinically to prevent lipid absorption by intestinal 
enterocytes [47]. However, prior to the addition of LDL or VLDL orlistat increased 
neutral lipid vesicle number in both CD16neg and CD16pos monocytes, although most 
notably in CD16pos (Figure 4.9B), making its use as an inhibitor of LDL or VLDL 
induced lipid accumulation challenging to interpret.  
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Figure 4.9 Cell surface LPL staining and orlistat treatment of human monocytes.  
Human monocytes were purified and stained for the presence of lipoprotein lipase (LPL) and 
actin using immunofluorescence. (A) A representative confocal micrograph of monocyte LPL and 
actin staining, scale bar represents 10µm. Monocytes were treated with 50µg/ml orlistat or 
vehicle control for 1 hour and intracellular neutral lipid was quantified using LipidTOX by confocal 
microscopy, n=20-25 cells. (B) Number of neutral lipid vesicles per cell after orlistat or vehicle 
treatment. Error bars show the mean±SEM, groups were compared using a two-tailed Mann 
Whitney U test. 
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4.3. Discussion	  
The data presented here clearly demonstrate that human monocytes will undergo 
cytoplasmic neutral lipid accumulation in response to LDL or VLDL, similar to that 
observed in the Ldlr-/- fed HFD. Monocytes also internalize fluorescently labeled LDL 
and VLDL as assessed by flow cytometry, although it is unclear how related these 
two phenotypes are. The kinetics of uptake would suggest that neutral lipid 
accumulation is not a direct metric of lipoprotein internalization, as while neutral lipid 
content peaks at 30 minutes incubation and is lower at subsequent time points, LDL 
and VLDL uptake increases over time in a fairly linear fashion. However, it is 
important to note that quantifying amount of LDL or VLDL internalized by flow 
cytometry was challenging and hampered by low sensitivity, limiting quantification of 
lipoprotein uptake to percentage of cells LDL or VLDL positive. The low proportion of 
LDL/ VLDL positive cells by flow cytometry also suggests that sensitivity may be an 
issue in this assay. While DIO- signal did increase over time, generally only around 
15% of monocytes had detectable uptake after 2 hours; considerably lower than 
neutral lipid staining that in CD16neg LDL treated monocytes reached 100% at 150 
minutes incubation.  
 
The specificity of LipidTOX used for neutral lipid staining and DIO for LDL/VLDL 
labeling may also be useful in understanding differences in uptake patterns. 
Although the structure of LipidTOX remains unpublished, it is reported to have high 
specificity for neutral lipid droplets. Neutral lipids are a broad group of lipid species 
encompassing triacylglycerols, sterol esters and wax esters, which acts as storage 
molecules for sterols and FFAs and cannot be incorporated into membrane bilayers 
due their lack of charged groups [48]. It is well known that there are triacylglycerol 
and cholesterol ester specific lipid droplets in many cell types for lipid storage, 
although these are distinct organelles surrounded by a phospholipid monolayer and 
originating from the endoplasmic reticulum (ER), not as a direct result of 
endocytosis. Once LDL or VLDL undergoes endocytosis it is delivered to lysosomes 
where cholesterol esters are hydrolysed forming unesterified cholesterol. Lipoprotein 
derived cholesterol is then delivered to the ER, where excess is re-esterified by 
ACAT and is subsequently packaged into neutral lipid droplets for storage [18,20]. 
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Previous work in macrophages has demonstrated that internalized VLDL associates 
with ribosomal, ACAT-rich structures after only 10 minutes of incubation [49], 
emphasizing the rapid kinetics of this process. As such, it is conceivable that the 
initial increase in neutral lipid staining at 30 minutes in Figure 4.2B represents 
staining of cholesterol esters in endocytosed VLDL, which subsequently decreases 
at 60 minutes as the cholesterol esters are hydrolysed and begins to increase again 
at 150 minutes as the cholesterol is re-esterified by ACAT. In contrast to LipidTOX, 
DIO is a lipophilic carbocyanine dye that predominantly labels the cell membrane, 
thus implying specificity for polar lipids such as non-esterified sterols and 
phospholipids. It is also possible that low rates of LDL and VLDL uptake by DIO 
labeling are due to dye degradation, as the acidic pH of the lysosome and lysosomal 
hydrolases result in a complete digestion of LDL proteins to their constituent amino 
acids within 60 minutes of endocytosis [18]. 
 
While the work presented here is primarily focused on lipid uptake, impaired 
cholesterol efflux is also a key pathway in the formation of macrophage foam cells 
(Reviewed in [50]). Notably, myeloid knockout of the efflux-associated cholesterol 
transporters ABCA1 and ABCG1 promotes macrophage foam cell formation and 
atherosclerosis progression in mice [51] and these macrophages develop lipid 
droplet accumulation in response to cholesterol in vitro [39]. In the context of 
monocytes, the non-classical subpopulation has been shown to have increased 
cholesterol efflux in vitro compared to classical monocytes [52]. However, monocytes 
from the Ldlr-/- mouse are theoretically efflux-competent, as they possess the 
necessary transporter proteins and are in the presence of cholesterol acceptors such 
as HDL. Given that these monocytes still accumulate neutral lipid droplets on HFD 
and that this is most pronounced in the GR1low non-classical population, the data 
suggest that a lack of effective cholesterol efflux is not a major contributor to this 
phenotype.  In addition, a low plasma level of cholesterol acceptors (i.e. HDL) is a 
key feature of the dyslipidemia that drives cardiovascular disease [52,53]. Given 
these data, cholesterol acceptors were not added to in vitro cultures used in the 
experiments presented here.  
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Intriguingly, receptor-blocking experiments also suggest that neutral lipid 
accumulation and LDL/ VLDL endocytosis may be mediated via separate pathways. 
Using DIO labeling it appears that the LDLR and its associated family has only a 
modest contribution to in vitro LDL and VLDL uptake in these experiments, as 
suggested by in vivo data. This is fairly unsurprising as LDLR mediated uptake is 
thought to be a regulated, homeostatic process that should not result in excessive 
intracellular lipid accumulation. In addition, the LDL used in these experiments has 
undergone a degree of oxidative modification as measured by conjugated diene 
formation, thus presumably generating electronegative LDL that would be targeted to 
scavenger receptors. Consistent with this hypothesis, LDL-DIO uptake can be 
significantly impaired by blockade of CD36, although this is not true to VLDL. 
Although VLDL has high conjugated diene content in our experiments, this does not 
increase after storage under air and the role of oxidative modification in VLDL uptake 
is still subject to debate [13,14]. When an attempt was made to examine the potential 
for MSRA mediated VLDL uptake, experiments were hampered by clear off target 
effects of the inhibition, particularly for the control treatment with chondroitin sulphate 
(CS). CS both increased VLDL uptake and completely prevented the detection of 
any CD16pos monocytes by flow cytometry. The increase in uptake may be due to CS 
stimulating a compensatory increase in membrane receptor turnover, while the lack 
of CD16 staining on monocytes is more difficult to explain. One possibility is that CS 
is competing for CD16 binding with the anti-CD16 antibody, although more work 
would be required to investigate this hypothesis.  
 
However, unexpectedly CD36 blocking did not alter significantly neutral lipid 
accumulation after LDL treatment. This was further confounded by the finding that 
heparinase removal of HSPGs almost completely abolishes neutral lipid vesicle 
formation after LDL and VLDL treatment, but only in CD16pos monocytes. One 
possibility is that while CD16neg monocyte lipoprotein uptake is mediated by 
endocytosis through an undetermined receptor, CD16pos cells also utilize the 
pathway proposed by Ira Goldberg, where lipoproteins bind to HSPGs and their 
triacyglycerols are hydrolysed to free fatty acids, allowing passage through the cell 
membrane [37]. Alternatively, CD16neg cells could undergo faster proteoglycan 
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synthesis than the rate of removal by heparinase, or utilize alternative proteoglycan 
species such as chondroitin sulphate for LDL binding as has been reported in 
macrophages [54]. While all interesting possibilities, at this stage there is little 
evidence for any of these hypotheses. Investigation of this pathway was also 
impaired by the rapid formation of neutral lipid vesicles in monocytes treated with the 
lipase inhibitor orlistat, independent of lipoprotein treatment. In retrospect, this is 
unsurprising: cholesterol esters in macrophages have been reported to undergo a 
continuous cycle of hydrolysis and re-esterification by various lipases (cholesteryl 
ester hydrolases) and ACAT respectively [55]. By inhibiting lipase-mediated 
hydrolysis, one presumably causes cholesterol in the cell to become retained in an 
esterified, neutral state, resulting in more LipidTOX staining.  
 
Clearly, there are multiple receptors and uptake pathways utilized by monocytes in 
the internalization of LDL and VLDL. While CD36 dependent uptake is important in 
LDL endocytosis, it does not appear to be involved in VLDL uptake, nor does it 
mediate the neutral lipid accumulation seen after LDL/ VLDL treatment.  Many 
studies of uptake mechanisms in primary cells are hampered by a lack of appropriate 
tools, as receptor blocking strategies can have unexpected off- target effects. A key 
conclusion can be drawn from these data: LDL and VLDL uptake occurs in human 
and mouse monocytes, leading to intracellular lipid accumulation. The exact 
mechanisms of this await discovery and require more detailed investigation, possibly 
in a more genetically tractable system such as an immortalized monocyte cell-line. 
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5. THE	  EFFECTS	  OF	  ATHEROGENIC	  
LIPOPROTEINS	  ON	  MONOCYTE	  
FUNCTION	  
5.1. Introduction	  
Traditionally, any work performed assessing monocyte function in response to 
dyslipidaemia has focused on one of two contexts: 1) hypercholesterolemia 
characterized by elevated LDL and VLDL or 2) post-prandial lipaemia, characterized 
by raised chylomicrons, free-fatty acids (FFAs) and VLDL. In both contexts, much of 
the past literature is compromised by an assumption that monocytes are a 
homogenous population that must differentiate to tissue macrophages in order to 
have immune effector functions.  Nonetheless, some interesting work exists on the 
monocyte response to atherogenic lipoproteins.  
 
In the context of LDL and VLDL, studies have been performed on monocytes from 
patients with familial hypercholesterolemia (FH). Initially, Mosig et al noted that a 
greater proportion of monocytes from FH homozygotes contain neutral lipid than 
healthy controls [1]. A concurrent gene expression microarray of monocytes healthy 
controls, FH heterozygotes and FH homozygotes demonstrated that monocytes from 
FH patients have alterations in cholesterol metabolism that increase in severity in 
homozygotes [1].  Interestingly, an increase in CD36 and LRP1 expression is 
accompanied by down-regulation of ABCA1 in FH monocytes, which is hypothesized 
to increase uptake of oxidized LDL and decrease cholesterol efflux leading to an 
intracellular lipid overload [1]. This increased CD36 expression was subsequently 
confirmed by others and associated with atherosclerosis severity in FH 
heterozygotes [2]. Functional analysis in monocyte subsets from FH patients 
demonstrated increased surface integrin expression in both CD16pos and CD16neg 
subpopulations accompanied by altered adhesion to an endothelial monolayer, 
although this phenotype was most pronounced in CD16pos monocytes [3].  
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Phagocytosis of latex beads was also impaired in FH monocytes in both subsets, 
both at baseline and following LDL stimulation [4]. Although this study did not assess 
any further functional impact of hypercholesterolemia on monocytes in the context of 
inflammation, in vitro oxLDL treatment has been shown to both increase[5] and 
inhibit[6] inflammatory cytokine production both alone and in response to TLR 
stimulation in human monocytes, highlighting the on-going confusion in this field.  
 
A high fat meal significantly elevates plasma chylomicrons, VLDL and free fatty 
acids, peaking at 3 to 4 hours post-prandially [7]. As such, post-prandial analysis of 
monocytes can be used to study the acute effects of triglyceride-rich lipoproteins 
(TGRL) on these cells. 13C –labelled palmitic acid has been tracked into leukocytes 
following a high fat meal [8], indicating that this stimulus could have a functional 
impact. Analysis of monocyte postprandial gene expression has revealed increased 
expression of integrins, including CD11b (ITGAM) and CD11c (ITGAX) and 
alterations in lipid handling genes including ABCA1 and APOB48R [9,10]. Using a 
mixed high fat meal, Simon et al demonstrate that monocytes can acutely 
accumulate intracellular lipid, resulting in an up-regulation of surface CD11c protein 
and increased adhesion to a VCAM-1 layer during perfusion [11], which has 
subsequently been hypothesized to lead to increased recruitment to the 
atherosclerotic plaque [12]. Postprandial VLDL lipolysis products have also been 
shown to increase monocyte surface integrins and adhesion to an endothelial 
monolayer in vitro, via an NF-κB/ ERK2 dependent pathway [13]. Interestingly, the 
transcriptional effect of post-prandial lipaemia effect appears to be specific to 
saturated fatty acids (SFAs) and not polyunsaturated fatty acids (PUFAs), consistent 
with a role for PUFAs as protective in cardiovascular disease [10]. In addition, dietary 
supplementation with PUFA-rich fish oil inhibits the expression of monocyte 
adhesion molecules [14], decreasing monocyte adhesion to an endothelium and 
subsequent neutrophil recruitment [15]. However, this is not accompanied by a 
decrease in inflammatory cytokine production [15] and the mechanisms of this 
phenotype are poorly described. Despite this intriguing literature there is very little 
data on the functional impact of TGRLs on monocyte subpopulations and 
postprandial studies are often confounded by effects concurrent to lipaemia, 
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including elevated plasma glucose and insulin [7]. As such, I planned to further 
investigate the functional response of LDL and VLDL treated monocyte 
subpopulations in vitro, given the pronounced uptake of these lipoprotein species 
exhibited by both human and mouse monocytes.  
5.2. Results	  
5.2.1. The	  effect	  LDL/VLDL	  on	  monocyte	  apoptosis	  
Given previous literature demonstrating the ability of oxLDL to induce macrophage 
apoptosis [16,17], the first logical stage of functional analysis in LDL and VLDL 
treated human monocytes was to confirm that in vitro lipoprotein exposure was not 
inducing cell death. Total monocytes were isolated from human peripheral blood and 
treated with 100µg/ml LDL or VLDL for two hours, as in previous experiments. At this 
time point, cells were stained for CD14, CD16 and HLA-DR expression to distinguish 
monocyte subpopulations by flow cytometry and for apoptosis using a fluorescently 
labelled Annexin V. Annexin V is a cellular protein of unknown function that binds to 
phosphatidylserine (PS), which becomes exposed on the surface of cells undergoing 
programmed cell death [18]. It is important to note that activated platelets also 
express PS, making exclusion of platelet contamination important to obtain an 
accurate result. (See Chapter 2.2 for details). Using this metric approximately 5% of 
monocytes were apoptotic in both subpopulations and this number was unchanged 
by LDL or VLDL treatment (Figure 5.1A). A representative flow cytometry histogram 
for Annexin-V staining of total monocytes is shown in Figure 5.1B. As such, I 
concluded that LDL and VLDL treatment is not affecting monocyte cell death.  
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Figure 5.1 Monocyte apoptosis following LDL/ VLDL treatment.  
CD16pos and CD16neg human monocytes were first incubated with and without 100µg/ml LDL or 
VLDL for 2 hours and analysed by flow cytometry, n= 3 donors. (A) Percentage of CD16pos/ 
CD16neg monocytes which are apoptotic as assessed by annexin-V staining. (B) Representative 
Annexin-V intensity histogram of total monocytes treated with PBS or LDL and stained with 
Annexin-V or unstained (US). Error bars show the mean ± SEM. 
 
5.2.2. Modulation	  of	  monocyte	  activation	  and	  cytokine	  
production	  by	  LDL/	  VLDL	  
Given that apoptosis is unaffected, I then investigated whether lipoprotein treatment 
causes an ‘activated’ phenotype in human monocytes. Monocyte activation following 
TLR stimulation and the process of monocyte to macrophage differentiation are both 
accompanied by a modulation of CD16, CD14 and HLA-DR expression, which are 
also used to distinguish monocyte subsets [16,17]. As such, I utilised flow cytometry 
of human PBMCs following 2 hours of LDL or VLDL treatment in order to assess cell 
surface levels of these antigens. HLA-DR, CD14 and CD16 were all unchanged 
compared to PBS stimulation by both LDL (Figure 5.2A-C) and VLDL (Figure 5.2E-
G) at this time in both CD16pos and CD16neg monocytes.  As discussed previously, 
TGRLs can also cause up-regulation of surface integrin expression in murine 
monocytes, most notably CD11c [11]. In addition, Wu and colleagues recently 
reported that a population of CD11cpos CD36pos lipid-loaded monocytes appears 
when Apoe-/- mice are fed HFD. However, CD11c (Figure 5.3A-B) and CD36 (Figure 
5.3C-D) surface expression was unchanged following 2 hours LDL and VLDL 
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treatment in both monocyte subpopulations. While both monocyte subpopulations 
express CD11c and CD36, CD11c was elevated in CD16pos monocytes and CD36 
was enriched in the CD16neg population, consistent with previously published work 
[18]. These data therefore suggest that in vitro treatment with these lipoproteins at 2 
hours does not cause overt monocyte activation.  
 
Figure 5.2 Effect of LDL/ VLDL treatment on monocyte surface marker expression.  
For all experiments, CD16pos and CD16neg human monocytes were first incubated with and 
without 100µg/ml LDL or VLDL for 2 hours, n=3-4 donors. After LDL treatment: cell surface (A) 
HLA-DR MFI, (B) CD14 MFI and (C) CD16 MFI.(D-F) Corresponding data after VLDL treatment. 
Error bars show the mean ± SEM. 
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Figure 5.3 Effect of LDL/ VLDL treatment on monocyte surface CD11c and CD36.  
For all experiments, CD16pos and CD16neg human monocytes were first incubated with and 
without 100µg/ml LDL or VLDL for 2 hours, n=3-4 donors. Cell surface protein was assessed by 
flow cytometry (A) CD11c MFI, (B) Representative CD11c histograms. (C-D) Same data is 
shown for CD36. Error bars show the mean ± SEM. 
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The role of exogenous lipid in the response to inflammation by monocytes and 
macrophages remains controversial, and a lack of changes in surface marker 
expression led me to investigate this further by assessing the monocyte cytokine 
response. When mRNA abundance was measuring using qPCR following 2 hours of 
LDL (Figure 5.4A) or VLDL (Figure 5.4B) stimulation there was no change in 
transcription of IL1B, TNF or IL8 in either CD16pos or CD16neg monocytes, indicating 
that inflammatory gene expression was not affected. Although there are subtle 
changes such as an increase in IL-8 transcription in CD16neg monocytes, these data 
are presented on a log2 ratio scale and the changes observed are extremely limited. 
However, at this early time point in macrophages some cytokines (i.e. TNF-α) are not 
transcriptionally regulated, but instead derived from a constitutively transcribed pool 
of mRNA that is rapidly stabilized and translated following stimulation [19]. In 
addition, lipid loading has been shown to both inhibit and perpetuate TLR- driven 
inflammatory responses in monocytes and macrophages. As such, I examined the 
effect of LDL and VLDL pre-treatment on monocyte IL-1β and TNF-α production in 
response to 16 hours LPS and R848 stimulation using a multiplex bead array. Using 
a mixed inflammatory stimulus of LPS and R848 allows direct comparison of 
CD16neg and CD16pos monocytes, since these subpopulations exhibit an optimal 
cytokine response to TLR4 and TLR7/8 agonists respectively [19].While LPS and 
R848 exposure induced a robust cytokine response as expected, LDL (Figure 5.4C-
D) or VLDL (Figure 5.4E-F) treatment had no significant effect on the IL-1β or TNF-α 
production induced by TLR activation. However, VLDL alone did induce a modest 
decrease in CD16neg monocyte TNF-α levels (Figure 5.4F). Taken together, these 
data confirm that this in vitro lipoprotein treatment in human monocytes is definitively 
not an inflammatory stimulus and may in fact cause a slight inhibition of TNF-α 
production under homeostatic conditions, as has been previously proposed for the 
cholesterol biosynthesis intermediate desmosterol in macrophages [20].  
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Figure 5.4	  Effect of LDL/ VLDL treatment on monocyte cytokine response.  
Human CD16pos and CD16neg monocytes were purified and treated (2hrs) with LDL or VLDL 
(100µg/ml). Cytokine gene expression was analysed by qPCR after (A) LDL or (B) VLDL 
treatment (n=3 donors in duplicate).  Following LDL/ VLDL treatment, monocytes were incubated 
for 16 hours with or without LPS (100ng/ml) and R848 (2µg/ml). Supernatants were collected for 
cytokine analysis (n=3-4 donors in duplicate). (C) IL-1β and (D) TNF-α secretion after LDL pre-
treatment. (E-F) Same as C-D except with VLDL treatment.  Error bars show the mean±SEM, 
groups were compared using a two-tailed Mann-Whitney U test. 
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5.2.3. Monocyte	  phagocytosis,	  chemotaxis	  and	  chemokinesis	  
following	  LDL/	  VLDL	  treatment.	  
Given that HFD reduces monocyte accumulation in the peritoneum of the mouse 
during inflammation, I hypothesized that neutral lipid loaded monocytes may have an 
intrinsic migratory defect. In addition, migration and phagocytosis of exogenous 
particles are intrinsically linked processes and monocytes from FH patients have 
been previously reported to have a defect in phagocytosis [4]. As such, I initially 
examined phagocytosis of fluorescent latex beads by flow cytometry in monocyte 
subsets treated with LDL or VLDL for 2 hours. Number of internalized latex beads 
can clearly be gated in monocytes using peaks in fluorescence intensity, as shown in 
Figure 5.5A. After 1 hour, only approx. 5-10% of CD16neg monocytes and 25-30% 
CD16pos monocytes remained negative for bead uptake (Figure 5.5B), with >80% 
CD16neg and >35% CD16pos cells having phagocytosed more than 4 beads (Figure 
5.5C). These proportions were largely unaffected by LDL or VLDL treatment, with a 
slight trend towards more phagocytosis following lipoprotein incubation. This was 
supported by the median bead fluorescence intensity in the bead-positive population, 
which does not change significantly between the control, LDL and VLDL groups, 
indicating that the amount of intracellular beads is equal (Figure 5.5D). As such, it 
appears that acute lipoprotein exposure does not mediate the same phagocytic 
defect reported in FH patient monocytes and in general there is a trend towards the 
opposite phenotype. 
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Figure 5.5 Effect of LDL/ VLDL treatment on monocyte phagocytosis.  
CD16pos and CD16neg human monocytes were first incubated with or without 100µg/ml LDL or 
VLDL for 2 hours. Cells were then incubated with carboxylated 1µm latex beads to assess 
phagocytosis. (A) Representative histogram of latex bead gating.  (B) % of cells which are 
beadneg or (C) which have phagocytosed >4 beads after 1 hour incubation. (D) Bead median 
fluorescence intensity (MFI) in bead-positive cells. n=3 donors in duplicate. Error bars show the 
mean±SEM. 
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Cholesterol loading has also been reported to impair macrophage chemotaxis in 
ABCA1/ ABCG1-/- cells [21] and as such I then investigated the ability of monocytes 
to migrate towards a chemoattractant, in this case C5a, after treatment with 
100µg/ml LDL or VLDL for two hours. C5a is a well-characterized chemoattractant 
for monocytes [22] and transgenic mice lacking C5 have a strongly impaired 
response to thioglycollate peritonitis [23]. Initially, I utilized a simple transwell 
chamber assay where treated monocytes are seeded onto the top of a porous, 
polycarbonate membrane and migrate through the membrane towards a 
chemoattractant gradient in the bottom of the chamber. Cells on the underside of the 
membrane can then be stained and counted by microscopy. Using this approach, 
VLDL treatment caused an approx. 50% reduction in the number of CD16pos 
monocytes that had migrated and a subtle, non-significant decrease in CD16neg 
monocyte migration (Figure 5.6A), representative images of the nuclei of migrated 
cells for counting are shown in Figure 5.6B. LDL treatment also caused a decrease 
in monocyte migration although in this case only in CD16neg monocytes (Figure 
5.6C), potentially highlighting subset specific effects of the two lipoprotein species.  
 
However, in transwell assays it is difficult to determine whether true chemotaxis is 
occurring towards a stimulus, or to make any accurate assessment of effects on cell 
kinematics. As such, I used a 2D chemotaxis chamber slide in order to assess 
monocyte migration towards a C5a gradient in real time following 2 hours of VLDL 
treatment. From this point onwards, I chose to focus predominantly on VLDL, since 
this is the lipoprotein most elevated in the Ldlr-/- mouse on HFD [24] and causes a 
monocyte migratory defect in transwells. Unlike the transwell assay, total monocytes 
were seeded and an anti-CD16 fluorescent antibody was used to distinguish CD16pos 
and CD16neg subsets. Cells were tracked in real time over approx. 90 minutes and 
representative track projections are shown in Figure 5.6D. The track projections 
demonstrate an almost complete inhibition of monocyte chemotaxis by VLDL and 
this is confirmed by track analysis: both monocyte subpopulations have a decreased 
track confinement ratio (Figure 5.6E) and displacement (Figure 5.6F) in the presence 
of VLDL and CD16neg monocytes also display a significant decrease in track speed 
(Figure 5.6G). Interestingly and agreement with previous in vivo data [19,25], the 
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migratory behaviour of CD16pos non-classical monocytes is slower than the CD16neg 
population. One obvious explanation for this VLDL induced phenotype would be that 
lipid-loaded monocytes are down-regulating expression of the C5a receptor CD88. 
To exclude this possibility, LDL or VLDL treated monocytes were analysed for cell 
surface CD88 expression using flow cytometry. While monocytes expressed CD88 
as expected, neither lipoprotein species caused any change in CD88 levels in either 
CD16pos or CD16neg monocytes (Figure 5.6H) and a representative histogram of total 
monocyte CD88 staining is shown in Figure 5.6I. As such, lipoprotein treated 
monocytes should still be capable of responding to C5a at a receptor level.  
 
In addition to polarising and migrating towards a chemoattractant, monocytes will 
also undergo random, chemokinetic movement both with and without stimulation 
[26]. In the Cx3cr1gfp/+ animals utilized previously, HFD did not affect non-classical 
monocyte intravascular patrolling, during which monocytes appear to have random 
directionality[25] (Figure 3.7). I therefore hypothesized that VLDL treatment may only 
affect monocyte polarization towards a stimulus, rather than random chemokinetic 
migration. To test this hypothesis in human cells, experiments were performed as 
above using 2D chemotaxis chambers with a diffuse concentration of C5a rather 
than a gradient. As expected, track projections reveal cells migrating in all directions 
(Figure 5.7A). However, this migration was impaired in both CD16pos and CD16neg 
monocytes by VLDL pre-treatment, as quantified by displacement (Figure 5.7B), 
track speed (Figure 5.7C) and confinement ratio (Figure 5.7D). As such, VLDL does 
not require monocyte polarization towards a chemoattractant in order to inhibit cell 
migration in vitro.  
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Figure 5.6 Effect of LDL/ VLDL treatment on monocyte chemotaxis. 
 (A) Transwell migration of CD16pos and CD16neg monocytes to C5a (250ng/ml) with or without 
VLDL pre-treatment (2hrs; 100µg /ml). Data represents 12 fields of view from 3 independent 
experiments. (B) Representative cells/field migrated shown in (A) (scale bar = 100µm). (C) 
Transwell migration as in (A), but following LDL treatment. (D) Representative track projections 
from CD16pos and CD16neg monocytes with or without VLDL pre-treatment (2hrs; 100ug/ml) in a 
2D real-time chemotaxis assay towards a C5a gradient (n=3 independent experiments). Tracks 
were analysed for (E) confinement ratio (F) displacement (µm) and (G) speed (µm/sec) (n=120-
800 cells) (H) CD16pos and CD16neg monocyte cell surface expression of CD88 after 2 hours 
LDL/VLDL treatment, assessed by flow cytometry (n = 2 donors in duplicate). (I) Representative 
histogram of CD88 expression or isotype control signal (Iso) on total monocytes. Error bars show 
the mean±SEM, groups were compared using a two-tailed Mann-Whitney U test  
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Figure 5.7 Effect of VLDL treatment on monocyte chemokinesis.  
(A) Track projections from CD16pos and CD16neg monocytes with or without VLDL pre-treatment 
(2hrs; 100µg/ml) in a 2D real-time chemokinesis assay with diffuse C5a stimulation. Tracks were 
analyzed for (B) displacement (µm) (C) speed (µm/sec) and (D) confinement ratio (AU). n=50-
160 cells per condition, 1 representative experiment of 2. Error bars show the mean±SEM, 
groups were compared using a two-tailed Mann-Whitney U test 
  
The	  Effects	  of	  Atherogenic	  Dyslipidaemia	  on	  Blood	  Monocyte	  Function	  	  William	  Jackson-­‐	  January	  2016	  
The	  Effects	  of	  Atherogenic	  Lipoproteins	  on	  Monocyte	  Function	   	   	   123	  
 
5.2.4. 	  The	  effect	  of	  LDL/	  VLDL	  treatment	  on	  monocyte-­‐	  
endothelial	  adhesion	  and	  transendothelial	  migration.	  
A key factor in the regulation of monocyte chemotaxis and cell polarity is integrin-
mediated adhesion [27]. Since LDL and VLDL treatment has previously been 
reported to increase monocyte adhesion [13,28], I investigated the effects of 
lipoprotein treatment on CD16pos and CD16neg monocyte static adhesion to an 
endothelial layer. Human venous endothelial cells (HUVECs) were cultured in 
chamber slides to confluence and either CD16pos/CD16neg human monocytes or the 
HUVECs were treated with LDL or VLDL for 2 hours. Following treatment, 
monocytes were stained with a fluorescent nuclear dye for imaging and incubated 
with the HUVEC for 30 minutes, before paraformaldehyde (PFA) fixation of adherent 
monocytes and quantification by confocal microscopy. LDL treatment of monocytes 
caused an increase in the number of adherent CD16neg monocytes per field and a 
trend towards more adherent CD16pos cells (Figure 5.8A). Interestingly, LDL 
treatment of the endothelium did not have the same effect, as there was no 
significant change in the adherence of either subpopulation (Figure 5.8B). The same 
experiment with VLDL treatment did not produce any changes in adhesion when 
either the monocytes (Figure 5.8C) or the endothelial cells (Figure 5.8D) were 
treated. A representative image of fluorescently labelled monocytes adhered to a 
HUVEC monolayer for analysis is shown in Figure 5.8E.  
 
However, given the chemotaxis and chemokinesis impairment seen in VLDL treated 
monocytes in chamber slides, I hypothesized that LDL or VLDL treatment would 
impair monocyte transendothelial migration (TEM) in transwell chambers. HUVECs 
were grown on transwell membranes to confluence and activated with TNF-α in 
order to induce monocyte TEM. CFSE- labelled monocytes were LDL/VLDL pre-
treated as above and seeded onto the endothelium for 2 hours, before analysis by 
fluorescence microscopy. Somewhat unexpectedly, both LDL (Figure 5.8F) and 
VLDL (Figure 5.8G) treatment significantly increased monocyte TEM selectively in 
the CD16neg subpopulation, raising the interesting possibility that monocyte 
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chemotaxis is impaired by LDL/ VLDL following TEM exclusively in the extravascular 
compartment.  
 
Figure 5.8 Effect of LDL/ VLDL treatment on monocyte adhesion to HUVEC and 
transendothelial migration.  
(A-B) Adhesion of CD16pos and CD16neg monocytes to HUVECS, after (A) Monocyte pre-
treatment with VLDL (2hrs; 100 µg/ml), normalised to CD16neg PBS treated (n= 4 donors). (B) 
Same as (A) with only HUVECS treated with VLDL. (C-D) Corresponding data for LDL treatment. 
(E) Representative image of fluorescently labelled monocytes adhered to a HUVEC monolayer, 
scale= 500µm.  (F-G) Transmigration of CD16pos and CD16neg monocytes pre-treated with or 
without (F) LDL, or (G) VLDL (2hrs, 100 µg/ml) through TNF activated HUVEC: cells per field, 
normalised to CD16neg PBS treated (n=4 donors). Error bars show the mean±SEM, groups were 
compared using a two-tailed Mann-Whitney U test 
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5.3. Discussion	  
In previous literature, exposure to TGRLs or LDL is reported to have a profound 
inflammatory or anti-inflammatory effect in macrophages, as evidenced by cytokine 
transcription and release [5,6,29,30]. Largely through TLR signalling, modified LDL 
has been shown to modulate inflammation [5,6,29,30], while cholesterol crystals can 
activate the inflammasome [31]. Interestingly, Spann et al have subsequently 
suggested that these effects will be counter regulated via LXR-signalling during 
chronic dyslipidaemia, since accumulation of the cholesterol anabolic intermediate 
desmosterol leads to a deactivated phenotype in macrophage foam cells [20]. It is 
therefore somewhat surprising that the LDL and VLDL treatments used here did not 
modulate the transcription or release of the cytokines tested, both during 
homeostasis and after mixed TLR stimulation.  
 
However, given that most previous work in this field focuses on macrophages, it is 
important to emphasize that monocytes and macrophages are metabolically distinct 
cells that may differ in their lipid handling and inflammatory response to lipid signals 
[32-34]. Metabolic profiling during human monocyte to macrophage differentiation in 
vitro reveals a dramatic up-regulation of fatty acid synthesis, which is essential for 
normal macrophage function [34]. This is accompanied by a down-regulation of 
SREBP2 target genes involved in cholesterol synthesis and results in a shift in 
cellular lipid composition from predominantly free cholesterol in monocytes to 
phosphatidylcholine in macrophages [34]. In addition, the polarization signals 
received by monocyte-derived macrophages also affect their metabolic program 
[35,36].  While LPS/ IFNγ stimulated ‘M1’ macrophages rely on aerobic glycolosis, 
IL-4 stimulated ‘M2’ macrophages undergo extensive fatty acid oxidation, inhibition 
of which can prevent M2 differentiation [35]. Interestingly in the context of the work 
presented here, this metabolic program results in the presence of cytoplasmic 
neutral lipid droplets in M1, but not M2 polarized macrophages [35], suggesting that 
monocytes may not be utilizing fatty acid oxidation as a primary energy source. 
There is also some evidence that non-classical monocytes have increased 
mitochondrial oxygen consumption versus the classical subpopulation [37], which 
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may contribute to the lower levels of neutral lipid accumulation observed here in non-
classical CD16pos monocytes. 
 
Regarding cytokine transcription, it is possible 2 hours of LDL/VLDL stimulation may 
be too short a time frame for cytokines to be regulated at this level. In particular this 
is true for TNF-α, which is regulated largely by post-transcriptional mRNA processing 
and stored as large reserves of immature transcript [33]. However IL-8, which was 
also unchanged by LDL/VLDL exposure, is rapidly transcriptionally regulated in 
response to appropriate stimuli. For example, IL-1 can cause RNA-polymerase II 
recruitment and binding to the IL-8 (CXCL8) promoter within less than 30 minutes 
[38]. In addition, CXCL8 gene induction can be extremely dramatic, with some stimuli 
such as IL-1 causing a >100-fold up-regulation of expression [38]. Similarly rapid 
transcription kinetics have also been reported for IL1B, which can be induced by LPS 
stimulation in human monocytes and U937 monocytic cells within 1 hour [39]. As 
such, it appears physiologically possible that LDL and VLDL could induce cytokine 
transcription within 2 hours in monocytes, although this clearly does not occur in the 
experiments performed here. 
 
In addition, a lack of change in IL-1β release following LDL or VLDL stimulation with 
or without LPS and R848 suggests that the inflammasome is not being modulated in 
this context.  Following IL1B mRNA induction, pro- IL-1β  protein is synthesized and 
requires a second signal to be cleaved into its biologically active and secreted form. 
This occurs through caspase-1, which is activated via inflammasome complexes 
such as the NLRP3 inflammasome [40]. Cholesterol crystals have been reported to 
induce activation of this process in both monocytes and macrophages [31]. Given 
that no such phenotype is observed here, this effect may be mediated by the 
crystalline structure itself of the cholesterol rather than via the storage of cholesterol 
esters. Indeed, other crystals such asbestos and silica have also been demonstrated 
to activate the NLRP3 inflammasome [37], suggesting that this process may be 
independent of cholesterol. 
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Surface integrin expression levels have previous been shown to be a marker of 
monocyte activation[38] and receptors such as CD16 and HLA-DR are modulated 
during early monocyte- macrophage differentiation [17]. In keeping with the above 
observations that LDL and VLDL are not inflammatory in our experiments, I observed 
no changes in surface CD11b in vivo, or in CD14, CD16, HLA-DR, CD36 and CD11c 
levels during in vitro stimulation. Given that monocyte activation and increased 
integrin expression is strongly linked to monocyte adhesion, it is fairly unsurprising 
that I also observed limited differences in monocyte adherence to an endothelial 
monolayer. In my experiments, only CD16neg monocytes exhibited any change in 
adherence, and this was exclusively after LDL treatment. This subset specific effect 
may be due to different adhesion molecules utilized by CD16neg and CD16pos 
monocytes in their interactions with the endothelium: while CD16neg cells utilize the 
classical adhesion cascade, CD16pos monocytes depend on the Β2 integrin LFA-1 
and the chemokine receptor CX3CR1[41]. In addition, many studies prior to 
knowledge of monocyte heterogeneity used enrichment of CD14high cells to isolate 
monocytes, which excluded the CD14low CD16pos non-classical population.  
 
However, one must reconcile the data here with previous studies that have shown 
monocyte activation after VLDL or TGRL exposure [8,11,13]. Ultimately, nuances in 
the lipoprotein species used may explain differing the phenotypes. While the data 
presented here uses incubation with commercially available VLDL isolated from 
blood-bank plasma, both Gower et al and Alipour et al utilise either leukocytes from 
subjects who have ingested a high fat meal, or in vitro incubation with TGRLs 
isolated from post-prandial plasma [8,11]. Although not addressed in this study, the 
fatty acid composition of TRGLs including VLDL is known to change in the 
postprandial period depending on dietary intake [42]. As such, mixed commercial 
VLDL may not be comparable to VLDL isolated from subjects undergoing 
postprandial lipaemia from a high fat meal. It is unclear which of these stimuli would 
best represent what occurs in chronic elevation of TGRLs, such as in LPL-deficient 
patients [43].  
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Most strikingly in these experiments, VLDL caused a pronounced inhibition of both 
monocyte chemotaxis and chemokinesis. In transwell experiments, VLDL impairs 
migration in CD16pos monocytes with little effect on the CD16neg subpopulation, while 
LDL selectively affects CD16neg  cells. Although when a real time chemotaxis assay 
is used migration is clearly impaired in both subpopulations, the transwell data may 
indicate a subset specific response of monocytes to these different lipoprotein 
species. CD16pos non-classical monocytes have been shown to undergo increased 
fatty acid oxidation compared to CD16neg cells [37], which may relate to their specific 
response to fatty-acid rich VLDL in this assay. In addition, CD16pos monocytes have 
been hypothesized to be functionally similar to ‘M2-like’ alternatively- activated 
macrophages [44], which also preferentially utilize fatty acid oxidation rather than 
aerobic glycolysis in comparison to ‘M1-like’ cells [35]. Moreover, monocyte subsets 
have differential express of adhesion molecules which result in distinct migration 
kinetics, with non-classical monocytes exhibiting higher levels of the chemokine 
receptor CX3CR1 and the Β2-integrin LFA-1[25]. As such, it is possible that the 
lipoproteins are affecting the expression or organization of these monocyte subset-
specific receptors. Further work is required to determine the effect of LDL in a real- 
time chemotaxis assay. While there may indeed be monocyte subset specific 
signalling, another possibility is that the crude transwell method of assessing 
chemotaxis does not give an entirely accurate result. Although still widely utilized 
transwell assays can cause difficulties due to an inability to quantify or maintain a 
gradient of chemoattractant, an inability to accurately count migrated cells and vast 
experimental variability between labs and transwell membrane manufacturers [45]. 
As observed in macrophages, cells may also translocate their nucleus through 
transwell pores and therefore stain as having migrated, while the remainder of the 
cell body stays un-retracted and dysfunctional within the transwell membrane [46]. 
 
Moreover, it is interesting that monocyte TEM does not appear to be impaired by 
LDL or VLDL. Indeed, CD16neg monocyte TEM is increased by both LDL and VLDL 
treatment, seemingly the opposite of what would be expected from the 2D real-time 
migration assay. However, if a similar phenotype is occurring in our peritonitis model 
on HFD, monocyte retention in the omentum en route to the peritoneal cavity may 
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occur subsequent to TEM. At this stage, it is only possible to speculate what may 
promote this increase, although clearly TEM is a much more elaborate process than 
crawling on a 2D surface. One potential explanation may be found in the method by 
which monocytes cross the endothelium; leukocytes can undergo canonical, 
paracellular migration at endothelial cell junctions or in some circumstances can 
pass directly through the endothelial cell itself in a process known as transcellular 
migration [47]. Some have hypothesized that transcellular migration can increase 
when leukocytes are unable to execute the locomotion events required reach an 
appropriate endothelial junction. For example, CD11b deficient leukocytes [48] or 
leukocytes with cytoskeletal disruption [49] tend to preferentially use the transcellular 
route of TEM. Strikingly, disrupting the cytoskeletal GTPase RAP1B in neutrophils 
increased the rate of neutrophil TEM exclusively via the transcellular route both in 
vitro and in vivo [50]. Among others, this observation then led me to further 
investigate the role of the cytoskeleton in regulating the monocyte migratory 
phenotype described here. 
 
However, one consideration when interpreting these data is that all adhesion and 
TEM experiments performed here were under static conditions, which may not 
represent the effects of physiological rheology. Arterial shear stress is known to have 
a pronounced affect on endothelial adhesion molecule expression (i.e. ICAM-1) and 
to alter monocyte-endothelial interactions [51-53]. This may be particularly important 
in the context of dyslipidaemia, since atherosclerotic plaques occur preferentially at 
sites of disrupted rheology such as vascular bifurcations [54]. While static leukocyte- 
endothelial co-cultures have been published on extensively due to their ease of use, 
they do not allow for the assessment of the transition from leukocyte rolling to initial 
firm adhesion. As such, future work would be required to confirm the observations on 
monocyte adhesion and TEM under physiological rheology, either in an in vitro 
perfusion system or via further intravital imaging.  
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6. CYTOSKELETAL	  REGULATION	  IN	  LIPID-­‐
LOADED	  MONOCYTES	  
6.1. Introduction	  
6.1.1. Cytoskeletal	  regulation	  during	  cell	  migration	  
Cell migration is a complex, tightly regulated process that is fundamental to 
development, tissue homeostasis and disease. In the context of immunology, 
efficient leukocyte migration is required is required to mount an appropriate 
inflammatory response. While processes such as embryogenesis or wound healing 
require the collective migration of tightly associated layers of cells, the migration of 
leukocytes occurs almost exclusively as individual cells in an amoeboid manner [1]. 
Genes involved in cytoskeletal regulation compose 4.2% of all open reading frames 
in the human genome [2] and have spawned an entire field of ongoing research, thus 
it is challenging to present any more than a basic summary here. Nonetheless, some 
basic mechanisms of cell motility span most cell types and migratory processes.  
 
In leukocytes, chemotaxis is initiated by attachment and firm adhesion to the 
endothelium or substratum, mediated largely by selectins and integrins respectively. 
This process is specific to leukocyte subpopulations and has been reviewed 
extensively elsewhere [3,4]. Regardless of this initial step, once adhered there are a 
number of basic processes that must occur in order for a leukocyte to undergo 
polarization and locomotion towards a stimulus, all of which are actin- dependent. 
Actin accounts for 20-30% of total protein content in highly motile cells such as 
leukocytes and exists in monomeric, globular subunits (G-actin), or polymerized 
filamentous F-actin [5]. Transition between G- and F- actin is catalysed by ATP 
hydrolysis and allows for the extension and retraction of actin microfilaments, which 
are the key regulator of both morphology and motility in all cells [6]. Microfilaments 
are polar in structure and consistent of a ‘pointed’ origin end and a ‘barbed’ 
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protrusion that grows away from the origin [7]. In addition, actin filaments also 
undergo lateral cross-linking, thus forming either parallel or anti-parallel bundles via 
a number of adaptor proteins [8].  
 
Initially, a migrating cell will extend protrusions generally in one of two morphologies: 
1) lamellipodia or 2) filopodia. A lamellipodium is an F-actin rich fan-shaped structure 
at the leading edge of motile cells moving on a flat substratum, which protrude and 
retract in a transient manner. When long, thin protrusions extend beyond the 
lamellipodia, these are termed filopodia and are formed of unbranched, parallel actin 
bundles. Generally, these filopodia are thought to allow a cell to explore its extended 
environment prior to commitment to migration [9]. However, it is important to note 
that in some situations leukocytes appear to be able to migrate by membrane 
blebbing independent of lamellipodia [10,11], although the significance of this 
process remains controversial. Regardless, in presence of a chemoattractant 
gradient the cell then senses the migratory cue, often via asymmetric ligation of G-
protein-coupled receptors (GPCR) [12] and begins the process of front-back 
polarization towards the stimulus.  
 
Critical effectors in polarization are Rho family of GTP hydrolases (GTPase), which 
fluctuate between a GDP-bound ‘inactive’ and a GTP-bound ‘active’ state to act as 
molecular switches for cytoskeletal rearrangement [13]. The transition between these 
two states is controlled by guanine-nucleotide exchange factors (GEFs), which 
cause GTPase activation via the exchange GDP to GTP and GAPS, which promote 
GTP hydrolysis [14]. Upon GPCR binding, activation of phosphoinositide 3-kinase 
(PI3K) generates a gradient of the lipid second messenger phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) at the newly established leading edge of the cell, thus 
leading to GEF recruitment [12]. This in turn sequentially activates the GTPases 
CDC42 and RAC to promote rapid actin polymerization and lamellipodia protrusion 
[14]. Despite CDC42 and RAC acting in a cooperative manner to form lamellipodia, 
filopodia formation is promoted by CDC42 activity via N-WASP and the ARP2/3 
complex, but may conversely inhibited by RAC [15], thus highlighting the complexity 
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of this process. In addition, other less well-characterized GTPases can also promote 
filopodia extension, including RIF [16]. 
 
Once polarity and forward protrusion have been established via RAC and CDC42, 
the cell must contract and detach the rear of the cell (or uropod) in order to move 
forward in a process dependent on RHOA and Myosin-II [17]. Key to this process is 
an inverse spatial correlation of RHOA and RAC activities to maintain cell polarity 
through a poorly characterized negative feedback loop [17,18]. Myosin-II is an actin-
binding motor protein with one pair of heavy chain peptides (MHC) and two pairs of 
light chains (MLC), with phosphorylation of one of the MLC pairs regulating Myosin-II 
activity [17].  It is Myosin-II that can induce tension or propel the movement of actin 
filaments via ATPase activity. When GTP-bound, RHOA activates Myosin-II via Rho 
Kinase (ROCK) by directly phosphorylating MLC and inhibiting MLC phosphatase, 
thus causing actomyosin contraction [17]. MLC can also be activated directly by 
increased intracellular calcium via myosin light chain kinase (MYLK) and this process 
may be important for contraction at the cell periphery [19]. As well as stimulating 
actomyosin contractility, ROCK also stabilizes actin filaments via inactivation of the 
actin- binding protein cofilin [20].  Finally, in some cells the tension generated on the 
rear of the cell during cytoskeletal contraction can be sufficient to mechanically open 
calcium channels, which may signal via calcium-activated proteases and 
phosphatases to detach adhesions in the uropod from the substratum [21]. This 
process is summarised in Figure 6.1. 
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Figure 6.1 Summary of cytoskeletal regulation during cell migration. 
(1) In the presence of a migratory stimulus, asymmetrical ligation of GPCRs leads to extension of 
an F-actin rich lamellipodia or filopodia towards the stimulus, mediated by RAC1/CDC42 and 
CDC42 respectively. (2) Clusters of integrins at the leading edge form focal adhesions between 
the cell and the extracellular matrix. (3) Activation of RHOA and inactivation of RAC1 at the rear 
of the cell activates myosin-II, which induces contraction of actin filaments to propel the rear of 
the cell, or uropod, forward. (4) Tension generated at the rear of the cell opens mechanosensitive 
calcium channels, activating effectors including proteases and myosin-II in order to detach the 
uropod from the substratum.   
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6.1.2. Cell	  migration	  in	  Drosophila	  hemocytes	  	  
The mechanisms of cytoskeletal regulation during single cell migration are heavily 
evolutionarily conserved across billions of years from the simple eukaryote 
Dictyostelium discoideum to humans [8]. The fruit fly Drosophila melanogaster also 
has professional, monocyte/ macrophage- like phagocytes termed hemocytes. 
Strikingly, Drosophila hematopoiesis is controlled by many homologous transcription 
factors and signaling pathways to those involved in the mammalian process i.e. 
GATA and RUNX families and JAK/STAT signaling. Embryonic hemocytes are highly 
motile cells that migrate along fixed pathways during embryogenesis. An initial 
dispersal from the head mesoderm along the ventral midline is followed by rapid 
lateral migration facilitated by cytoskeletal small GTPases, the chemoattractants 
Pvf2/3 and contact inhibition of locomotion[22,23]. Since hemocytes are relatively 
superficial to the embryo surface, migration can be imaged at high spatio-temporal 
resolution in vivo [23]. Using the GAL4-UAS system, gene expression in Drosophila 
can be manipulated in a highly tissue-specific manner, thus making Drosophila 
hemocytes an elegant system to elucidate phagocyte cytoskeletal dynamics in vivo. 
Interestingly, Drosophila hemocytes become dysfunctional when flies are fed a high 
fat diet, and efficiently phagocytose human LDL [24].  
 
While delivery of both LDL and cyclodextrin-bound free cholesterol has been shown 
to disrupt the cytoskeleton in macrophages via modulation of Rac[25,26] and 
Rho[27] activity, the mechanism and specificity of this interaction remains unclear. In 
addition, no work has been performed in either total monocytes or monocyte 
subsets. Since it has long been appreciated that monocyte differentiation to 
macrophage leads to profound changes in the cytoskeleton [28], I attempted to 
determine whether similar mechanisms might be governing the migratory inhibition 
observed here in LDL and VLDL treated monocytes. 
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6.2. Results	  
6.2.1. Cytoskeletal	  gene	  expression	  changes	  during	  
hypercholesterolemia.	  
During peritonitis experiments using the Ldlr-/- mouse on HFD (Chapter 3.2.2), RNA 
from peritoneal cells after thioglycollate was stored to subsequently analyse gene 
expression by RT-qPCR. In the context of impaired monocyte migration into the 
peritoneum after HFD and after LDL/VLDL treatment in vitro, I assessed mRNA 
abundance of the cytoskeletal small GTPases CDC42, RHOA and RAC1. While 
there was no pronounced change in CDC42 or RAC1 expression, there was a 
significant down-regulation of RHOA (Figure 6.2A). However, the composition of the 
peritoneal infiltrate is clearly altered after HFD, thus these data could be the result of 
RNA harvested different proportions of cells. To assess this further, I analysed 
publicly available microarray data from monocytes of patients with familial 
hypercholesterolemia (GEO Accession GDS3668, [29]). Strikingly, expression of 
CDC42, RAC1 and RAC2 was up regulated in FH homozygotes compared to healthy 
controls, while RHOA expression was decreased (Figure 6.2B) as observed in the 
Ldlr-/- mouse on HFD. This opposite regulation of RHOA versus CDC42 and RAC1/2 
is consistent with previous data demonstrating that these proteins are functionally 
antagonistic in regulating cell morphology and migration [17,18]. To confirm whether 
this was a monocyte specific phenotype or applied to all leukocytes in a 
hypercholesterolemic environment, I analysed another microarray of blood T-cell 
gene expression from the same group (GEO Accession GDS3669, [29]). While 
CDC42 was also up regulated in FH homozygotes, there was no significant change 
in RAC1, RAC2 or RHOA (Figure 6.2C), suggesting a monocyte specific phenotype. 
To investigate small GTPase transcriptional regulation following LDL/ VLDL in vitro 
treatment, monocytes were incubated with lipoproteins for 2 hours as described in 
previous experiments and transcript abundance analysed by RT-qPCR. There was 
no significant change in CDC42, RHOA or RAC1 expression versus PBS after LDL 
(Figure 6.2D) or VLDL (Figure 6.2E) treatment, although taken overall there was a 
general trend towards the down-regulation of these genes in both monocyte 
subpopulations. However, as discussed in the introduction, changes in Rho-GTPase 
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transcript abundance do not necessarily translate to an increase in active GTP-
bound protein and this was the next obvious pathway to investigate.  
6.2.2. Cytoskeletal	  GTPase	  activation	  levels	  following	  VLDL	  
treatment.	  
As discussed previously, Rho-family GTPases can exist in either a GDP-bound 
inactive form or a GTP-bound active form (illustrated in Figure 6.3A), facilitating the 
phosphorylation of downstream effector proteins such as ROCK for RHOA or PAK1 
for RAC1 and CDC42 [17]. Given the gene expression changes observed in the Ldlr-
/- mouse and in FH patients, I hypothesized that activation of these proteins, 
particularly RHOA, would be altered by acute neutral lipid loading of human 
monocytes.  CD16pos or CD16neg human monocytes from healthy donors were 
therefore incubated for 2 hours with 100µg/ml VLDL and the cell lysates were 
analysed for active RHOA using ELISA. However, VLDL alone produced no change 
in levels of RHOA activity in either monocyte subpopulations (Figure 6.3B). Following 
this observation, I postulated that VLDL might not affect RHOA under homeostatic 
conditions, but may instead impair the spatio-temporally regulated activation required 
during polarization and migration. As such, I utilized the RHOA activator CN03 
concurrent with VLDL incubation, which is based on the catalytic domain of 
bacterial cytotoxic necrotizing factor toxins and causes RHOA to become 
constitutively GTP-bound [30]. When CN03 was added at 2µg/ml for 2 hours as 
previously reported [31], both CD16pos and CD16neg cells displayed a marked 
increase in RHOA activation as expected (Figure 6.3C). However, this effect was 
significantly abrogated by simultaneous treatment with 100µg/ml VLDL, suggesting 
that neutral lipid accumulation is directly inhibiting the GTP-binding of RHOA (Figure 
6.3C).  
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Figure 6.2 Leukocyte small GTPase gene expression during dyslipidaemia.  
(A) Cytoskeletal small GTPase gene expression assessed by RT-qPCR in peritoneal cells from 
Ldlr-/- mice on chow or HFD following thioglycollate peritonitis (See also Figure 3.4), n=4 per 
group. Error shows the mean±SEM. (B) Small GTPase gene expression in monocytes from 
heterozygous FH patients (FHhet), homozygous FH patients (FHhom) or healthy controls (Ctrl), as 
presented in GEO microarray GDS668 [29], n= 4-13. (C) As (B), but data for blood T-
lymphocytes, GEO microarray GDS669, n= 3-13. Boxes display 10th-90th percentile. (D) 
Cytoskeletal small GTPase gene expression assessed by RT-qPCR in human CD16negCD16pos 
monocytes incubated with (D) LDL, or (E) VLDL. Data shown as log2 ratio versus PBS, n=3. 
Error shows the mean±SEM, groups were compared using a two-tailed Mann-Whitney U test.  
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Figure 6.3 RHOA activation levels following VLDL treatment.  
(A) Schematic of Rho-family GTPase activation, demonstrating shuttling between active (Rho-
GTP) and inactive (Rho-GDP) forms. (B) RHOA activation in human CD16pos/CD16neg 
monocytes after VLDL treatment (2 hours, 100µg/ml), n=3 donors in duplicate. (C) As in (B), 
except monocytes were additionally treated with or without CN03 (2µg/ml), n=3 donors in 
duplicate. Error bars show the mean±SEM. groups were compared using a two-tailed Mann-
Whitney U test. 
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To investigate effects on the RHOA pathway further, I tested the hypothesis that 
MLC phosphorylation downstream of RHOA would also be affected by VLDL 
treatment. When CD16pos and CD16neg monocytes were treated with VLDL alone, no 
significant effect was observed on levels of pMLC as assessed by Western blot 
(Figure 6.4A-B). However, as in RHOA it was possible that a phenotype might only 
be visible when cells were required to activate MLC signaling. Calcium (Ca2+) influx 
causes RHOA dependent and independent MLC phosphorylation (pMLC) [32,33] 
and can occur due to mechanical forces during cell migration [21]. As such, the 
calcium ionophore A23187 was used following 2 hours of VLDL pre-treatment. As 
expected, A23187 caused an increase in pMLC in both monocyte subpopulations, 
but surprisingly VLDL only caused a significant impairment of MLC phosphorylation 
in CD16pos monocytes, with a subtle trend towards less pMLC in the CD16neg 
population (Figure 6.4A-B). Contrary to RHOA activation data, this implies that VLDL 
may have a monocyte subset-specific effect on the cytoskeleton. 
 
Furthermore, separate to the RHOA/ MLC pathway others have previously 
demonstrated increased cell membrane cholesterol in macrophages modulating the 
activity of other cytoskeletal GTPases, including RAC1 [25,26]. To simultaneously 
screen for activity of multiple cytoskeletal GTPases, I assessed phosphorylation of 
PAK1 and PAK2, effector kinases downstream of both CDC42 and the RAC family, 
which are antagonistic to RHOA [34]. Using Western blot, there was no apparent 
change in either PAK1 or PAK2 phosphorylation after 2 hours of VLDL treatment in 
both monocyte subpopulations (Figure 6.5A). This was further confirmed at the level 
of CDC42, which also had unchanged activity in response to both LDL and VLDL as 
assessed by ELISA (Figure 6.5B). It was therefore inferred that the RAC/ CDC42/ 
PAK pathway is not altered by neutral lipid loading in blood monocytes.  
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Figure 6.4 Myosin Light Chain phosphorylation in VLDL treated human monocytes. 
 CD16neg and CD16pos human monocytes were treated with PBS or VLDL (2 hours, 100µg/ml) 
followed by PBS or A23187 for 15 minutes and MLC phosphorylation was assessed by Western 
blot. (A) Relative pMLC levels measured by band densitometry, normalized to total P38, n=4 
donors from 3 independent experiments. (B) Representative Western blot example of data 
displayed in (A). Error bars show the mean±SEM, groups were compared using a two-tailed 
Mann-Whitney U test. 
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Figure 6.5 CDC42 and PAK pathway activity after monocyte LDL and VLDL treatment.  
Human CD16pos and CD16neg monocytes treated with PBS, LDL or VLDL (100ug/ml) for 2 hours. 
(A) PAK1/2 phosphorylation following PBS or VLDL treatment using Western blot, a 
representative blot of two is shown. (B) CDC42 activity measured using ELISA after PBS/ LDL/ 
VLDL, n=3 donors. Error bars show the mean±SEM. 
 
6.2.3. Monocyte	  morphological	  changes	  induced	  by	  VLDL	  or	  
RHOA	  activation.	  
While the data presented thus far strongly suggest that RHOA/ MLC inactivation may 
be responsible for the altered motility observed in VLDL treated monocytes, this 
hypothesis required support with functional data. Since the cytoskeleton is 
composed primarily of actin and controls cell shape [8] and VLDL seems to prevent 
RHOA activation (Figure 6.3A), I reasoned that VLDL and CN03 should promote 
distinct and antagonistic effects on monocyte morphology. To test this, human 
monocyte subpopulations were treated with PBS or VLDL in conjunction with/ 
without CN03 for 2 hours, before being allowed to adhere to tissue culture treated 
plastic for 45 minutes. Cells were then fixed and actin was fluorescently stained 
using phalloidin in order to visualize the cytoskeleton by fluorescence confocal 
microscopy. Representative images of CD16neg and CD16pos cell morphology after 
these treatments are shown in Figure 6.6A. Cell morphology was then assessed 
using automated analysis for cell area, where a higher value indicates increased cell 
spreading, and circularity, where a lower value generally indicates the presence of 
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more protrusions such as filopodia. After control PBS treatment, there was already 
subset- specific morphology evident in monocytes. While CD16neg monocytes will 
spread on a plastic surface and form lamella-like structures without stimulation, 
CD16pos monocytes remain smaller and highly circular (Figure 6.6B). VLDL treatment 
reverses this phenotype; CD16neg monocytes no longer spread, evidenced by lower 
cell area and higher circularity, while CD16pos monocytes become significantly less 
circular and extend filopodia-like protrusions at what appears to be the rear of the 
cell (Figure 6.6A-C). After CN03 treatment, both cell populations spread, form 
pronounced lamella and have increased cell area with no change in circularity, as 
would be expected from previous data in fibroblasts [35]. Strikingly, concurrent 
treatment with VLDL and CN03 completely reverses the CN03-indcued spreading 
and this can be seen in both subpopulations as a significant decrease in their cell 
area (Figure 6.6B). While the circularity of CD16neg cells again remained unchanged, 
CD16pos monocytes had substantially decreased circularity due to the extension of 
long (>20µm), thin protrusions from the cell in a manner not seen in any of the other 
treatments (Figure 6.6C). Evidently, there is clearly some degree of cytoskeletal 
signalling that is specific to monocyte subpopulations that requires further 
exploration. However, VLDL obviously reversed cell spreading and lamella extension 
induced by CN03, confirming the previous RHOA activation data (Figure 6.3A) in a 
more functional setting.  
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Figure 6.6 The effects of VLDL treatment and RHOA activation on monocyte 
morphology.  
Human CD16neg and CD16pos monocytes were treated with PBS or VLDL (2 hours, 100µg/ml), 
with or without CN03 (2µg/ml). Cells were adhered to tissue culture plastic and actin stained with 
fluorescent phalloidin. (A) Representative examples of cell morphology (green= phalloidin, blue= 
DAPI). Images were analyzed for (B) Cell area (µm) and (C) Circularity. n= 20-25 cells per 
condition, data shows one representative experiment from two. Error bars show the mean±SEM, 
groups were compared using a two-tailed Mann-Whitney U test. 
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6.2.4. Monocyte	  motility	  following	  pharmacological	  RHOA	  
activation.	  
With the knowledge that VLDL incubation was able to CN03-induced monocyte 
spreading, I hypothesized that RHOA activation using CN03 might also improve the 
migratory impairment in neutral-lipid loaded monocytes. To test this, I used a simple 
real-time chemokinesis assay (as in Figure 5.7) in total monocytes that had been 
treated with PBS or VLDL (2 hours, 100µg/ml), with or without CN03. After 90 
minutes of imaging, as seen previously (Figure 5.7), VLDL caused a subtle yet 
significant decrease in monocyte displacement (Figure 6.7B), speed (Figure 6.7C) 
and confinement ratio (Figure 6.7D). However, in this experiment CN03 caused a 
similar inhibition of migration that was more pronounced than the effects of VLDL 
when measured as displacement (Figure 6.7B) and confinement ratio (Figure 6.7D). 
In addition, CN03 did not reverse the VLDL migratory inhibition as hypothesized, but 
instead the CN03 and VLDL combination caused a more severe impairment of 
migration than either of these treatments alone (Figure 6.7A-D). As such, 
pharmacological activation of RHOA is not able to restore migration in VLDL treated 
monocytes, which may concur with morphological data showing that treatment with a 
CN03/VLDL combination prevents cell spreading in both monocyte subpopulations 
(Figure 6.6).  
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Figure 6.7 Monocyte chemokinesis after VLDL and CN03 treatment. 
 (A) Track projections from total human monocytes treated with PBS or VLDL (2 hours, 
100µg/ml), with or without CN03 (2µg/ml) in a 2D real-time chemokinesis assay with diffuse C5a 
stimulation. Tracks were analyzed for (B) displacement (µm) (C) speed (µm/sec) and (D) 
confinement ratio (AU). n=75-205 cells per condition. Error bars show the mean±SEM, groups 
were compared using a two-tailed Mann-Whitney U test. 
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6.2.5. Drosophila	  hemocyte	  migration	  following	  LDL	  injection.	  
Given the inconclusive data obtained with CN03 and lack of appropriate reagents for 
studying primary monocyte GTPase activity during cell migration in vitro, I sought an 
appropriate in vivo model to validate my hypotheses. Drosophila hemocytes have 
previously been shown to efficiently phagocytose human LDL and respond to a high 
fat diet [24]. The genetic tractability of Drosophila also allows the generation of flies 
that express a constitutively active Rho (RhoV14) exclusively in hemocytes, as 
previously described [36]. Using flies that express a UAS-GFP construct under the 
control of the hemocyte-specific promoters croquemort (crq) and serpent (srp), I 
investigated the effects of LDL on hemocyte migration during embryogenesis in 
collaboration with the group of Prof Will Wood at University of Bristol. The aims of 
this work were two-fold: 1) To establish whether the migratory inhibition of 
mononuclear phagocytes by lipoproteins was evolutionarily conserved in Drosophila, 
and 2) to determine whether expression of a constitutively active Rho could be used 
to reverse any LDL-induced migratory impairment.  
 
When Crq/ Srp-Gal4; UAS-GFP Drosophila embryos were injected with fluorescent 
LDL, it rapidly (<2 hours) localized inside hemocytes (Figure 6.8A), confirming 
previously published data [24]. In agreement with data from human monocytes, LDL 
injection appeared to visually decrease migration in hemocytes (Figure 6.8B). This 
could be quantified as a significant decrease in cell speed (Figure 6.8C) and 
displacement (Figure 6.8D), although this was less pronounced than in VLDL 
incubated monocytes and no significant change was seen in confinement ratio 
(Figure 6.8E). However, expression of RhoV14 caused no detectable alteration in any 
metric used to assess cell migration when compared to wild type, both after PBS and 
LDL injection (Figure 6.8C-E). No gross defects in cell morphology were observed in 
any condition, although this was challenging to analyze formally without higher 
resolution imaging or a fluorescent cytoskeletal reporter such as actin-GFP. As such, 
it was concluded that while LDL-induced migratory impairment appears to also occur 
in Drosophila hemocytes, expression of constitutively active Rho is unable to reverse 
this phenotype. 
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Figure 6.8 LDL induced migratory impairment in Drosophila embryonic hemocytes.  
Hml-GFP Drosophila embryos expressing either wild-type (w118) or constitutively active (RhoV14) 
Rho1 were injected with PBS or LDL-AlexaFluor-594 and imaged by confocal microscopy 2 
hours post-injection. (A) Representative examples of hemocyte and LDL localization. Scale bar= 
50µm. (B) Track projections from migrating hemocytes. Hemocyte locomotion was analysed and 
quantified as (C) speed (µm/ sec), (D) displacement (µm) and (E) confinement ratio. n=115-145 
hemocytes per group, from 5-6 flies per group. Error bars show the mean±SEM, groups were 
compared using a two-tailed Mann-Whitney U test. 
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6.3. Discussion	  
These data clearly demonstrate that the monocyte cytoskeleton is perturbed by 
exposure to either in vivo dyslipidaemia or in vitro VLDL exposure, most notably 
through regulation of the small GTPase RHOA. Interestingly, this occurs not only at 
the level of RHOA activation, but also through transcriptional modulation of Rhoa in 
Ldlr-/- mice and of RHOA, CDC42, RAC1 and RAC2 in FH patients. However, the 
same transcriptional changes are not present at monocytes treated acutely with 
VLDL in vitro, indicating that transcriptional regulation of these cytoskeletal proteins 
may be a delayed response during chronic exposure to dyslipidaemia. The 
mechanism linking transcriptional regulation to reduced RHOA activity is unclear, but 
may represent a negative feedback loop orchestrated by RHOA itself. RHOA is 
known to activate several transcription factors and therefore modulate a range of 
inflammatory and metabolic targets via NFkβ, GATA-4, C/EBPβ, MRTF and c-MYC 
[37-41]. While inhibition of the RHOA effector kinase ROCK decreases levels of 
MYC expression [41], knockdown or deletion of MYC also conversely decreases 
levels of RHOA transcript and active protein in cancer cells [42], and thus is the most 
likely candidate to participate in a negative- or positive-feedback loop. In the 
currently proposed model, c-MYC co-operates with the E3-ligase SKP2 to bind a 
non-canonical E-box motif in the RHOA promoter, recruiting the MYC co-activators 
MIZ1 and EP300 in order to induce RHOA transcription [42].  
 
This complex feedback loop linking Rho-family GTPase activity to gene expression 
also highlights the difficulties in interpreting functional data Rho-GTPase-null animals 
or cell lines, due to the vast number of transcriptional targets that will presumably 
also be modulated in this case. For example, data from Rhoa/Rhob-/- mouse 
macrophages shows that knockout of this pair causes morphological defects, but in 
fact increases speed of chemotaxis both in vitro and during peritonitis, the opposite 
effect to what would be hypothesized from the data presented here [43].  
Conversely, pharmacological inhibition of RHOA signaling in both leukocytes and 
fibroblasts greatly decreases chemotaxis [35,44]. In addition, while termed ‘inactive’ 
there is evidence that Rho-family GTPases may in reality have effector functions 
while GDP-bound. For example, RHOA-GDP binding decreases the stability of 
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RHOB protein, which is therefore strongly up regulated when RHOA is silenced [45]. 
This may explain functional discrepancies between experiments employing GTPase 
inactivation versus genetic suppression or deletion. 
 
Under homeostatic conditions, VLDL treatment had no effect on monocyte levels of 
RHOA-GTP. However, a strong inhibition of activation was seen in both CD16pos and 
CD16neg monocytes after addition of the RHOA activator CN03. CN03 prevents 
RHOA from dissociating from a GTP-bound to a GDP-bound inactive state and it is 
via this mechanism that its derivative bacterial toxin cytotoxic necrotizing factor 1 
facilitates Escherichia coli invasion across the blood-brain barrier endothelium [30]. 
Since RHOA activation is required for cell migration as discussed above, the 
inhibition of monocyte motility by VLDL may only become evident following an 
inflammatory or activatory stimulus, such as C5a. Given the mode of action of CN03, 
VLDL is most probably acting directly on RHOA to prevent its association with GTP, 
or on the guanine exchange factors (GEFs) that catalyze this process.  
 
One likely mechanistic candidate for neutral lipid modification of this process is 
RHOA prenylation. Prenylation involves the addition of a hydrophobic farnesyl or 
geranylgeranyl isoprenyl group to a protein by the enzymes farnesyl transferase, 
Caax protease or geranylgeranyl transferase I [46] and is crucial for RHOA biological 
activity [47]. Most notably, prenylation is essential for the interaction of the Rho-
family with RHO-GDI, which acts as a chaperone during membrane delivery and 
recycling of Rho-GTPases [48]. This interaction is key for the subcellular localization 
and membrane binding of Rho-GTPases [49], which in turn is essential for their 
activation and function [50,51]. Cholesterol is itself an isoprenoid, meaning that 
cholesterol metabolism and protein prenylation are intricately linked. Both 
geranylgeranyl pyrophosphate and farnesyl pyrophosphate are synthesized by the 
HMG-CoA reductase pathway and the combination of two farnesyl pyrophosphate 
molecules forms squalene, a direct precursor for cholesterol via lanosterol [52]. 
Unsurprisingly in this context, the inhibition of HMG-CoA reductase with statins to 
treat hypercholesterolemia has also been shown to inhibit Rho-family prenylation in 
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endothelial cells [53]. As such, it is highly conceivable that an excess of intracellular 
cholesterol ester could alter Rho-family prenylation and activation, although currently 
it is less clear why this effect would be RHOA-specific at early time points. Further 
work would be required to decipher the exact subcellular localization of these 
GTPases during monocyte migration, which may reveal why VLDL is inhibiting 
RHOA, while RAC1 and CDC42 seem unaffected. In addition, it is possible that while 
PAK1/2 phosphorylation is unchanged by VLDL, Rac signaling may be bypassing 
this pathway. RAC2 is expressed in myeloid cells and can signal independently of 
PAK1/2 to mediate chemotaxis [54], and therefore may be affected in VLDL treated 
monocytes. 
 
While RHOA activation is impaired by VLDL treatment in both monocyte subsets, 
inhibition of MLC phosphorylation in response to a calcium ionophore (A23187) 
appears to be specific to CD16pos cells. Calcium influx can cause MLC 
phosphorylation in a RHOA-dependent manner or independent of RHOA via MYLK 
[17,19,32]. Analysis of published microarrays on human monocyte subpopulations 
(GEO Accessions GSE18565[55], GSE16836[56]) shown that MYLK transcript is 
expressed at much higher levels in CD16neg monocytes than in CD16pos. As such, 
CD16neg monocytes may utilize the MYLK pathway to continue to phosphorylate 
MLC in response to calcium in the absence of sufficient RHOA activity.  
 
However, migration and cell morphology are disrupted by VLDL in both CD16pos and 
CD16neg monocytes, so this continued ability to phosphorylate MLC is clearly not 
sufficient to rescue the functional impact of RHOA inhibition. In addition, activation of 
RHOA using CN03 does not restore normal morphology or chemokinesis in VLDL 
treated monocytes. While this may indicate that these phenotypes are not RHOA 
mediated, it is more likely that the use of pharmacological activation does not restore 
the fine balance of spatio-temporal Rho-GTPase regulation that is required for 
proper cytoskeletal function [50,51]. Indeed, in the chemokinesis assay a 
combination of VLDL and CN03 actually caused a more severe migratory inhibition 
than either alone, emphasizing the complexity and subtlety of the signals required for 
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correct cell migration and the challenging nature of targeting cytoskeletal GTPases 
therapeutically. 
 
In the time remaining of this PhD, it was not feasible to generate Rhoa mutant mice, 
whether over expression or constitutive activation. In addition, for reasons outlined 
above, pharmacological manipulation of Rho-GTPases is challenging and can 
generate data that is difficult to interpret. The high level of spatial and temporal 
resolution possible during in vivo imaging and ease of genetic manipulation made 
Drosophila embryos an interesting model to study mononuclear phagocyte migration 
in response to lipoproteins. It is also useful for data interpretation purposes that 
Drosophila possess only one GTPase of the Rho subfamily [57], while in mammals 
RHOA, RHOB and RHOC have a degree of functional redundancy and can 
compensate in cases where the function of one family member is disrupted [43]. 
Interestingly, LDL injection also causes migratory impairment in Drosophila 
hemocytes, suggesting that the phenotype presented here may be via an 
evolutionarily conserved mechanism. Constitutive activation of Rho1 was unable to 
reverse this phenotype, but crucially, did also not cause any obvious migratory or 
morphological defect after PBS injection, potentially suggesting that hemocyte 
migration is Rho-independent. Some functional discrepancies between human 
RHOA and Drosophila Rho1 are inevitable, given that the pair share only 73% cDNA 
sequence homology (Ensembl 2015[58]). In addition, while Drosophila possess 
several apoB-lipoproteins for lipid transport including apolpp and apoltp, these are 
structurally distinct from human LDL and no apoA orthologue has been found in the 
fly genome[59]. As such, this may represent a response of hemocytes to the 
phagocytosis of any exogenous material via scavenger receptors, rather than a lipid-
specific phenotype. These data warrant further investigation, as the high-resolution, 
real-time imaging of actin dynamics that is possible in Drosophila hemocytes [23] 
may present an elegant in vivo system to study the effects of lipoproteins on the 
cytoskeleton.  
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7. DISCUSSION	  
7.1. Summary	  of	  findings	  
Taken together, these data add to the relatively limited pool of published knowledge 
on the response of monocyte subpopulations to dyslipidaemia. Since the 1960s, the 
circulating lipophage has been an enigma that is often ignored [1]. This work 
confirms that these cells are neutral lipid- laden monocytes and that there is a 
functional impact of this lipid uptake. Fundamentally there are a number of key 
conclusions that can be drawn from this work: 
1. Monocytes from the dyslipidaemic Ldlr-/- mouse on HFD accumulate 
cytoplasmic neutral lipid via a mechanism independent of the LDLR and this 
occurs to a lesser extent in C56Bl/6 wild-type animals.  
2. Following an appropriate stimulus, such as peritonitis, monocytes from a 
dyslipidaemic mouse transmigrate appropriately from the blood, but are then 
less able to move to the site of inflammation. In wild-type animals on HFD, 
non-classical monocyte patrolling remains largely unaffected. 
3. LDL or VLDL is internalized by human monocytes and also leads to 
cytoplasmic neutral lipid accumulation via an undetermined mechanism. 
Although kinetics are similar, levels of neutral lipid are higher in CD16neg than 
CD16pos monocytes. 
4. There is no pronounced affect of LDL or VLDL treatment on monocyte 
apoptosis, cytokine transcription or release, surface marker expression or 
phagocytosis. Subtle, subset specific effects were observed on adhesion and 
transmigration on an endothelial layer. 
5. VLDL causes a strong pronounced inhibition of monocyte chemotaxis and 
chemokinesis in both subpopulations, accompanied by modulation of 
cytoskeletal regulation via RHOA and MLC. This mechanism may be 
responsible for an impaired monocyte response to peritonitis on HFD.  
These conclusions are summarised in Figure 7.1. These conclusions have 
implications in a wide range of pathophysiological contexts, including 
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atherosclerosis, infection and inflammatory disease. These implications will be 
discussed further in turn below.  
 
Figure 7.1 Summary schematic of proposed migratory dysfunction in monocyte 
lipophages.  
Monocytes of both subsets accumulate neutral lipid vesicles during elevated VLDL or LDL 
exposure. These lipophages can adhere to, crawl on and transmigrate through the endothelium, 
but have impaired chemotaxis and chemokinesis towards in the extravascular environment. This 
is accompanied by adherent cytoskeletal regulation via RHOA inactivation.  
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7.2. Therapeutic	  implications	  
7.2.1. Atherosclerosis	  
It seems reasonable to presume that neutral lipid- loaded blood monocytes occur in 
dyslipidaemic patients at high risk of cardiovascular disease, although this 
hypothesis is not directly tested here. Based on previous data, extreme plasma 
dyslipidaemia in familial hypercholesterolemic (FH) patients does cause increased 
intracellular lipid in monocytes [2], although more moderate hyperlipoproteinemia 
has been reported to cause no detectable accumulation [3]. To directly relate these 
findings to atherosclerosis, more work is required to determine the plasma lipid 
threshold at which monocyte dysfunction begins to occur. However, even if 
conclusions are restricted to FH patients there are clearly implications of these data 
for cardiovascular disease. 
 
When the vascular endothelium becomes activated by deposition of modified LDL, 
monocytes undergo transendothelial migration (TEM) into the arterial intima [4]. In 
CD16neg classical monocytes, the prime contributors to the atherosclerotic plaque in 
mouse models [5], LDL treatment increases TEM (Figure 5.8). As such, classical 
monocytes that are already lipid laden in circulation could have a greater propensity 
to accumulate in the arterial intima and contribute to atherosclerotic plaque 
formation. As discussed previously, I hypothesize that this is due to an increased 
propensity of dysfunctional, lipid loaded monocytes to undergo transcellular 
migration, although this has never been tested either in vitro or in atherosclerosis. 
Further, I find that both monocyte subpopulations have impaired migration and 
cytoskeletal regulation after lipoprotein exposure. If these data are extrapolated to 
atherosclerosis, initial monocyte accumulation in the plaque due to increased TEM 
may then be perpetuated by a failure of monocytes to leave the intima due to 
cytoskeletal- related migratory defects. In the past similar hypotheses have been 
made for macrophages that phagocytose modified apoB-lipoproteins within the 
plaque [6,7] and more recently it has been demonstrated that lipid loaded, CD11cpos 
blood monocytes contribute to early atherogenesis [8]. However, this may only be 
applicable to cases of extreme dyslipidaemia, since the monocyte phenotype 
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reported in the Apoe-/- mouse on HFD[8] is much less pronounced in experiments 
performed here utilizing the Ldlr-/-. 
 
Fundamentally, the importance of these findings for atherosclerosis hinges upon an 
on-going debate in the field regarding the relative important of monocyte recruitment 
and resident macrophage proliferation in atherogenesis. While some data argue that 
macrophage proliferation is the key contributor to the plaque following early 
monocyte recruitment [9], this is contradictory to decades of research, including their 
own, demonstrating that progressive monocyte recruitment is proportional to plaque 
burden and disease severity [5,10,11]. These data offer no further insight into that 
debate and it awaits resolution by further research. Regardless, it is possible that 
these two processes are linked by lipid loading of blood monocytes affecting the 
phenotype of macrophage that monocytes differentiate to once within the vessel 
wall. While monocytes do not proliferate in the blood [12], lipid loading could drive 
subsequent proliferation and inflammation once monocytes have differentiated to 
macrophages following extravasation. Although this is a bold hypothesis, recent work 
on monocyte epigenetic memory supports this theory. When monocytes are exposed 
to oxLDL acutely and subsequently differentiated, the resulting macrophages have 
an inflammatory phenotype in response to TLR stimulation via modulation of histone 
methylation at relevant promoter sites [13]. This also occurs following initial 
inflammatory priming with β-glucan prior to differentiation, affecting over 3000 
genomic distal regulatory elements [14]. This phenomenon, termed ‘trained innate 
immunity’, may be a greatly underestimated factor in the contribution of 
environmental stimuli to inflammatory disease.  
 
In addition, atherosclerosis is largely thought of as a chronic, inflammatory disease, 
yet contradictory data on the inflammatory effects of VLDL and LDL on monocytes 
and macrophages make it unclear exactly how subpopulations of these cells 
contribute to this process. It is certain that multiple macrophage phenotypes exist in 
the plaque, with >30% estimated exhibit ‘M2-like’ anti-inflammatory function in the 
lesions of Ldlr-/- mice [15]. Related to this, HFD exposed peritoneal macrophages 
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from the same mice exhibit a striking, deactivated phenotype characterized by 
decreased expression of inflammatory response genes and resulting from 
modification of LXR- signalling by the cholesterol intermediate desmosterol [16]. In 
confirmation of this, I found expression of Il1b and Cxcl10 were significantly down 
regulated in the inflamed peritoneum of Ldlr-/- mice on HFD versus chow.  However, I 
find no clear effect of LDL or VLDL on the in vitro inflammatory response of 
monocytes at both a transcriptional and protein level. It is possible that 
embryonically- derived local resident macrophages and infiltrating monocyte- derived 
macrophages have distinct functions and phenotypes within the plaque, which may 
help to explain the range of effects of LDL that have been observed on mononuclear 
phagocytes. In addition, caution must be taken when interpreting data using bone 
marrow derived macrophages culture in vitro, as the complex contribution of the 
tissue microenvironment in determining macrophage function means that traditional 
culture methods rarely generate anything resembling cells found in vivo [17]. For 
example, bone marrow derived dendritic cells (DCs) are generally produced using 
GM-CSF treatment, however in reality this generates a mixed population of DCs and 
CD11cpos macrophages [18]. In this sense, freshly isolated monocytes that have 
undergone limited manipulation could be argued to better represent the physiological 
response.  
7.2.2. Infection	  
While atherosclerosis is the most widely studied disease process in the context of 
dyslipidaemia, the impairment of monocyte chemotaxis and chemokinesis presented 
here has broad implications for a range of inflammatory processes. Currently, 
greater than 6% of patients in England contract an infection resulting from treatment 
in a healthcare setting, amounting to over 1 million patients per year [19]. Patients in 
the 95th percentile of stratified total cholesterol levels are 4-fold more likely to 
develop a nosocomial infection following general surgery and in the UK in 2011, 50% 
of adults had a total plasma cholesterol above the target value of 5mmol/L [20]. As 
such, the scale of potential impact for monocyte dysfunction in dyslipidaemia is 
immense. Interestingly, the use of statins to lower plasma cholesterol levels has 
been repeatedly reported to reduce severity of bacterial infections [21] [22], although 
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some meta-analyses have failed to support this trend [23]. Somewhat confusingly, it 
is suggested that this difference in infection severity and mortality is due to inhibition 
of HMG-CoA by statins and a subsequent impairment of Rho-GTPase prenylation 
and activation [24], as discussed earlier. Since it has also been demonstrated here 
that hypercholesterolemia interferes with this process, the precise relationship 
between intracellular neutral lipid and the cytoskeleton remains enigmatic.  
 
In addition, infection can result in dyslipidaemia in what may in some instances 
represent a host defence mechanism and in others a destructive feedback loop 
evolved and initiated by the invading pathogen. Perhaps the most well studied 
infection in this context is human immunodeficiency virus (HIV). While dyslipidaemia 
in HIV is a well-established phenomenon, it was thought to derive primarily as a side 
effect of the protease inhibitors used to treat the infection via poorly characterized 
mechanisms [25]. However, there is also a direct role for HIV itself, since the HIV 
protein Nef markedly elevates plasma total cholesterol and triglyceride levels in 
mice, leading to accelerated atherosclerosis [26]. The same effect has also been 
demonstrated for simian immunodeficiency virus (SIV) Nef in macacques, through a 
mechanism that appears to involved inhibition of ABCA1-dependent reverse 
cholesterol transport [27]. Currently, around 29% of HIV mortality is due to 
secondary infections related to AIDS. Although this is primarily thought to be a result 
of T-lymphocyte deficiency, dyslipidemia-related monocyte immunosuppression may 
also be contributing to this problem and require further therapeutic attention [28].  
7.2.3. Chronic	  inflammatory	  disease	  
Modulation of the innate immune system by dyslipidemia may also have implications 
for other chronic inflammatory processes, including autoimmune diseases such as 
rheumatoid arthritis (RA). Compared to the healthy population, RA patients have a 
twofold increase in morbidity from cardiovascular disease [29], although there is 
ongoing debate as to whether this is driven by conventional dyslipidemia [30]. 
However, while dyslipidemia is often thought of as a consequence of anti-TNFα 
therapy in RA patients [31], data from the last decade also hi-light it as a potential 
risk factor for the disease. In a retrospective study of 1078 RA patients, elevated 
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plasma levels of total cholesterol, apoB lipoproteins, triglyceride and low levels of 
HDL were present at least 10 years prior to disease onset [32]. In addition, factors 
that improve these metrics of plasma lipid profile such as omega-3-fatty acid 
consumption [33,34] and statin treatment  [35,36] have been associated with 
reduced onset and amelioration of clinical symptoms in RA. 
 
Massive infiltration of the synovial membrane by monocytes is a major contributor to 
RA pathophysiology [37], most notably by CD14high classical and intermediate 
monocytes [38]. Once within the inflamed joint, these monocytes are activated by 
TNF-α and IL-1β to produced intracellular IL-17 and activate a Th17 response via a 
cell-contact dependent mechanism [37]. In some instances lipid-laden macrophage 
foam cells similar to those in the atherosclerotic plaque have also been reported to 
be present in the synovial membrane of RA patients, emphasizing some analogous 
pathogenic features between the two diseases [39]. Much like in the plaque, 
monocyte and macrophage retention in the synovia clearly escalates disease and a 
decrease of monocyte and macrophage numbers in the synovia are strong 
associated with positive response of RA to treatment and clinical improvement [40]. 
As such, impaired monocyte motility due to dyslipidemia in RA may perpetuate joint 
inflammation and destruction.  
 
Another notable chronic inflammatory pathology accompanied by dyslipidemia is 
inflammatory bowel disease (IBD), which can be split primarily into ulcerative colitis 
and Crohn’s disease [41]. Much like RA, IBD patients are prone to atherosclerosis 
and are over 4 times more likely to suffer a cardiovascular event than the general 
population [42]. Although variation has been observed in different patient 
populations, the dyslipidemia of IBD is predominantly an elevation of plasma 
triglyceride accompanied by lower levels of HDL [43,44]. The exact pathological 
initiating mechanisms of IBD are not entirely understood, but Crohn’s disease is 
characterized by macrophage aggregation in mucosal lesions to form granulomas, 
where they perpetuate the inflammation via the production of TNF-α and IL-1β 
[41,45]. As reviewed in Chapter 1.1.2, gut macrophages require continuous 
The	  Effects	  of	  Atherogenic	  Dyslipidaemia	  on	  Blood	  Monocyte	  Function	  	  William	  Jackson-­‐	  January	  2016	  
Discussion	   	   	   167	  
 
replenishment from GR1high blood monocytes [46]. During IBD, infiltrating blood 
monocytes arrest in a CX3CR1low inflammatory state during maturation to 
macrophages, thus simultaneously increasing the production of inflammatory 
cytokines and failing to replenish the IL-10 producing regulatory tissue population 
[46]. It has been hypothesized for dendritic cells that a chemokine mediated retention 
traps mature myeloid DC at the site of inflammation during IBD maintaining a cycle 
of autoimmune inflammation, although it is unclear whether these DC are monocyte 
derived [47]. It is possible that a similar retention could be occurring in infiltrating 
CX3CR1low inflammatory monocyte- derived macrophages, perpetuated by 
dyslipidemia impairing macrophage egress from mucosal lesions. 
7.3. Future	  work	  
While providing insight into monocyte subset biology in dyslipidaemia, there are a 
number of key questions that arise from these data that require future investigation. 
7.3.1. Lipid	  uptake	  
On a basic level, it is important to understand the origin and composition of the 
neutral lipid vesicles observed in monocytes after HFD and LDL or VLDL exposure. 
A lipidomic analysis of monocytes using mass spectrometry may yield further insight 
into the precise lipid molecular species that are enriched in monocytes following 
lipoprotein exposure, as has been reported during monocyte activation [48]. There is 
some indication from mechanistic work in Chapter 4 that these neutral lipid punctae 
are not simply internalized lipoprotein particles, but may be derived from a 
biosynthetic pathway. As such, co-localization of exogenously stained lipoproteins 
with neutral lipid stain over time may provide insight into how LDL and VLDL are 
trafficked and contribute to this neutral lipid pool. This could be performed both in 
vitro using human monocytes and in vivo using IV injection of fluorescent lipoproteins 
into mice. The potential for dissociation of the lipid and protein portions of LDL and 
VLDL once internalized, as occurs in the LDLR pathway [49], is also a source of 
confusion. This could be usefully addressed by distinct labeling of these two 
subfractions i.e. with both a lipophilic dye such as DIO or BODIPY and amine 
labeling of APOB protein using a fluorochrome such as the AlexaFluor family. High 
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speed live cell imaging of vesicle trafficking may also be useful for deciphering this 
relationship, as has been previously described for LDLR-dependent cholesterol 
trafficking [50].  
 
Similar strategies could also be utilized to further investigate the mechanism of LDL 
and VLDL uptake in monocytes subsets. It is clear that CD36 is important for LDL 
uptake in both subpopulations (Figure 4.6), but does not seem to be involved in 
neutral lipid accumulation (Figure 4.7), indicating disparate pathways. There is also 
an effect of CD36 knockout on lipid- loaded ‘foamy monocyte’ formation in the Apoe-/- 
mouse, although the subtle nature of the phenotype implies that other pathways are 
also involved. A different lipid accumulation mechanism may exist in these mice, 
since APOE reconstitution reduces neutral lipid load in blood monocytes by 
promoting cholesterol efflux [51]. In this context, it would be interesting to investigate 
whether over expression of Apoe in Ldlr-/- mice is able to exert a similar effect and 
examining monocytes from the Cd36-/- Ldlr-/- mouse on HFD could also provide 
further insight [52]. 
 
Moreover, it is unclear whether elevated levels of LDL and VLDL are sufficient to 
drive monocyte lipid loading, or if this is also affected by the structure and 
composition of these lipoprotein species. Studies in humans have found both acute 
[53,54] and chronic [55,56] changes in LDL and VLDL composition in response to 
different dietary fats, as measured by protein to lipid ratio, levels of cholesterol 
species and triacylglycerol content. Interestingly, supplementation with short chain 
poly-unsaturated fatty acids from fish oils has been demonstrated to be 
atheroprotective in Ldlr-/- mice [57]. However, while moderate consumption appears 
to be beneficial, current results from human trials using fish oil supplementation are 
contradictory and inconclusive [58]. One suggested mechanism for fish oil- mediated 
cardiovascular benefits is an increase in the size of LDL particles [59], thus reducing 
the presence of small, dense LDL that has been associated with atherosclerosis 
progression and cardiovascular events [60,61]. Although research into fish oil in 
atherosclerosis in humans is still on-going, it may be informative to change the fatty 
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acid profile of the HFD fed Ldlr-/- and determine whether a HFD rich in MUFA or 
PUFA yielded the same functional effect on monocytes.  
 
In addition, it is possible that post-prandial changes in plasma lipid profile also 
mediate the same effect on monocyte function acutely. It is broadly recognised that a 
meal high in saturated fats will elevate VLDL levels within 4 hours of eating [62] [63]. 
Dietary fatty acids are incorporated into these lipoproteins within 6 hours [53] and 
have subsequently been tracked into leukocytes using isotope labelling [64]. As 
discussed above, dietary fat intake can alter the structure, composition and 
metabolic properties of both LDL and VLDL [53,63]. As such, perhaps the 
discrepancies seen between this work and others on monocyte activation and 
adhesion after LDL and VLDL exposure [65,66] are due to the precise lipid profile of 
the lipoproteins used in vitro. Chylomicrons and free fatty acids are also elevated 
post-prandially [67] and both represent another avenue for investigation into 
monocyte function and are currently being investigated in the Woollard lab.  
7.3.2. 	  Monocyte	  migration	  
It is clear from both thioglycolate and LPS peritonitis experiments that less 
monocytes and macrophages accumulate in the peritoneal cavity at 72 hours when 
Ldlr-/- mice are fed a HFD. Intravenous bead labelling confirms that this is at least in 
part accounted for by impaired blood monocyte migration, while it seems that blood 
monocytes are retained in the omentum en route to the peritoneum. Although 
technically challenging and time consuming, adoptive transfer of monocytes from 
Ldlr-/- mice into wild-type animals would confirm that this phenomenon is driven by 
monocyte lipid loading and not by effects on tissues such as the endothelium, as I 
hypothesize from in vitro data. Cell phenotypes in the omentum after peritonitis 
suggest that HFD delays monocyte-macrophage differentiation, since the number of 
CD115low F4/80hi resident macrophages is decreased on HFD (Figure 3.4). While 
flow cytometry could be used to track fluorescently labelled monocytes into the 
peritoneum and omentum in these experiments, this would require many animals 
and would intrinsically limit the number of time points that could be studied. A more 
elegant solution may be the use of far-red fluorescent monocyte labelling and 
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fluorescence molecular tomography (FMT) as previously described in myocardial 
infarction [68]. When combined with micro-CT, this provides a non-invasive method 
of tracking cells in vivo over time to known organs and tissues [68]. However, 
preliminary work in the Woollard lab using FMT indicates that the majority of 
adoptively transfer monocytes rapidly pool in the liver, spleen and lungs, as 
previously reported [67], which can hamper detection of cells in the peritoneal cavity 
(Data not shown). 
 
In addition, it would be important to confirm these findings from the Ldlr-/- mouse in a 
clinically relevant human in vivo or ex vivo setting. The obvious candidate for this is 
the use of monocytes from patients with familial hypercholesterolemia, that have 
been previously reported to be lipid loaded [2]. Options for studying leukocyte 
migration in vivo in humans are limited, but one possibility is the use of a cantharidin 
blister model [69]. Cantharidin is a defensive compound of the beetle Meloidae 
coleopteran that disrupts cell-cell junctions in the skin epidermis when applied 
topically, leading to blistering and leukocyte recruitment [70]. Its validity as an in vivo 
model of inflammation have been validated in recent years, with anti-TNF treatment 
shown to produce a pronounced inhibition of neutrophil recruitment [71]. 
Alternatively, comparison of monocytes from FH with those from healthy donors in 
the established 2D chemotaxis assay would also confirm the physiological relevance 
of the described migratory phenotype described in VLDL treated cells.  
 
Of the observations made here, the discrepancy between lipid treated monocyte 
migration in 2D in vitro assays and peritonitis versus those during TEM is one of the 
most difficult to reconcile and warrants further experiments. While CD16neg 
monocytes have a pronounced migratory inhibition in transwells after LDL exposure 
and in real-time migration assays after VLDL, both of these treatments promote 
increased TEM. As alluded to previously, this may be due to a preference for 
monocytes with cytoskeletal dysfunction to utilise transcellular migration, thus 
leading a total increase in TEM despite inhibition of locomotion. In order to test this, 
future experiments would require real-time, high-resolution imaging of TEM 
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accompanied by staining of endothelial cell-cell junctions to determine the route of 
transmigration. However, in vivo endothelial cells are constantly subject to 
haemodynamic mechanical forces resulting from the shear stress of the blood flow. 
In turn this triggers a variety of signalling events that alter endothelial cell function via 
a mechanosensory complex of PECAM-1 and VE-cadherin [72,73]. In the current 
model, blood flow triggers cytoskeletal signalling through an unidentified 
mechanosensor in endothelial cells, reducing myosin-dependent tension in VE-
cadherin and simultaneously increasing tension in junctional PECAM-1, triggering 
intracellular signalling events [72,73].  In areas of disturbed flow, PECAM-1 signalling 
in this manner can activate the transcription factor NFkB and the subsequent 
expression of inflammatory genes [73].  There is also some evidence that low or 
oscillatory shear stress alters monocyte adhesion to the endothelium, and may be 
responsible for preferential atherogenesis at vascular bifurcations [74,75]. As such, 
while TEM experiments performed here were under static conditions, these 
conclusions should be repeated and confirmed in real time under physiological 
perfusion rates.  
  
Alternatively, Nourshargh and colleagues have recently pioneered the use of 
intravital microscopy to study leukocyte TEM in vivo in real time [76] and this may 
also be possible if an appropriate fluorescent reporter mouse was created on an Ldlr-
/- background. During this project I utilised the available Cx3cr1-GFP mouse, which 
allows for delineation of CX3CR1high GR1low intravascular patrolling monocytes by 
intravital confocal microscopy [77]. However, this mouse is of limited use to study 
TEM for several reasons. Firstly, GR1low monocytes have never been observed 
leaving the blood in the steady state [77] and rarely transmigrate during inflammation 
[78,79]. Moreover, when GR1high monocytes transmigrate in response to sterile injury 
they up-regulate Cx3cr1 expression [78], thus making classical and non-classical 
monocytes indistinguishable by imaging in this mouse. A more suitable option for 
studying monocyte TEM in vivo would be the recently created CD68-GFP mouse, as 
it allows for universal stable monocyte labelling that persists following transmigration 
into the tissue and monocyte- macrophage differentiation [80]. Alternatively, a dual 
colour approach to label both monocyte subsets, such as a combination of Cx3cr1-
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GFP and Ccr2-RFP may also provide more information on monocyte dynamics prior 
to and following TEM [78]. 
7.3.3. 	  Cytoskeletal	  regulation	  
While decreased RHOA activation and transcription in lipid-loaded monocytes has 
been observed here concurrent with a migratory defect, it has not been possible to 
definitively prove that these two observations are functionally linked. This is clearly a 
key area of future work before these findings can be translated to therapeutic use. 
Investigating the subcellular localization of active Rho-GTPases could provide insight 
into the underlying mechanisms of lipid- cytoskeleton interactions. The development 
of the Raichu fluorescent resonance energy transfer (FRET) biosensors for RHOA, 
RAC1 and CDC42 activity in the last decade now allows for this to be visualized in 
real time in migrating cells [81,82]. However, these probes would require transfection 
in order to achieve stable expression in primary cells, something that is challenging 
in freshly- isolated monocytes and may result in TLR activation, particularly since 
non-classical monocytes mount a robust inflammatory response to nucleic acids via 
TLR7/8 [83]. As such, quantification of FRET by fluorescence lifetime imaging 
microscopy (FLIM) in this context may require the use of a genetically tractable 
monocytic cell line, as has been described for the analysis of L-Selectin shedding in 
THP-1 monocyte-like cells [84]. Such an approach would also hopefully shed light on 
the precise effects of dyslipidaemia on other GTPases such as RAC1 and clarify 
discrepancies between this work and that in cholesterol-loaded macrophages [85]. 
 
Another potential future option is the use of the available constitutively active RHOA 
mouse [86,87], which could be used to reconstitute bone marrow in the Ldlr-/- HFD 
model prior to peritonitis experiments, thus providing selective activation of RHOA in 
myeloid cells. However, for the same reasons discussed for pharmacological 
activation of RHOA using CN03, it is unlikely that this experiment would yield 
meaningful data. Over-activation of Rho-GTPases can be as detrimental as under-
activation during cell migration, and simply constitutively activating RHOA would not 
provide the fine spatio-temporal balance required for chemotaxis [88,89]. However, 
further investigation into Rho-GTPase prenylation in lipid treated cells may provide 
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more opportunities for therapeutic intervention. If dyslipidaemia causes adherent 
RHOA prenylation and trafficking, there are several pharmacological options to 
target this pathway including the use of statins to reduce HMG-CoA reductase 
activity and the synthesis of isoprenoids [90]. This could be a more elegant method 
of restoring appropriate levels of RHOA activation in lipid-loaded cells with drugs that 
are already in clinical use.  
7.4. Conclusion	  
In conclusion, the work presented in this thesis details the interactions of monocyte 
subsets with lipoproteins during dyslipidaemia. In a more detailed confirmation of 
previous observations, I demonstrate that monocytes accumulate neutral lipid in 
response to LDL and VLDL in a potentially subset specific manner, via various 
receptors including CD36, but independent of the LDL receptor in vivo. While this 
does not impair many aspects of their response to inflammation, including cytokine 
production, there is a clear effect of dyslipidaemia on monocyte locomotion and 
cytoskeletal regulation in both CD16pos and CD16neg subpopulations. In the setting of 
infection, this phenotype may impair monocyte recruitment and clearance of invading 
pathogens. Conversely, in chronic inflammatory disease such as atherosclerosis and 
rheumatoid arthritis dyslipidaemia may perpetuate inappropriate retention of 
monocytes at the site of inflammation. These findings underscore the functional 
independence of monocytes from macrophages and their importance as immune 
effector cells prior to monocyte- macrophage differentiation. Further work is now 
required to continue to decipher the interactions of environmental and dietary stimuli 
with the innate immune system, in the context of ever-expanding knowledge on the 
functional role of monocyte subpopulations.  
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